8-Gastroenterology and Hepatology
8-Gastroenterology and Hepatology
8-Gastroenterology and Hepatology
12/15/10
8:36
Page i
MEDICAL MASTERCLASS
EDITOR-IN-CHIEF
JOHN D FIRTH
DM FRCP
GASTROENTEROLOGY AND
HEPATOLOGY
EDITOR
SATISH C KESHAV
Second Edition
GAH_A01
12/15/10
8:36
Page ii
Disclaimer
Although every effort has been made to ensure that drug doses
and other information are presented accurately in this publication, the
ultimate responsibility rests with the prescribing physician. Neither the
publishers nor the authors can be held responsible for any consequences
arising from the use of information contained herein. Any product
mentioned in this publication should be used in accordance with the
prescribing information prepared by the manufacturers.
The information presented in this publication reflects the opinions of its
contributors and should not be taken to represent the policy and views of the
Royal College of Physicians of London, unless this is specifically stated.
Every effort has been made by the contributors to contact holders of
copyright to obtain permission to reproduce copyrighted material. However,
if any have been inadvertently overlooked, the publisher will be pleased to
make the necessary arrangements at the first opportunity.
GAH_A01
12/15/10
8:36
Page iii
LIST OF CONTRIBUTORS
Dr RJ Atkinson
MRCP(UK)
Dr JS Leeds
MBChB MRCP(UK)
GAH_A01
12/15/10
8:36
Page iv
GAH_A01
12/15/10
8:36
Page v
CONTENTS
GASTROENTEROLOGY
AND HEPATOLOGY
2.1
2.2
2.3
2.4
2.5
Oesophageal disease 60
2.1.1 Gastro-oesophageal
reflux disease 60
2.1.2 Achalasia and
oesophageal
dysmotility 62
2.1.3 Oesophageal cancer
and Barretts
oesophagus 63
Gastric disease 66
2.2.1 Peptic ulceration and
Helicobacter pylori 66
2.2.2 Gastric carcinoma 68
2.2.3 Rare gastric tumours
69
2.2.4 Rare causes of
gastrointestinal
haemorrhage 70
Small bowel disease 71
2.3.1 Malabsorption 71
2.3.1.1 Bacterial
overgrowth 71
2.3.1.2 Other causes of
malabsorption
72
2.3.2 Coeliac disease 73
Pancreatic disease 75
2.4.1 Acute pancreatitis 75
2.4.2 Chronic pancreatitis
78
2.4.3 Pancreatic cancer 80
2.4.4 Neuroendocrine
tumours 82
Biliary disease 83
2.5.1 Choledocholithiasis 83
2.5.2 Primary biliary
cirrhosis 85
2.5.3 Primary sclerosing
cholangitis 87
GAH_A01
12/15/10
8:36
Page vi
CONTENTS
vi
Self-assessment 147
Investigations and Practical
Procedures 136
3.1 General investigations 136
3.2 Tests of gastrointestinal and
liver function 137
GAH_A01
12/15/10
8:36
Page vii
FOREWORD
Since its initial publication in 2001, Medical Masterclass has been regarded
as a key learning and teaching resource for physicians around the world.
The resource was produced in part to meet the vision of the Royal College of
Physicians: Doctors of the highest quality, serving patients well. This vision
continues and, along with advances in clinical practice and changes in
the format of the MRCP(UK) exam, has justified the publication of this
second edition.
The MRCP(UK) is an international examination that seeks to advance the
learning of and enhance the training process for physicians worldwide. On
passing the exam physicians are recognised as having attained the required
knowledge, skills and manner appropriate for training at a specialist level.
However, passing the exam is a challenge. The pass rate at each sitting of
the written papers is about 40%. Even the most prominent consultants
have had to sit each part of the exam more than once in order to pass.
With this challenge in mind, the College has produced Medical Masterclass,
a comprehensive learning resource to help candidates with the preparation
that is key to making the grade.
Medical Masterclass has been produced by the Education Department of
the College. A work of this size represents a formidable amount of effort
by the Editor-in-Chief Dr John Firth and his team of editors and authors.
I would like to thank our colleagues for this wonderful educational product
and wholeheartedly recommend it as an invaluable learning resource for all
physicians preparing for their MRCP(UK) examination.
Professor Ian Gilmore MD PRCP
President of the Royal College of Physicians
vii
GAH_A01
12/15/10
8:36
Page viii
PREFACE
viii
GAH_A01
12/15/10
8:36
Page ix
PREFACE
I hope that you enjoy using Medical Masterclass to learn more about
medicine, which whatever is happening politically to primary care,
hospitals and medical career structures remains a wonderful occupation.
It is sometimes intellectually and/or emotionally very challenging, and also
sometimes extremely rewarding, particularly when reduced to the essential
of a doctor trying to provide best care for a patient.
John Firth DM FRCP
Editor-in-Chief
ix
GAH_A01
12/15/10
8:36
Page x
ACKNOWLEDGEMENTS
Medical Masterclass has been produced by a team. The names of those who
have written or edited material are clearly indicated elsewhere, but without
the support of many other people it would not exist. Naming names is risky,
but those worthy of particular note include: Sir Richard Thompson (College
Treasurer) and Mrs Winnie Wade (Director of Education), who steered the
project through committees that are traditionally described as labyrinthine,
and which certainly seem so to me; and also Arthur Wadsworth (Project
Co-ordinator) and Don Liu in the College Education Department office. Don
is a veteran of the first edition of Medical Masterclass, and it would be fair to
say that without his great efforts a second edition might not have seen the
light of day.
John Firth DM FRCP
Editor-in-Chief
GAH_A01
12/15/10
8:36
Page xi
KEY FEATURES
We have created a range of icon boxes that sit among the text of the
various Medical Masterclass modules. They are there to help you identify key
information and to make learning easier and more enjoyable. Here is a brief
explanation:
xi
GAH_A01
12/15/10
8:36
Page xii
GAH_C01
12/9/10
9:01
Page 1
GASTROENTEROLOGY AND
HEPATOLOGY
Authors:
SC Keshav
Editor-in-Chief:
JD Firth
GAH_C01
12/9/10
9:01
Page 2
GAH_C01
12/9/10
9:01
Page 3
TABLE 1 DIFFERENTIAL
DIAGNOSIS OF DYSPEPSIA
Common
Less common
Rare
Gastric ulceration/gastritis1
Duodenal ulceration/duodenitis1
Gastric carcinoma
Functional dyspepsia
Cholecystitis/gallstones
Chronic pancreatitis
Pancreatic carcinoma
Dear Doctor,
his dyspepsia?
Pain
Yours sincerely,
Introduction
Dyspepsia is an unpleasant sensation
in the upper abdomen. If new, it is
an alarm symptom in patients over
the age of 45 years and requires
rapid investigation because of the
obvious concern that it is due
to a carcinoma of the stomach.
The most common cause is
inflammation or ulceration of the
upper gastrointestinal tract; other
causes are listed in Table 1.
It is important to remember that
pain or discomfort in the upper
Other symptoms
Key issues to ask about include the
following.
Vomiting: may indicate
obstruction. The nature of the
vomitus is important: gastric
outlet obstruction leads to
regurgitation of undigested food,
sometimes many hours after
it was ingested; haematemesis
clearly suggests peptic ulceration.
Reflux of an acid taste into the
mouth: suggests hiatus hernia.
Smoking and alcohol history
along with caffeine intake are
important in those with reflux
symptoms as they represent
GAH_C01
12/9/10
9:01
Page 4
Endoscopy
Any structural abnormalities
can be visualised and biopsied;
biopsy of the stomach near the
antrum can also be used to help
detect the presence of H. pylori by
commercially available urease tests.
Imaging
Upper abdominal ultrasound
scanning allows imaging of the liver,
pancreas and biliary tree and is the
radiological investigation of choice.
It is best used for imaging solid
organs (Fig. 1) and gives little
information on the stomach and
small intestine unless there is
marked pathology, eg gastric cancer
causing thickening of the stomach
wall. Remember that it is not
infallible and can miss distal
common bile duct stones and
minimal changes in the pancreas.
Other tests
If a biliary or pancreatic cause is
likely, then CT or MRI scanning
may be appropriate. If endoscopy is
contraindicated, then a barium meal
GAH_C01
12/9/10
9:01
Page 5
Management
Introduction
Dysphagia means difficulty
swallowing and is an alarm
symptom that should be investigated
rapidly. It may be due to dysfunction
Dear Doctor,
Re: Mrs Deborah Finch, aged
67 years
I would be grateful for your
assessment of this woman who
has noticed increasing difficulty
TABLE 2 DIFFERENTIAL
DIAGNOSIS OF DYSPHAGIA
Common
Less common
Rare
Pharyngeal pouch
Achalasia
External compression from
lung lesion
Scleroderma
Motor neuron disease
Myasthenia gravis
Parkinsons disease
Multiple sclerosis
GAH_C01
12/9/10
9:01
Page 6
Other symptoms
Any mechanical blockage to the
passage of food into the stomach
will restrict calorie intake and result
in weight loss. Severe and rapid
weight loss tends to point to a
malignant process.
Is there a history of reflux acidity
with an acid taste coming up into
the mouth? Chronic acid reflux can
lead to oesophagitis with subsequent
stricture formation, and patients with
gastro-oesophageal reflux disease
(GORD) can also develop dysmotility
due to chronic acid damage.
Epigastric pain may suggest
peptic ulcer disease and reflux.
Patients with some neurological
diseases can develop dysphagia due
to involvement of the upper third of
the oesophagus (striated muscle).
Stroke with pseudobulbar palsy is
the most common, but dysphagia
can also be seen in motor neuron
disease, multiple sclerosis,
Parkinsons disease and
myasthenia gravis.
Social history
Alcohol excess and smoking are both
risk factors for the development
of oesophageal cancer as well as
being aspects of lifestyle that could
be usefully modified in patients
with GORD.
Investigation of dysphagia
Barium swallow (urgent).
Endoscopy: biopsy and brushings to
exclude malignancy if any stricture
is identified.
Manometry: consider if endoscopy or
barium study negative to exclude
achalasia.
GAH_C01
12/9/10
9:01
Page 7
Dysphagia without
oesophageal narrowing should
lead to consideration of dysmotility,
which can be identified and classified
by manometry.
Other tests
Management
Specific management will depend
on the cause identified (Table 2).
Patients with neurological causes
may require artificial feeding,
particularly if the condition is
non-reversible and likely to
deteriorate over time. Nasogastric
tube feeding may be necessary in
the short term, but for extended
feeding programmes the best
option is percutaneous endoscopic
gastrostomy.
GAH_C01
12/9/10
9:01
Page 8
TABLE 3 DIFFERENTIAL
Type of condition
Diseases/comments
Intestinal inflammation
Intestinal neoplasia
Malabsorption
Thyrotoxicosis
Secretory neuroendocrine tumours, such as carcinoid,
phaeochromocytoma, VIPoma
Diarrhoea is a frequent side effect of some drugs, such as
olsalazine, mycophenolate mofetil, misoprostol, colchicine
and antibiotics1
Factitious/fictitious
Laxative abuse
Dear Doctor,
Re: Mr Darren Weaver, aged
24 years
Thank you for seeing this
married man with no significant
past medical history who
complains of a 6-month history
of diarrhoea with blood mixed in
with the stool. Problems started
after he ate a dodgy meal and
he assumed that they were
infective, but matters have not
improved. He has lost some
weight and also complains of
arthralgia. What do you think is
responsible for these problems?
Yours sincerely,
Introduction
This man is most likely to have
idiopathic inflammatory bowel
disease (IBD), but it is important
to exclude chronic infection and to
consider other causes of chronic
diarrhoea (Table 3). In older patients
intestinal neoplasia and paradoxical
overflow diarrhoea caused by
chronic constipation must not be
forgotten, and always check that the
patient does actually have diarrhoea,
ie increased daily stool volume.
GAH_C01
12/9/10
9:01
Page 9
Other symptoms
Systemic: in any patient
presenting with chronic
diarrhoea ask specific questions
to determine if there has been
weight loss or a systemic response
revealed by fevers and sweats.
Non-specific malaise, with or
without weight loss, is frequently
present in uncomplicated
ulcerative colitis and coeliac
disease. Weight loss, fever, night
sweats and malaise are usually
prominent in patients with
Crohns disease and intestinal
tuberculosis.
Pain: cramping abdominal pain
often accompanies diarrhoea of
any cause. Deep-seated abdominal
pain should alert to the possibility
of Crohns disease, intestinal
tuberculosis and neoplasia.
Pain suggesting pancreatitis or
cholelithiasis may provide a clue
to the cause of steatorrhoea.
Blood tests
Routine blood tests include
FBC (anaemia, leucocytosis),
electrolytes (hypokalaemia),
renal/liver (hypoalbuminaemia)/
bone profile, inflammatory markers,
iron/ferritin/folic acid/vitamin
B12; clotting screen; anti-tissue
transglutaminase antibodies
(virtually diagnostic of coeliac
disease, although the test may be
falsely negative in patients with
IgA deficiency).
GAH_C01
12/9/10
9:01
Page 10
Intercurrent infectious
diarrhoea should always be
considered, even in patients with
known IBD, particularly before starting
immunosuppression.
10
Management
Specific management will
depend on precise diagnosis.
Attention to nutrition is required
in all cases of chronic diarrhoeal
illness.
Introduction
Rectal bleeding is a common
problem and has a wide differential:
the most common causes are
GAH_C01
12/9/10
9:01
Page 11
TABLE 4 DIFFERENTIAL
Common
Less common
Rare
Haemorrhoids
Diverticular disease
Colorectal carcinoma
Anal fissure
Mesenteric ischaemia
Intussusception
Volvulus
Radiation colitis/proctitis
Trauma
Bleeding disorder
Portal hypertension with
rectal varices
TABLE 5 DIFFERENTIAL
Common
Uncommon
Rare
Appendix mass:
abscess, mucocele
Ovarian carcinoma1
Other symptoms
Perianal: discomfort or itch may
indicate haemorrhoids. Anal
fissures may be exquisitely
painful: haemorrhoids are not
usually painful unless they have
thrombosed.
Abdominal pain: that caused by
diverticular disease is typically felt
in the left iliac fossa. Cramping
pain may occur in colitis. Pain is
generally a late sign in neoplasia.
Severe pain accompanying
bleeding in an ill patient is
highly suggestive of mesenteric
ischaemia.
Alteration in bowel habit:
any change, particularly to
diarrhoea/looseness, is highly
significant, especially in the
presence of rectal bleeding. This
would probably indicate colorectal
11
GAH_C01
12/9/10
9:01
Page 12
hypercholesterolaemia, because
they are relevant to treatment
options that might be considered
(eg assessment of surgical risk)
and because the presence of
vascular disease would increase
the likelihood of symptoms being
due to mesenteric ischaemia.
Angiodysplastic bleeding from the
colon is said to be more common in
patients with aortic valve stenosis.
Drugs
Anorexia and (particularly)
weight loss: these are worrying
symptoms, again possibly
indicating a neoplasm but also
seen in inflammatory bowel
disease and intestinal TB, and
can considerably pre-date bleeding
and the development of an
abdominal mass.
Systemic symptoms: fever may be
vague and at best non-specific, but
reports of mouth ulcers, arthralgia
and gritty eyes are common in
patients with Crohns disease.
Symptoms of pelvic disease: ask
explicitly about urethral discharge
and pneumaturia (which means
that there must be a fistula
between bladder and bowel),
and in women also enquire about
vaginal symptoms such as
discharge.
12
Family history
The scenario states that this patients
mother had bowel cancer: try to
elicit exactly what the problem
was. A family history of colorectal
carcinoma or colonic polyps
strengthens the argument for
thorough investigation, particularly
in a younger patient, although in
this mans case there is no debate:
he has caecal carcinoma until
proved otherwise. A family history
of inflammatory bowel disease might
also be relevant, and remember that
the rare condition of hereditary
haemorrhagic telangiectasia is an
autosomal dominant disorder.
GAH_C01
12/9/10
9:01
Page 13
Laparoscopy/laparotomy: in some
patients it may not be possible
to fully characterise a mass with
non-invasive imaging techniques,
in which case direct visualisation
and biopsy may be necessary.
Surgery may also be needed if
there are symptoms suggestive
of intestinal obstruction such as
nausea or vomiting.
Management
Barium enema This is generally
less reliable than colonoscopy in
detecting colonic neoplasia and
diverticular disease, cannot
diagnose vascular lesions such
13
GAH_C01
12/9/10
9:01
Page 14
TABLE 6 CAUSES
Type of condition
Cause
Gastrointestinal
Coeliac disease1
Crohns disease
Pancreatic insufficiency
Endocrine
Diabetes mellitus1
Thyrotoxicosis1
Addisons disease
Eating disorder
Deliberate dieting1
Anorexia nervosa1
Chronic infection
Tuberculosis2
Malignancy
Haematological
1. Common conditions.
2. Common in high-risk groups.
Dear Doctor,
Re: Mrs Sarah Jones, aged
24 years
This young woman has noticed
that her clothes are becoming
Introduction
Tiredness is a common and nonspecific symptom. Weight is usually
fairly constant and loss of 5% or
more of the usual body weight must
be taken seriously. Although
14
GAH_C01
12/9/10
9:01
Page 15
Imaging
CXR: look for tuberculosis,
mediastinal lymphadenopathy,
or (very unlikely in this woman,
but common in older smokers)
bronchial neoplasm or metastatic
disease.
Abdominal ultrasound or (better)
CT scanning are non-invasive and
may detect inflammatory masses
or thickened oedematous loops
of small bowel in Crohns disease,
intra-abdominal collections,
lymphadenopathy or renal
carcinoma.
Other tests
Management
Fig. 7 Coeliac disease: (a) histologically normal small bowel with normal villi contrasts with (b) total villous atrophy of coeliac disease.
15
GAH_C01
12/9/10
9:01
Page 16
Dear Doctor,
Re: Mr Geoffrey Archer, aged
67 years
This man, who does not readily
seek medical attention, came to
the surgery recently complaining
of a 6-month history of crampy
epigastric pain and one stone
Yours sincerely,
Introduction
The differential diagnosis of chronic
abdominal pain is shown in Table 7.
In this man there must clearly
be concern over the possibility
of a malignant cause, but his
cardiovascular risk factors make
mesenteric ischaemia a possibility.
Crohns disease can present with
abdominal pain and weight loss,
but the lack of bowel symptoms,
TABLE 7 DIFFERENTIAL
16
Common
Uncommon
Rare
Mesenteric ischaemia
Crohns disease
Subacute bowel obstruction
(adhesions, luminal stricture,
herniae)
Addisons disease
C1-esterase deficiency
Other symptoms
Weight loss: this man has lost
a stone in weight and, as with
nocturnal pain, weight loss
should raise thoughts of
significant pathology and
must not be dismissed lightly.
GAH_C01
12/9/10
9:01
Page 17
Endoscopy
In this man, where the epigastric
location of pain and presence of
weight loss indicates that peptic
ulceration or gastric malignancy
are the most likely diagnoses, upper
gastrointestinal endoscopy is the
investigation of choice. In contrast,
alteration in bowel habit associated
with abdominal pain and weight loss
should prompt you to consider
colonoscopy.
Radiological tests
Plain abdominal radiograph
and ultrasound scan: there is a
limited role for plain radiographs
unless you suspect an acute
obstructive or ischaemic
episode. Pancreatic calcification
may be seen in chronic
pancreatitis. Ultrasonography
may demonstrate gallstones,
biliary dilatation, liver metastases
or a pancreatic mass.
Significant mesenteric
ischaemia is unlikely unless
at least two of the major intestinal
arteries are involved, eg coeliac
plexus and superior mesenteric
artery.
Management
Management will be dictated by the
specific diagnosis made.
17
GAH_C01
12/9/10
9:01
Page 18
TABLE 8 LIVER
Blood test
Transaminases
Dear Doctor,
Re: Mrs Kate Beaumont, aged
Alkaline phosphatase These biliary enzymes usually indicate cholestatic liver disease
and GGT
or biliary tract disease
GGT levels are disproportionately raised in alcohol-related liver
disease, or where an enzyme-inducing drug such as phenytoin or
phenobarbital is used
Segmental non-obstructive damage to the biliary tree, as in
metastatic or infiltrative disease, often produces elevated biliary
enzymes, mildly elevated transaminases and normal serum bilirubin
Alkaline phosphatase can arise from liver, bone and intestine:
determination of isoenzymes can be used to distinguish between
these sources
Bilirubin
Albumin
Prothrombin time
50 years
Thank you for seeing this woman
who has recently been diagnosed
as having diabetes. She has a
history of long-standing obesity
and more recently of high
Introduction
Reduced liver function is hard to
detect clinically, except when the
liver is severely impaired. The liver
can be markedly damaged without
any overt clinical manifestation.
The standard liver function tests can
provide early warning of potentially
serious pathology (Table 8), but
significant liver disease, including
cirrhosis, can be present with
normal liver enzymes. The
detection of liver disease relies on
the combination of careful clinical
assessment, a variety of blood tests,
18
GAH_C01
12/9/10
9:01
Page 19
Blood tests
There are a large number of causes
of abnormal liver function tests. The
commonest causes of chronic liver
disease should always be looked
19
GAH_C01
12/9/10
9:01
Page 20
Imaging
The first-line imaging test should
be an abdominal ultrasound scan
to look at the liver (is it large, are
there abnormal areas, does it look
fatty, are its blood vessels normal?),
the gallbladder (is there evidence of
gallstones?) and spleen (is it large?).
Liver biopsy
Sometimes the information
from blood tests and ultrasound
examination is not enough to make
a confident diagnosis, or the degree
of liver damage needs to be more
thoroughly assessed in order to stage
disease, assess prognosis and guide
therapy, in which case a liver biopsy
may be indicated (Fig. 8).
Management
Management will be dictated by the
specific diagnosis made.
20
TABLE 9 DIAGNOSTIC
Genetic haemochromatosis
1-Antitrypsin deficiency
Wilsons disease
1. Note that in some cases acute viral hepatitis can be subclinical, so check IgM to
hepatitis A, E or B antigens if there is possible exposure.
ALT, alanine transaminase; AST, asparate transaminase; GGT, -glutamyltransferase; HBsAg,
hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; HBV, hepatitis B virus;
HCV, hepatitis C virus.
hypertriglyceridaemia and
hypertension is known as the
metabolic syndrome. NAFLD
appears to be the liver component of
this syndrome. Treatment of patients
Fig. 8 Microscopic appearance of hepatic steatosis (fatty liver). Fat droplets are seen filling most of the
hepatocytes, with the nuclei in the centres of the cells.
GAH_C01
12/9/10
9:01
Page 21
Introduction
It is unusual for abdominal swelling
to be an isolated problem: there will
often be additional symptoms or an
easily identifiable associated history.
The most important diagnostic
consideration is ascites, the
differential diagnosis of which
and of other causes of abdominal
swelling is given in Table 10.
TABLE 10 DIFFERENTIAL
Common
Uncommon
Rare
Non-ascitic causes of
abdominal swelling
Decompensated
chronic liver disease
Alcoholic hepatitis
Peritoneal tuberculosis
Right-sided heart failure/
constrictive pericarditis
Acute pancreatitis
Nephrotic syndrome
Myxoedema
Chronic constipation
Gaseous distension
Acute bowel obstruction/
paralytic ileus
Massive organomegaly
Obesity
Pregnancy
21
GAH_C01
12/9/10
9:02
Page 22
22
Blood tests
Routine blood tests will include the
following.
FBC: hypersplenism (low platelet
count, pancytopenia), alcoholic
aetiology (raised mean
corpuscular volume).
Alpha-fetoprotein (AFP): in
patients with known liver disease
who decompensate (become
jaundiced, encephalopathic or
develop ascites) unexpectedly
consider hepatocellular
carcinoma.
Imaging
Plain abdominal radiograph: if
bowel obstruction or ileus is
suspected.
Abdominal ultrasound: this may
confirm the diagnosis of ascites,
especially if the amount of free
fluid is small. It will also provide
GAH_C01
12/9/10
9:02
Page 23
Ascitic aspiration
Send for leucocytes, microscopy
and culture, albumin, amylase and
cytology. Spontaneous bacterial
peritonitis (SBP) is a serious
complication of ascites associated
with chronic liver disease and is
diagnosed by a leucocyte count
>250 cells/mL in the ascitic
fluid. Compare ascitic albumin
concentration with serum albumin
concentration: a gradient >11 g/L
suggests portal hypertension; a
gradient <11 g/L suggests an
exudative cause (neoplastic,
infective or pancreatitis).
Liver biopsy
Management
In most patients the presence of
ascites should prompt admission for
investigation and treatment.
Specific treatment Any specific
underlying cause of chronic
liver disease should be treated if
possible, including abstinence in
alcoholic liver disease, steroids
in autoimmune hepatitis and
venesection in haemochromatosis.
Cultures in spontaneous
bacterial peritonitis are often
negative and waiting for them should
not delay treatment.
Symptomatic management of
ascites The following therapies may
be appropriate.
Diuretics: most ascites should be
treated initially with a diuretic.
Begin with spironolactone, and
note that here is usually a delay of
23 days between introduction of
the drug and initial effect. Careful
use of furosemide may be required
but can precipitate dramatic
hyponatraemia.
Further discussion
Varices
Any patient with suspected
cirrhosis or portal hypertension
should be screened for oesophageal
varices.
Albumin infusion
The benefits of human albumin
solution in patients with ascites
and renal dysfunction, or in
those undergoing paracentesis,
are controversial and poorly
understood. In simplistic terms
it acts as a small-volume plasma
expander, improving renal perfusion
and function in hepatorenal
syndrome (2 units/day) and prevents
circulatory collapse and hepatorenal
syndrome after large-volume
paracentesis. For paracentesis,
100 mL of 20% human albumin
solution per 23 L drained is
usually administered.
23
GAH_C01
12/9/10
9:02
Page 24
General features
In routine clinical practice the
first concern is always whether the
patient is well, unwell or extremely
unwell, but patients who are acutely
unwell are not likely to appear in a
PACES examination. Important
issues to comment on before
proceeding to examination of
the abdomen itself include the
following.
Nutritional status: does the patient
look well-nourished? If given the
opportunity to ask, say that you
would like to know his
weight/height/BMI.
Hands: clubbing, leuconychia.
Eyes: anaemia is a frequent
complication of Crohns disease
and iritis an association.
Mouth: aphthous ulceration.
Legs: erythema nodosum;
peripheral oedema due to
hypoproteinaemia.
Features of chronic liver disease
(see Section 1.2.2): primary
sclerosing cholangitis (PSC) may
complicate ulcerative colitis or
Crohns disease.
Abdominal examination
External examination of the
abdomen may be unremarkable,
but look and palpate carefully for
the following.
24
Rectal examination
This is mandatory in clinical
practice and should be commented
on, although not performed, in the
setting of the PACES examination.
Features to look for would include
signs of:
excoriation at the anal verge
(may result from excess
secretions);
ulceration, fissuring and scarring
(signs of anorectal involvement);
blood and pus (indicative of active
proctitis/colitis).
Further discussion
Abdominal examination may be
completely normal in cases of
inflammatory bowel disease, but it is
likely that at least some features of
the general or specific examination
will be abnormal in a patient
appearing in PACES (although a
patient with no abnormal physical
signs can be included).
General features
The only common cause of
haematemesis associated with
abnormal physical signs is chronic
liver disease and the statement that
the patient had a brisk, painless,
large-volume haematemesis is
clearly a pointer to varices. In
routine practice your first concern
would be to assess the state of the
circulation, but patients who are
actively bleeding will not (or should
not) appear in PACES. What
evidence of chronic liver disease
might be apparent from the end
of the bed?
General appearance: is the patient
cachectic? If given the opportunity
to ask, say that you would like
to know his weight/height/BMI.
Gynaecomastia, loss of secondary
sexual hair (in men); tanned
appearance (consider
haemochromatosis).
Skin: jaundice, spider naevi,
bruising, scratch marks; tattoos,
signs of intravenous drug abuse
(risk factors for hepatitis B and C).
Hands: liver flap, clubbing,
leuconychia, palmar erythema,
Dupuytrens contracture.
Eyes: jaundice, anaemia.
Mouth: angular cheilosis, poor
dentition.
GAH_C01
12/9/10
9:02
Page 25
TABLE 11 CAUSES
Frequency
Condition
Common
Cushingoid features: suggest
long-term steroid treatment.
Less common
Pigmentation: consider
haemochromatosis (bronze
diabetes).
Rare
Abdominal examination
Comment on the presence or
absence of the following.
Distension.
Prominent anterior abdominal
wall veins with flow away from
the umbilicus (caput medusa).
Hepatomegaly: but remember
that most causes of chronic liver
disease are associated with a
shrunken liver. Listen for a bruit.
Splenomegaly: the key physical
sign indicating the presence
of portal hypertension in a
patient with chronic liver
disease, although the absence
of splenomegaly does not mean
that portal hypertension can be
excluded.
Ascites: test for shifting dullness.
Rectal examination for the formal
assessment of melaena remains
essential in routine clinical practice,
and a comment to this effect would
be appropriate in PACES.
Further discussion
1.2.3 Splenomegaly
Instruction
TABLE 12 CAUSES
General features
Look for features of chronic
liver disease (as described in
Section 1.2.2) and for evidence
of haematological disease:
pallor/polycythaemia, indwelling
OF PORTAL HYPERTENSION
Prehepatic
Hepatic
Posthepatic
25
GAH_C01
12/9/10
9:02
Page 26
Abdominal examination
Observe for scars and obvious
swellings before beginning to
palpate. After gentle palpation
in all quadrants to detect very
obvious masses and to see if the
patient is tender anywhere, examine
for hepatomegaly, splenomegaly
and renal enlargement using
standard technique. Look for
the other features described in
Section 1.2.2.
Further discussion
What are the common causes of
splenomegaly?
See Table 13.
General features
In routine clinical practice the first
priority would be determine whether
the patient was acutely unwell,
in which case acute intestinal
obstruction would be the immediate
concern. Patients with ileus,
pseudo-obstruction or constipation
are generally less unwell, although
they may vomit (look for a sick
bowl). Patients with ascites can
be moribund (acute hepatitis,
BuddChiari syndrome), quite
Abdominal examination
TABLE 13 CAUSES
OF SPLENOMEGALY
Frequency1
Condition
Common
Less common
Rare
26
GAH_C01
12/9/10
9:02
Page 27
1.3 Communication
skills and ethics
Further discussion
Scenario
Role: you are a junior doctor
working on a medical ward.
TABLE 14 CAUSES
OF ASCITES
Frequency
Causes
Common
Less common
Rare
BuddChiari syndrome
Constrictive pericarditis
Nephrotic syndrome
Pancreatic disease
Hypothyroidism
Malabsorption (or other cause of hypoalbuminaemia)
1. Rare in PACES.
TABLE 15 DIAGNOSTIC
Test
Details
Ascitic fluid
Blood tests
Imaging
FBC
Liver function tests: bilirubin, transaminases, alkaline phosphatase,
-glutamyltransferase, albumin, prothrombin time
Further investigations will be dictated by clinical suspicion and the results of initial
laboratory tests, eg to pursue the cause of chronic liver disease (see Section 1.2.2),
possible malignancy (CT scan, biopsy of abnormal tissue) or cardiac dysfunction (ECG,
echocardiography).
27
GAH_C01
12/9/10
9:02
Page 28
28
GAH_C01
12/9/10
9:02
Page 29
1.3.2 Limitation of
management
Scenario
Further discussion
Any form of artificial feeding is
a therapeutic intervention and
informed consent from the patient
or carers with legal authority must
be sought.
29
GAH_C01
12/9/10
9:02
Page 30
30
1.3.3 Limitation of
investigation
Scenario
Role: you are a junior doctor
working in a gastroenterology
outpatient clinic.
Mr David Chan is a 25-year-old
man who has experienced
symptoms of irritable bowel
syndrome for 8 years and has
been extensively investigated
previously. He is convinced that
his symptoms have worsened
considerably and is particularly
worried about a recent bout of
constipation because he thinks it
might indicate cancer. A physical
examination is unremarkable
and routine tests such as FBC
are entirely normal. He wishes
to have a colonoscopy, but
the consultant who saw him
previously said that this was not
indicated and declined to perform
the investigation.
Your task: to explain to the
patient the reasons why the test
is not indicated nor on offer, and
what the nature of irritable
bowel syndrome is.
GAH_C01
12/9/10
9:02
Page 31
Scenario
Role: you are a junior doctor
working on a general medical
ward.
Ms Cathy Evans, a 34-year-old
woman who says that she has
recently moved to the area and
is not registered with a GP, is
admitted with episodic severe
abdominal pain. At times this
seems to be excruciating, such
that she rolls around in agony
and calls out for pethidine, but
31
GAH_C01
12/9/10
9:02
Page 32
32
Introduction
GAH_C01
12/9/10
9:02
Page 33
TABLE 16 CAUSES
Mechanism
Type of problem
Example
Anxiety
Nociceptive event
Metabolic changes
Raised intracranial pressure
Drugs
Prior to procedure
Phlebotomy
Hyponatraemia
Cerebral tumour
Chemotherapeutic agents,
digoxin, theophyllline, opiates
Balance centre
Labyrinthitis
Mnires disease
Benign positional vertigo
Viral infection
Mechanical
Gut receptors
Ingested toxin
Infection
Examination
General features
33
GAH_C01
12/9/10
9:02
Page 34
Investigation
Other tests
Given the patients history of
chest pain, a 12-lead ECG should
be performed to look for evidence of
myocardial ischaemia, and this may
need repeating after 812 hours to
assess for evolving changes; also
check serum troponin.
Abdomen
Systematically consider the
following.
Inspection: scars (consider
adhesions), distension, abnormal
bruising (Cullens or Grey Turners
sign in acute severe pancreatitis).
34
Fig. 10 Plain abdominal radiograph showing dilated stomach and small bowel in a patient with colonic
obstruction.
GAH_C01
12/9/10
9:02
Page 35
Upper gastrointestinal
endoscopy contributes little
to the investigation of nausea and
vomiting (without haematemesis) and
is not without risk: the patient may
have a stomach full of fluid, increasing
the risk of aspiration and reducing the
chance of visualising any significant
pathology.
Management
Specific management will clearly be
dictated by the particular cause of
vomiting, but there are three main
areas to consider in the management
of all patients with this symptom:
resuscitation, control of pain, and
control of nausea and vomiting.
Resuscitation
Pain control
Patients with pain should be given
sufficient analgesia. If they are
vomiting, then the drug should be
delivered by a parenteral route,
either intramuscularly/intravenously
or subcutaneously depending on the
circumstances. Opiates titrated to
the level of adequate analgesia will
often be necessary for severe pain.
35
GAH_C01
12/9/10
9:02
Page 36
several days.
Introduction
This is an emergency: the patient
seems to be suffering circulatory
failure and neurological disturbance.
In a recently returned traveller from
Fig. 11 Pathways involved in nausea and vomiting with specific examples of potential antiemetics for relevant pathways.
36
GAH_C01
12/9/10
9:02
Page 37
TABLE 17 ANTIEMETIC
Antiemetic drug
Anxiolytics
Lorazepam
4 mg
Dopamine antagonists
Metoclopramide
Domperidone
Haloperidol
Levomepromazine (methotrimeprazine)
3080 mg
3080 mg
1.510 mg
12.575 mg
816 mg
Antimuscarinics
Prochlorperazine
530 mg
Antihistamines
Cyclizine
50150 mg
Steroids
Dexamethasone
820 mg
TABLE 18 CAUSES
RETURNING TRAVELLER
Type of cause
Condition
Enteral infection
Non-infectious
CMV, cytomegalovirus.
Examination
General features
37
GAH_C01
12/9/10
9:02
Page 38
If resuscitation is required,
start immediately.
Abdomen
Stool
Submit a stool sample for
microbiological assessment
(microscopy, culture, sensitivity;
testing for ova, cysts and
parasites; C. difficile toxin).
A freshly evacuated specimen needs
to be examined if amoebiasis is
suspected.
Imaging
Abdominal radiograph, looking in
particular for colonic dilatation,
toxic megacolon being defined as
a diameter of the transverse colon
>6 cm (Fig. 12).
Sigmoidoscopy
Rigid sigmoidoscopy with rectal
biopsy should be performed if the
patient has bloody diarrhoea or
is passing mucopus, suggesting
dysentery or colitis, and particularly
in an immunocompromised
individual, where there may be
viral colitis (eg caused by CMV)
or cryptosporidial infection. This
allows direct visualisation of colonic
mucosa and biopsy (see Fig. 4).
Other investigations
The need for other investigations
is determined by clinical progress
and the results of routine testing, eg
serological tests for amoebiasis and
yersiniosis (also for coeliac disease)
may be appropriate.
Investigation
38
GAH_C01
12/9/10
9:02
Page 39
Management
Further comments
Is there a public health issue: are
others affected, and was the airlines
caterer rather than the roadside food
vendor in Bangkok to blame?
Introduction
Haematemesis is due to bleeding
from the oesophagus, stomach or
duodenum; it is very unusual for
bleeding distal to the duodenojejunal
junction to return to the stomach.
The history of melaena (dark tarry
faeces containing blood) indicates
the patient has had a gastrointestinal
haemorrhage from a lesion
anywhere from the oesophagus to
the terminal ileum (Table 19), with
TABLE 19 DIFFERENTIAL
DIAGNOSIS OF MELAENA
Common
Less common
Rare
Duodenal ulceration
Gastric ulceration/erosions
Gastric carcinoma
NSAID-induced enteropathy
Oesophagitis
Oesophageal/gastric varices
Dieulafoy lesion1
Angiodysplasia
Aortoenteric fistulae2
Small bowel tumour
1. Bleeding from an arteriole protruding through a minute mucosal defect, usually in the
proximal stomach.
2. Rare complication of abdominal aortic aneurysm repair, very rare in other circumstances.
39
GAH_C01
12/9/10
9:02
Page 40
Drug history
Persistent life-threatening
bleeding can occur with
melaena in the absence of
haematemesis.
40
Fig. 13 Schematic diagram of the anatomy following a partial gastrectomy (Billroth I).
GAH_C01
12/9/10
9:02
Page 41
Fig. 14 Schematic diagram of the anatomy following a partial gastrectomy with a gastroenterostomy
(Billroth II).
Pulse: tachycardia.
Hypotension/postural hypotension
(lying and sitting): if BP falls
significantly on sitting up, then the
patients homeostatic mechanisms
are nearly overwhelmed.
JVP: can you see it?
Abdomen
Apart from confirming the presence
of melaena on rectal examination,
abdominal examination will
be normal in most cases of
gastrointestinal bleeding, but
check for any abdominal mass
and for features of portal
hypertension/chronic liver
disease (see Section 1.2.2).
Comorbidities
The presence of ischaemic heart
disease, chronic pulmonary disease
and/or organ failure (renal, cardiac
or liver) increases the morbidity
and mortality associated with
gastrointestinal bleeding. Risk scores
have been developed to take these
into account in determining the
management of gastrointestinal
bleeding.
If resuscitation is required,
start immediately.
TABLE 20 CLINICAL
Clinical parameter
Examination
General features
(ROCKALL
SCORE)
Score
0
Age (years)
Shock
Systolic BP (mmHg)
Pulse (bpm)
Comorbidity
<60
6079
>80
<100
<100
Nil
>100
>100
Other
<100
Total score
Mortality (%)
0
0.2
2
5
Cardiac failure
IHD
4
24
Renal failure
Liver failure
6
49
41
GAH_C01
12/9/10
9:02
Page 42
Investigation
Gastrointestinal endoscopy
Upper gastrointestinal
endoscopy is useful in the
management of upper gastrointestinal
bleeding but does not replace
adequate resuscitation and
management of comorbid illnesses.
It is dangerous to perform
endoscopy on a patient who is
hypovolaemic.
42
GAH_C01
12/9/10
9:02
Page 43
Venous access
Fig. 17 Varices at the gastro-oesophageal junction with surface ulceration and clot.
Radiological imaging
Most patients with gastrointestinal
bleeding do not require radiological
tests. An abdominal radiograph is
almost never indicated. An erect
CXR is appropriate if a perforation
is suspected (free air under the
diaphragm), if the patient has
vomited and there is the possibility
of aspiration pneumonia, or if
required for anaesthetic assessment
prior to theatre. In the very rare
circumstance of the patient with
an abdominal aortic graft and the
possibility of an aortoenteric fistula,
then CT of the abdomen may be
indicated.
Management
43
GAH_C01
12/9/10
9:02
Page 44
Is surgical or radiological
intervention required?
Inform surgical colleagues sooner
rather than later: as a rule of thumb
discuss any patient who merits
emergency endoscopy, has an initial
Rockall score over 3 or requires
significant transfusion. The decision
regarding the appropriateness and
timing of surgery can be very
difficult and should be made by
experienced, senior colleagues. Early
surgery, especially in older patients,
is associated with a lower overall
mortality and may be indicated for
those who meet criteria such as:
transfusion requirements of
>8 units (age <60 years) or >4 units
(age >60 years) in 24 hours; or
one rebleed; or
TABLE 21 THE
Cause
Frequency (%)
60
20
5
5
10
Further comments
Other treatments
There is no strong evidence for the
initiation of acid suppression until
after an endoscopic diagnosis has
been made. High-dose intravenous
proton pump inhibitor reduces
rebleeding in those who have
received endoscopic treatment of
44
Upper gastrointestinal
endoscopy can be both
diagnostic and therapeutic in the
patient with bleeding oesophageal
varices and should be performed as
soon as it is safe to do so when these
are suspected.
Pharmacological measures to
reduce variceal haemorrhage
by reducing splanchnic blood
flow: octreotide and vasopressin
analogues (eg terlipressin 2 mg
iv 4-hourly) should be used
when variceal haemorrhage
is suspected.
A large-volume painless
haematemesis is very suspicious
of oesophageal variceal bleeding,
particularly if there is any indication
of chronic liver disease. However,
portal hypertension and variceal
haemorrhage may occur in patients
without cirrhosis, eg as a result
of portal vein thrombosis (see
Correction of haemostatic/clotting
abnormalities: patients with
decompensated cirrhosis typically
have low platelet counts and a
prolonged prothrombin time.
It is usual practice to attempt to
correct any concomitant vitamin
K deficiency, to maintain platelet
counts above 50 109/L, and to
transfuse 2 units of fresh frozen
GAH_C01
12/9/10
9:02
Page 45
Fig. 18 Oesophageal varices: (a) large varices; (b) banded varices with superficial banding ulcers.
45
GAH_C01
12/9/10
9:02
Page 46
Introduction
Fig. 19 SengstakenBlakemore tube. This particular tube has a gastric (inflated) balloon, an oesophageal
(deflated) balloon, a gastric aspiration channel and an oesophageal aspiration channel. In most cases
tamponade can be achieved by just inflating the gastric balloon. The gastro-oesophageal junction is
40 cm from the mouth.
46
TABLE 22 DIFFERENTIAL
Common
Less common
Rare
Acute appendicitis
Biliary colic/acute
cholecystitis
Small bowel obstruction
Acute pancreatitis
Acute gynaecological
disease (including ectopic
pregnancy)
Gastric volvulus
Myocardial infarction2
Lower lobe pneumonia2
Other medical causes, eg
diabetes, herpes zoster (before
the rash), acute porphyria
(very rare)
GAH_C01
12/9/10
9:02
Page 47
Examination
General features
Vomiting
Type of pain
Pancreatic pain is usually constant,
epigastric and radiates through to
the back. Peptic ulcer pain is often
similar, and there may well be a
preceding history of indigestion,
but pain in the back would be an
unusual feature unless the ulcer
involves the posterior wall of the
duodenum. Biliary pain is typically
colicky, often focused in the right
upper quadrant and epigastrium,
and there may be radiation to the
shoulder or shoulder blade due to
diaphragmatic irritation. Small
bowel disease (obstruction or
infarction) is usually associated
with central or low abdominal pain,
whilst renal colic typically affects
the loin area (sometimes with classic
radiation to the groin). Appendicitis
typically begins with central colicky
abdominal pain that then moves to
the right iliac fossa. Rarely thoracic
problems can present as an acute
abdomen, so remember to check
for radiation in a cardiac pattern,
and for symptoms suggestive of
pneumonia.
Bowels
Absolute constipation (faeces and
flatus) suggests bowel obstruction.
47
GAH_C01
12/9/10
9:02
Page 48
Abdomen
48
Fig. 20 Plain abdominal radiograph showing pancreatic calcification in a patient with chronic
pancreatitis.
Investigation
Routine blood tests
Check FBC (anaemia, leucocytosis),
electrolytes, renal/liver/bone profiles,
amylase, clotting screen, group and
save. An amylase three times the
upper limit of the laboratory
normal range is diagnostic of acute
pancreatitis; lesser elevations are
common in other causes of acute
abdominal pain and are not
diagnostically useful. Check arterial
blood gases if the patient is very ill.
Imaging tests
A plain CXR may demonstrate free
air under the diaphragm if there
is perforation, a pleural effusion
(consider pancreatitis as well as
chest pathology) or occasionally
pneumonia. An abdominal
radiograph may show widespread
small bowel distension, an isolated
(sentinel) loop (associated with
acute pancreatitis) or pancreatic
Abdominal ultrasound
This may be used to visualise
the biliary tree (gallstones, tender
thick-walled gallbladder due to
cholecystitis, or biliary dilatation)
and pancreas (although of limited
use in diagnosing pancreatitis). Free
intra-abdominal fluid can also be
identified.
Abdominal CT scan
The use of CT in acute abdominal
pain is becoming more frequent,
particularly in the diagnosis of
appendicitis (ultrasound is an
alternative), small bowel
obstruction, acute pancreatitis,
as well as in cases of suspected
abdominal aortic aneurysm
(Fig. 21).
GAH_C01
12/9/10
9:02
Page 49
Fig. 21 Abdominal CT scan. (a) Normal pancreas (arrow). (b) Acute pancreatitis: the pancreas is swollen and oedematous (arrow) and a thrombus can be seen in
the splenic vein behind the pancreas ( just below point of arrowhead).
Management
Further comments
Management of acute pancreatitis
In some hospitals patients with
acute pancreatitis are managed on
medical wards by physicians, and
many hospitals have their own
protocols for doing so. Issues to
consider are as follows.
Analgesia: pethidine is preferred
in pancreatitis as morphine may
cause spasm of the sphincter of
Oddi and worsen the condition.
49
GAH_C01
12/9/10
9:02
Page 50
TABLE 23 DIFFERENTIAL
Acute pancreatitis may be due
to alcohol abuse: be vigilant for
signs of alcohol withdrawal and treat
this appropriately (see Section 1.4.3).
1.4.5 Jaundice
Scenario
Common
Less common
Rare
Acute hepatitis B
Acute hepatitis E
Autoimmune chronic
active hepatitis
TABLE 24 DIFFERENTIAL
Common
Less common
Rare
Choledocholithiasis
Carcinoma of pancreas
Chronic pancreatitis
Cholangiocarcinoma
External compression from
malignant hilar lymph nodes
Primary sclerosing
cholangitis
Introduction
Jaundice in adults is very rarely
due to a prehepatic cause
(eg haemolysis); hepatic
(eg parenchymal disease) or
50
GAH_C01
12/9/10
9:02
Page 51
Choledocholithiasis may
present some time after
previous cholecystectomy for
gallstones: this may be due to silent
stones having been missed in the CBD
at the time of operation, or possibly
formation of new stones in situ.
Drug history
It is essential to determine details of
all prescribed and non-prescribed
medications used by the patient
in the 6 weeks before jaundice
developed. Apparently innocent
medications can cause drug-induced
hepatotoxicity, common culprits
including Augmentin (co-amoxiclav)
and ibuprofen. Herbal and Chinese
medications have also been
implicated.
Travel history
Travel is a risk factor for jaundice: it
is essential to know if patients have
been abroad to a country where
hepatitis A or hepatitis E is endemic,
also if they have they been in contact
with anyone else with viral hepatitis.
Fig. 22 Number of units of alcohol present in various alcoholic beverages (10 g of alcohol = 1 unit).
51
GAH_C01
12/9/10
9:02
Page 52
Examination
General features
As always when dealing with an
acute case, the first priority is to
decide if the patient is well, ill, very
ill or nearly dead, and to begin
resuscitation and get help from the
intensive care unit immediately if
required (as described in Sections
1.4.1 and 1.4.3). Then, in a patient
presenting with jaundice, consider
the diagnoses listed in Tables 23 and
24 and look for evidence of:
sepsis (fever, tachycardia,
hypotension, confusion);
malignancy (cachexia,
lymphadenopathy);
chronic liver disease (see
Section 1.2.2);
alcohol withdrawal (agitation,
hallucinations, tremor);
hepatic encephalopathy (see
Section 1.4.6);
Wernickes encephalopathy
(nystagmus, ophthalmoplegia).
pancreatitis or pancreatic
carcinoma.
Liver: usually firm, tender and
enlarged up to 10 cm in acute
alcoholic hepatitis; may be irregular
if there is associated cirrhosis, but
firm irregular hepatomegaly must
raise suspicion of malignancy
(primary or secondary). A hepatic
bruit may be heard in severe
alcoholic hepatitis as well as
with hepatocellular carcinoma.
Splenomegaly: suggests portal
hypertension in this context.
Gallbladder: if palpable,
remember Courvoisiers law,
which states that in the
presence of jaundice an enlarged
gallbladder is unlikely to be due
to gallstones (carcinoma of the
pancreas or the lower biliary tree
are more likely).
Ascites: suggests chronic liver
disease or malignancy.
Melaena: indicates upper
gastrointestinal bleeding.
Investigation
Abdomen
Look in particular for evidence of
the following.
Scars: previous cholecystectomy,
previous resection of colorectal
malignancy, previous surgery for
52
GAH_C01
12/9/10
9:02
Page 53
Further imaging
If there is a focal lesion in the liver
or pancreas, then an abdominal
CT scan should usually be the
next investigation. In contrast, if
ultrasonography suggests biliary
pathology, then either endoscopic
retrograde cholangiopancreatography
(ERCP) (Fig. 23) or magnetic
resonance cholangiopancreatography
(MRCP) (Fig. 24) is indicated. In
centres where both of these tests
are available, ERCP should only
be performed if it is likely that a
therapeutic procedure is likely to be
performed because of the associated
morbidity and mortality.
Tissue biopsy
Broad indications for a liver
biopsy are when the aetiology of
liver disease is unclear, where the
degree of liver damage determines
the treatment (eg hepatitis B or C,
autoimmune hepatitis) or where
the nature of a focal lesion is
unclear.
Fig. 23 (a) Cholangiogram showing the CBD packed with stones. (b) The stones are seen within the
duodenum following a sphincterotomy and trawling of the CBD with a balloon.
Cholangitis
Management
If the patient is very ill, then
resuscitate as described in
Section 1.4.1. Specific management
will depend on the diagnosis.
53
GAH_C01
12/9/10
9:02
Page 54
Accumulation of sedatives
occurs in the presence of
alcoholic hepatitis and/or cirrhosis
and there is a risk of precipitating
encephalopathy: review dosing on a
daily basis and stop if the patient
becomes drowsy.
54
Introduction
Acute liver failure is characterised
by rapid deterioration of liver
function resulting in altered
mentation and coagulopathy in
previously normal individuals:
the simplest definition requires
evidence of coagulopathy, usually
an INR >1.5, and any degree of
encephalopathy in a patient without
pre-existing cirrhosis and with an
illness of <26 weeks duration.
It is most commonly caused by
paracetamol overdose, other
drug-induced liver injury or viral
hepatitis, but in 20% of cases the
GAH_C01
12/9/10
9:02
Page 55
TABLE 25 DIFFERENTIAL
Common
Less common
Rare
Paracetamol (acetaminophen)
overdose
Drug or toxin induced1
Cryptogenic (cause unknown)
Hepatitis A/hepatitis E
Hepatitis B2
Wilsons disease2
Autoimmune chronic
active hepatitis2
Hypotension/shock
Venous outflow obstruction
Hepatic veins (BuddChiari
syndrome)
Hepatic venules (venoocclusive disease)
Weils disease (leptospirosis)
Halothane
Acute fatty liver of pregnancy
TABLE 26 DIFFERENTIAL
DIAGNOSIS OF CONFUSION
Frequency1
Condition
Common
Hypoglycaemia
Urinary or chest infection
Drug side effect/drug withdrawal
Alcohol/alcohol withdrawal
Post ictal
Stroke
Unreported discomfort, eg urinary retention
Any cause of circulatory shock
Any cause of hypoxia
Less common/rare
Occasionally paracetamol
overdose can occur
unintentionally, with the drug taken
over several days for medicinal
purposes. Liver damage due to
paracetamol is potentiated by
concomitant alcoholic liver disease,
malnutrition and some regular
medications, eg phenytoin. Always
take a very careful history of drug use.
55
GAH_C01
12/9/10
9:02
Page 56
TABLE 27 DIFFERENTIAL
DIAGNOSIS OF COMA
Frequency1
Condition
Common
Hypoglycaemia
Opioid toxicity
Head injury2
Post ictal
Subarachnoid haemorrhage
Stroke
Alcohol
Less common/rare
56
(BuddChiari syndrome). In
paracetamol overdose the pain
typically subsides as the patient
gets better.
Examination
General features
GAH_C01
12/9/10
9:02
Page 57
Grades of hepatic
encephalopathy
Grade I: altered mood, impaired
concentration and psychomotor
function.
Investigation
Routine tests in any very ill patient
The onset of confusion or
drowsiness in a patient with
acute liver injury is ominous and
necessitates advice from a liver unit.
Development of bilateral
subconjunctival haemorrhages
seems to be a feature peculiar to
paracetamol-associated liver failure
and should raise suspicion of this
diagnosis in patients presenting late.
Abdomen
Right upper quadrant tenderness
may be present. If the liver cannot
be palpated, or the normal hepatic
dullness cannot be detected by
percussion, this may be indicative
of decreased liver volume due to
massive hepatocyte loss. An enlarged
liver may be seen early in viral
hepatitis or with malignant
infiltration, congestive heart failure
or acute BuddChiari syndrome.
57
GAH_C01
12/9/10
9:02
Page 58
Abdominal imaging
Where the prothrombin time
(PT) in seconds is greater than
the time after a paracetamol overdose
(in hours), eg a PT of 40 seconds
30 hours after the overdose as opposed
to a PT of 50 seconds 60 hours after
the overdose, there is a particular risk
of developing liver failure.
58
Management
Early involvement of specialist
hepatology services is important
in managing patients with acute
liver failure. The key aspects of
management include the following.
Oxygenation: give high-flow
oxygen to maintain arterial
saturation >92%.
Treat/prevent hypovolaemia: use
4.5% albumin (rather than 0.9%
saline in this context).
Treat/prevent hypoglycaemia: give
10% dextrose (or, if needed, and
by a central line, 50% dextrose) at
a rate to keep fingerprick blood
glucose in the range 4 7 mmol/L.
Correct electrolyte abnormalities,
including phosphate: but note
that hyponatraemia is due to
water excess and not to sodium
deficiency and should not be
treated by infusion of saline.
Monitor renal function closely:
renal replacement therapy should
be instituted sooner rather than
later if the patient develops renal
failure.
Avoid unnecessary medications:
in particular NSAIDs, diuretics,
opiates and sedatives.
Enteral or parenteral nutrition:
should be initiated without delay.
N-Acetylcysteine: give 150 mg/kg
in 1 L 5% dextrose over 24 hours
Hepatic encephalopathy
The patients neurological status
must be reviewed regularly: if
hepatic encephalopathy develops,
progression from grade I to grade IV
and development of cerebral oedema
may occur within an hour or two.
Patients who are agitated or
aggressive may need ventilation to
enable care to be given; those with
grade III or IV encephalopathy
should be ventilated electively
because of the risk of cerebral
GAH_C01
12/9/10
9:02
Page 59
Specific treatments
Paracetamol overdose Liver
failure from paracetamol overdose
is preventable if the patient presents
early and N-acetylcysteine is
correctly administered, and this
treatment improves prognosis even
in those who present over 16 hours
afterwards. Following loading
TABLE 28 GUIDELINES
24
Arterial pH <7.3
INR >3
Encephalopathy
Creatinine >200 mol/L
Hypoglycaemia
Arterial pH <7.3
INR >4.5
Encephalopathy
Creatinine >200 mol/L
Paracetamol overdose
If in doubt, give N-acetylcysteine.
Further comments
Criteria for liver transplantation
Urgent hepatic transplantation is
indicated in acute liver failure where
59
GAH_C02
12/9/10
9:03
Page 60
2.1 Oesophageal
disease
2.1.1 Gastro-oesophageal
reflux disease
Aetiology/pathophysiology/
pathology
Reflux of gastric acid into the
lower oesophagus can cause
mucosal injury (reflux oesophagitis).
Chronic reflux oesophagitis may
induce the appearance of ectopic
gastric and intestinal mucosa in
the lower oesophagus (gastric or
intestinal metaplasia), a change
termed Barretts oesophagus
that is considered premalignant
because it is associated with an
increased risk of oesophageal
adenocarcinoma. Chronic reflux
oesophagitis may also lead to
fibrotic healing and the formation
of a peptic stricture.
Incompetence of the lower
oesophageal sphincter is the main
factor in reflux of acid. Gastric
acid secretion is usually normal.
Hiatal hernias, occurring in
1015% of the general population,
are more prevalent with increasing
severity of reflux disease and may
contribute to abnormal reflux by
both reducing basal lower
oesophageal pressure and impairing
effective oesophageal clearance
of acid (Fig. 25).
Reflux may result in a spectrum
of damage to the oesophagus,
ranging from microscopic changes
only through to circumferential
60
Clinical presentation
Common
Burning retrosternal pain aggravated
by lying down or bending forwards,
and by spicy foods, citrus fruits and
alcohol. Regurgitation of acid, water
brash, chest pain, odynophagia
(painful swallowing) and dysphagia.
Epidemiology
Gastro-oesophageal reflux
symptoms (retrosternal
burning, acid regurgitation)
are common and occur on a
daily basis in up to 10% of the
population. Only about one-third
of patients will have endoscopic
evidence of oesophagitis. Peptic
strictures occur in 723% of
patients with untreated reflux
oesophagitis.
Uncommon
Haematemesis or iron-deficiency
anaemia.
Physical signs
Usually no physical signs.
Occasionally, severe acid reflux into
the pharynx can lead to hoarseness
and pharyngitis. Weight loss if there
GAH_C02
12/9/10
9:03
Page 61
Radiotherapy-induced
oesophagitis (eg treatment of
bronchial carcinoma).
Investigation/staging
Long-term
Treatment
Gastroscopy is mandatory
in those who have alarm
symptoms (haematemesis,
dysphasia, weight loss, anaemia)
and desirable in middle-aged or
elderly patients with new onset of
symptoms.
Patients in their twenties or early
thirties who require infrequent,
intermittent courses of acidsuppressing therapy probably do not
warrant endoscopy, but those with
persistent symptoms requiring longterm therapy should be examined
to define the extent and severity
of oesophagitis (or presence of
Barretts oesophagus) and thereby
guide therapy.
Differential diagnosis
Common differential diagnoses
include the following.
Cardiac pain.
Oesophageal carcinoma: benignlooking peptic strictures must be
brushed and biopsied to exclude
malignancy.
Infections with herpes simplex or
Candida.
Drugs (eg alendronate, NSAIDs,
ferrous sulphate, potassium salts)
that may cause oesophagitis.
Emergency
Patients with dysphagia need rapid
assessment with either a barium or
Gastrograffin swallow followed
by endoscopy. Barium swallow is
usually performed first to define
the position and extent of any
stricture. Patients with a stricture
demonstrated on barium swallow
should proceed to endoscopy for
biopsy and brushings to exclude
malignancy. All patients with benign
peptic oesophageal strictures should
be commenced on a proton pump
inhibitor (PPI) to prevent further
acid reflux and damage. Concurrent
oesophagitis per se may contribute
to the dysphagia. If symptoms are
significant, oesophageal dilatation
should be performed. Initial
improvement occurs in >80%,
although one-third require repeat
dilatation within 12 months despite
acid-suppression therapy.
Short-term
Treatment of uncomplicated
gastro-oesophageal reflux should be
directed at alleviating the symptoms.
A graded approach is usual, starting
with antacids and lifestyle measures
(stopping smoking, avoiding
precipitants), then histamine
H2 receptor antagonists with or
without prokinetic agents (eg
metoclopramide), and finally
PPIs or antireflux surgery. When
oesophagitis is demonstrated
endoscopically or microscopically,
aggressive initial treatment with a
PPI, followed by an H2 receptor
antagonist, and eventually
symptomatic treatment with
antacids should be initiated. Healing
of oesophagitis (grade II or more
severe) is desirable to prevent
Complications
Common
Most patients with gastro oesophageal
reflux disease can be well controlled
with acid-suppression therapy.
Relapse of symptoms is common
on withdrawal of treatment. It is
estimated that up to one-quarter
of patients with untreated reflux
oesophagitis will develop strictures.
Long-term acid reflux is important
in the development of Barretts
oesophagus.
Prognosis
The advent of the powerful PPI
agents means the vast majority
of patients can be rendered
asymptomatic. Antireflux surgery is
an alternative where medical therapy
fails, or if the patient is young and
unwilling to take medications
indefinitely. Although reflux disease
has little effect on life expectancy, it
may predispose to the development
of oesophageal adenocarcinoma.
Long-term severe reflux predisposes
to Barretts oesophagus with its
malignant potential.
Prevention
Aggressive control of acid
secretion is likely to be important
61
GAH_C02
12/9/10
9:03
Page 62
Clinical presentation
Common
Treatment
Disease associations
Scleroderma may result in
severe oesophagitis and stricture
formation.
FURTHER READING
Katz PO, ed. Gastroesophageal reflux
disease. Gastroenterol. Clin. North Am.
1999; 28.
Vigneri S, Termini R, Leandro G, et al.
A comparison of five maintenance
therapies for reflux esophagitis.
N. Engl. J. Med. 1995; 333: 110610.
Physical signs
Often absent, but weight loss may be
evident.
Investigation/staging
Barium or Gastrograffin swallow
Epidemiology
Achalasia is rare, with an
approximate incidence of 1 in
100,000 in the West. Less severe
forms of oesophageal dysmotility
may be more widespread and may
account for some cases of apparent
62
Medical
Explanation and reassurance are
essential. Prokinetic agents such
as metoclopramide may provide
some symptomatic relief. Calcium
antagonists (eg nifedipine 10 mg
tds) or nitrates (eg isosorbide) can
be tried, but response is variable. It
is pragmatic to offer a proton pump
inhibitor to minimise any effect
of gastro-oesophageal reflux.
Endoscopic and surgical treatments
should be explored if achalasia
progresses to cause dysphagia and
regurgitation.
Manometry
The typical pattern of progressive
peristaltic contraction waves in
the oesophagus in response to
swallowing is lost. There may be
diffuse spasm (diffuse oesophageal
spasm) or intense prolonged
contractions (nutcracker
oesophagus). In achalasia the
body of the oesophagus fails to
contract peristaltically and there
is increased pressure at the LOS,
which fails to relax in response to
swallowing.
Intrasphincteric injection of
botulinum toxin
Differential diagnosis
Complications
Common
Risk of oesophageal carcinoma is
increased about 15-fold in patients
with achalasia.
GAH_C02
12/9/10
9:03
Page 63
Prognosis
Over 90% of patients with achalasia
are improved following pneumatic
dilatation or surgical myotomy.
Repeat dilatation is frequently
required.
FURTHER READING
Leyden JE, Moss AC and MacMathuna
P. Endoscopic pneumatic dilation
versus botulinum toxin injection in
the management of primary achalasia.
Cochrane Database Syst Rev 2006; (4):
CD005046.
Seelig MH, DeVault KR, Seelig SK,
et al. Treatment of achalasia: recent
advances in surgery. J. Clin.
Gastroenterol. 1999; 28: 2027.
Epidemiology
Worldwide, squamous cell
carcinoma is most common. There
are geographical variations in its
63
GAH_C02
12/9/10
9:03
Page 64
TABLE 29 RISK
Adenocarcinoma
Smoking
Alcohol
Malnutrition
Achalasia
Postcricoid web1
Familial tylosis2
Barretts oesophagus
Gastro-oesphageal reflux
1. BrownKellyPaterson/PlummerVinson syndrome.
2. Hyperkeratosis of palms of hands and soles of feet.
Clinical presentation
Common
Progressive dysphagia with weight
loss is the usual presentation of
oesophageal cancer. Initially subjects
may have dysphagia only for solids
such as meat and bread, eventually
reporting difficulty swallowing
purees and liquids. May be
discovered as part of the work-up
of iron-deficiency anaemia.
Barretts oesophagus may be
asymptomatic, or it may be
discovered as a result of diagnostic
tests for gastro-oesophageal reflux
symptoms.
64
Uncommon
Dyspepsia or heartburn.
Pain due to local invasion into the
spine or intercostal nerves.
Hoarseness due to involvement
of the recurrent laryngeal nerve
by middle and upper third
oesophageal carcinomas.
Rare
Tracheo-oesophageal fistulae.
Physical signs
Signs may reflect the extent and
duration of disease, with weight loss,
evidence of complications such as
aspiration pneumonia, and rarely
hoarseness due to tumour invasion
of the recurrent laryngeal nerve.
Endoscopic ultrasound
If available this provides more
accurate local staging of the tumour.
Unfortunately most are advanced at
presentation: T3, with invasion
through the oesophageal wall into
the adventitia; or T4, with spread
into adjacent structures, eg aorta,
pulmonary vessels.
Differential diagnosis
Benign oesophageal stricture:
usually obvious at endoscopy,
confirmed with biopsy and
brushings, but repeat sampling if
clinical suspicion but histology
negative.
Gastric carcinoma (usually from
the cardia) invading the lower
oesophagus.
Note that biopsy from a point distal
to the squamouscolumnar junction
(eg from the proximal end of a hiatus
hernia) will lead to a false-positive
diagnosis of Barretts oesophagus.
Investigation/staging
Treatment
Barium or Gastrograffin swallow
This is the initial investigation of
choice for patients presenting with
dysphagia (Fig. 27).
Emergency
Presentation with complete or
near-complete obstruction (liquids/
liquidised food) is not unusual, in
which case dilatation may be needed
at the time of diagnostic endoscopy.
GAH_C02
12/9/10
9:03
Page 65
Short-term
Aim is rapid work-up to select
appropriate candidates (less than
one-third) for curative surgery,
usually with thoracoabdominal
CT and endoscopic ultrasound
if available. Preoperative enteral
or parenteral nutrition and
physiotherapy are important.
Subtotal oesophagectomy with
anastomosis to fashioned gastric
tube is often employed.
Long-term
Palliation indicated in most cases,
with either endoscopic or
radiological positioning of
expandable metal stents, laser
photocoagulation or radiotherapy
(internal or external).
Complications
Oesophagectomy
Anastomosis may leak or dehisce
(has less rich blood supply
compared with rest of intestine).
Oesophageal stent
Perforation during stent placement
and laser photocoagulation. Stent
migration.
Prognosis
Fig. 27 Barium swallow showing an irregular malignant stricture in the distal oesophagus.
Morbidity
Aim with the majority is palliation,
ie ensuring reasonable swallowing.
Mortality
Overall median survival <1 year;
5-year survival rate 5%. Earlier
stage and absence of lymph node
involvement yields better results.
There is 510% mortality with
oesophagectomy.
65
GAH_C02
12/9/10
9:03
Page 66
Prevention
Primary
Aggressive suppression of acid
secretion in patients with Barretts
oesophagus or reflux oesophagitis.
Long-term acid suppression may
arrest or reverse Barretts changes.
FURTHER READING
Allum WH, Griffin SM, Watson A
and Colin-Jones D (on behalf of the
Association of Upper Gastrointestinal
Surgeons of Great Britain and Ireland,
the British Society of Gastroenterology,
and the British Association of Surgical
Oncology). Guidelines for the
management of oesophageal and
gastric cancer. Gut 2002; 50 (Suppl. 5):
v1v23. Full text available at
http://www.bsg.org.uk/
Physical signs
Anaemia.
Epigastric tenderness.
Investigations/staging
Aetiology/pathophysiology/
pathology
Helicobacter pylori infection
and NSAID use are the two most
common aetiological factors. Risk
of peptic ulceration appears to be
higher in NSAID users if they are
also infected with H. pylori. There
are different H. pylori strains, Cag-A
being associated with more severe
gastritis and intestinal metaplasia.
H. pylori is unique in that it
produces a urease that is made
use of in diagnostic tests.
Endoscopy
To establish the diagnosis and to
take biopsies from a gastric ulcer
to ensure it is benign.
Antral and gastric body biopsies
for H. pylori.
Risk of rebleeding can also be
assessed in those presenting with
haematemesis or melaena.
Epidemiology
In the UK, serological testing for
H. pylori shows that up to 50% of
50 year olds and up to 20% of
20 year olds have been infected.
This is a cohort effect and does
not mean that 1% acquire the
infection each year. H. pylori causes
90% of duodenal ulcers and 60%
of gastric ulcers.
The lifetime risk of duodenal ulcer
is 410% and of gastric ulcer
34%, males more than females.
H. pylori detection
There are many methods by
which H. pylori can be identified.
Serological testing for IgA or IgG
antibodies to H. pylori is only useful
if previously untreated. Samples
taken at endoscopy can be subjected
to a CLO test or histological
examination (silver stain) (Figs 29
and 30).
Clinical presentation
Serology cannot be used to
assess whether the infection
has been successfully eradicated with
treatment, as antibodies persist often
for decades.
Common
Epigastric pain or indigestion.
66
13
Uncommon
If present in the pylorus there may
be gastric outlet obstruction with
vomiting.
Rare
Perforation with abdominal pain
and signs of an acute abdomen.
GAH_C02
12/9/10
9:03
Page 67
Long-term
Fig. 29 CLO test. This relies on the fact that H. pylori produces a urease. A gastric biopsy is placed on the
test card. If H. pylori is present, the indicator turns from yellow to red. A result is obtained in 1 hour.
Complications
Perforation and bleeding.
Gastric carcinoma: less than 3% of
gastric ulcers are malignant.
Fig. 30 Histology of gastric mucosal biopsy showing the presence of H. pylori on the epithelial surface.
Differential diagnosis
Prognosis
Treatment
Emergency
See Section 1.4.3. Endoscopic
therapy can be used to try to control
Short-term
Eradication of H. pylori
Triple-drug regimens are effective
in 8095% of cases, eg 7 days of
twice-daily proton pump inhibitor
(PPI), clarithromycin 500 mg
bd or amoxicillin 1 g bd, and
metronidazole 500 mg bd.
Prevention
Primary
Avoidance of NSAIDs and smoking.
Use misoprostol or PPI with an
NSAID.
67
GAH_C02
12/9/10
9:03
Page 68
Disease associations
Gastrinoma is associated with
multiple peptic ulcers. May occur in
isolation or associated with multiple
endocrine neoplasia (MEN) type 1.
FURTHER READING
Malfertheiner P, Megraud F, OMorain
C, et al. Current concepts in the
management of Helicobacter pylori
infection: the Maastricht III Consensus
Report. Gut 2007; 56: 77281.
Clinical presentation
Common
Small superficial tumours are
often asymptomatic. Later
symptoms are weight loss (61%),
abdominal pain (51%), nausea
(34%) and dysphagia (26%). Malaise
due to iron-deficiency anaemia.
Acute upper gastrointestinal
haemorrhage.
Rare
Rostom A, Dube C, Wells G, et al.
Prevention of NSAID-induced
gastroduodenal ulcers. Cochrane
Database Syst Rev 2002; (4): CD002296.
Physical signs
Common
Epidemiology
The highest incidence is in Japan and
China; in the USA, incidence is 10 per
100,000. Overall the incidence is
falling, but adenocarcinoma affecting
the cardia and gastro-oesophageal
junction is becoming more common.
It rarely occurs before the age of
40 years, peaking in the seventies.
68
Treatment
Surgery
Indicated if early tumour confined to
stomach (ie stage I).
Uncommon
Epigastric mass.
Malignant ascites due to
peritoneal seeding.
Rare
Enlarged supraclavicular lymph
node (Virchows).
Chemotherapy
Neoadjuvant chemotherapy
may reduce tumour bulk
and invasion prior to surgery.
Combined surgery and
chemotherapy are better
than chemotherapy alone.
Conservative
Complications
Haemorrhage.
Investigations
FBC: an iron-deficiency anaemia
is present in 42%.
Tumour markers:
carcinoembryonic antigen is
not helpful diagnostically. It is
elevated in 1020% of patients
with resectable tumour.
Endoscopy: essential for
histological diagnosis and
assessment of size and position
of the tumour (Fig. 31).
Prognosis
The 5-year overall survival rates
are poor in the UK at 15%. Stage I
(confined to stomach) with surgery
has a 5-year survival rate of 50% in
the UK and 90% in Japan.
Prevention
Screening by endoscopy is advocated
in Japan, where 4060% of early
gastric cancers can be identified,
but this is not the case in the UK,
Europe and the USA.
GAH_C02
12/9/10
9:03
Page 69
Disease associations
Pernicious anaemia is associated
with a two- to three-fold increased
risk of carcinoma of stomach.
FURTHER READING
Allum WH, Griffin SM, Watson A
and Colin-Jones D (on behalf of the
Association of Upper Gastrointestinal
Surgeons of Great Britain and Ireland,
the British Society of Gastroenterology,
and the British Association of Surgical
Oncology). Guidelines for the
management of oesophageal and
gastric cancer. Gut 2002; 50 (Suppl. 5):
v1v23. Full text available at
http://www.bsg.org.uk/
Leiomyoma
This is a benign tumour of smooth
muscle. Most tumours less than
2 cm are asymptomatic. In contrast,
tumours greater than 2 cm may
ulcerate and cause profuse
gastrointestinal haemorrhage.
Submucosal endoscopic biopsy
is often non-diagnostic, but
Gastrinoma
Gastrinoma causes multiple
duodenal ulcers and is associated
with steatorrhoea due to acidic
destruction of pancreatic lipase. It
may be sporadic or associated with
multiple endocrine neoplasia type 1.
Sporadic tumours are usually single
69
GAH_C02
12/9/10
9:03
Page 70
FURTHER READING
Banks PM. Gastrointestinal
lymphoproliferative disorders.
Histopathology 2007; 50: 4254.
Hong SS, Jung HY, Choi KD, et al.
A prospective analysis of low-grade
gastric malt lymphoma after
Helicobacter pylori eradication.
Helicobacter 2006; 11: 56973.
Fig. 32 Angiodysplastic lesion found in the duodenum of a patient with severe iron-deficiency anaemia.
70
Hereditary haemorrhagic
telangiectasia
This is an autosomal dominant
condition associated with skin and
mucosal haemorrhage. The vascular
lesions commonly occur in the
stomach and small bowel and
GAH_C02
12/9/10
9:03
Page 71
Meckels diverticulum
This congenital abnormality is
present in 0.33% of the population.
It is found on the antimesenteric
border of the small bowel within
100 cm of the ileocaecal valve.
Most are asymptomatic, but 80%
contain ectopic gastric mucosa.
Complications include haemorrhage
(melaena or dark red blood
per rectum), obstruction or
intussusception. The diagnosis is
made by small bowel enema or
technetium-99 scan (which detects
parietal cells).
Epidemiology
Incidence and prevalence are
unknown but may be decreasing
as a result of reduced surgical
intervention for peptic ulcer disease.
Clinical presentation
Common
Chronic diarrhoea or steatorrhoea.
Uncommon
Neurological disorder, eg peripheral
neuropathy, subacute combined
degeneration of the spinal cord
(secondary to B12 deficiency). Folic
acid deficiency in the elderly is
sometimes the only indicator of
malabsorption.
Differential diagnosis
Other causes of diarrhoea and
steatorrhoea (see Sestions 1.1.3
and 1.4.2).
Physical signs
Treatment
Investigation
Bacterial overgrowth
Be alert to the diagnosis in
patients developing diarrhoea who
have a predisposition for this problem,
eg those with structural abnormalities
of the small bowel.
Complications
Malnutrition, neuropathy and
deficiencies of fat-soluble vitamins.
Prognosis
Most of the predisposing conditions
are not correctable, so is often a
chronic recurring condition unless
cyclical antibiotics are employed.
Morbidity probably mostly due to
lack of diagnosis. Unlikely to have
any effect on mortality.
Disease associations
See Table 30.
71
GAH_C02
12/9/10
9:03
Page 72
Hypolactasia
TABLE 30 CAUSES
OF BACTERIAL OVERGROWTH
Anatomical
Functional
Immune deficiency
Autonomic neuropathy
Amyloid
Diabetes mellitus
Systemic sclerosis
Hypogammaglobulinaemia
Achlorhydria
FURTHER READING
Quigley EM and Quera R. Small
intestinal bacterial overgrowth:
roles of antibiotics, prebiotics, and
probiotics. Gastroenterology 2006;
130 (2 Suppl. 1): S78S90.
Singh VV and Toskes PP. Small bowel
bacterial overgrowth: presentation,
diagnosis, and treatment. Curr. Treat.
Options Gastroenterol. 2004; 7: 1928.
Whipples disease
A rare disease caused by Tropheryma
whippelii that usually occurs in
white middle-aged or elderly men.
It is characterised by malabsorption,
migratory polyarthritis, anaemia
and weight loss. Neurological and
cardiac involvement may occur, as
well as pigmentation and clubbing.
Jejunal biopsy shows large foamy
72
Giardiasis
Caused by the flagellated protozoan
Giardia lamblia. It is usually
contracted abroad, although it
can occur in UK. It has faecaloral
transmission and is characterised by
persistent diarrhoea after an acute
diarrhoeal episode. Malabsorption
is unusual but can occur. Diagnosis
is made by finding trophozoites in
jejunal aspiration and biopsy (stool
culture is less sensitive). Tinidazole
2 g as a single dose or metronidazole
800 mg tds for 3 days is very effective.
GAH_C02
12/9/10
9:03
Page 73
duodenum in a Billroth II
gastrectomy, vagal denervation, or
rapid gastric emptying preventing
optimal mixing with pancreatic juices.
FURTHER READING
Nightingale J and Woodward JM
(on behalf of the Small Bowel and
Nutrition Committee of the British
Society of Gastroenterology).
Guidelines for management of
patients with a short bowel. Gut 2006;
55 (Suppl. 4): iv1iv12. Full text available
at http://www.bsg.org.uk/
Marsh grade
Histological findings
0
1
2
3a
3b
3c
Normal
Increased intraepithelial lymphocytes
1+ crypt hyperplasia
2+ partial villous atrophy
2+ subtotal villous atrophy
2+ total villous atrophy
Epidemiology
Coeliac disease was once thought to
be rare but has been shown by large
screening studies in Europe and the
USA to affect 1 in 100200 people.
It is rare in Africa and has not been
TABLE 32 SYMPTOMS
Clinical presentation
Symptoms and signs are as shown in
Table 32.
Common
Less common
Rare
Infertility/amenorrhoea
Bone pain: osteomalacia,
osteoporosis
Dermatitis herpetiformis
Neurological: peripheral
neuropathy, cerebellar
ataxia, etc.
Tetany: hypocalcaemia
Rickets
Bruising and nightblindness: deficiencies of
fat-soluble vitamins A and K
Constipation
73
GAH_C02
12/9/10
9:03
Page 74
Barium follow-through
Blood tests
Differential diagnosis
Investigation
Serology
Anti-gliadin antibodies are
commonly present but have a lower
sensitivity than other serological
markers. The combination of antiendomysial antibody (anti-EMA)
and anti-tissue transglutaminase
antibody (anti-tTG) has a sensitivity
and specificity above 95%. Some
patients have an associated IgA
deficiency that can render these
tests negative as they are IgA based.
However, one of the anti-gliadin
antibodies is IgG based and there
are IgG versions of anti-EMA and
anti-tTG.
Histology
Histological examination of small
bowel biopsies remains the gold
standard for diagnosing coeliac
disease, and should be performed
if the condition is suspected whilst
the subject is on a gluten-containing
diet. Previously jejunal material was
obtained via a Crosby capsule, but
74
Persistence of anti-EMA
6 weeks after starting dietary
therapy suggests non-compliance.
Dietary supplementation
Iron, folate, vitamin D and calcium
supplementation may be required at
diagnosis depending on the degree
of abnormality and symptoms.
Immunosuppression
Treatment
Gluten-free diet
Strict withdrawal of gluten from
the diet is advocated: 85% of cases
respond to this and relapse on its
reintroduction. Physicians and
dietitians should be involved in
educating the patient about the
condition, and membership of
Coeliac UK encouraged. Compliance
can be assessed using serial antibody
measurements, which usually
diminish once gluten is withdrawn
from the diet. The small intestinal
mucosa may take many years to
normalise, if at all, and therefore
GAH_C02
12/9/10
9:03
Page 75
TABLE 33 CONDITIONS
Condition
Dermatitis herpetiformis
Type 1 diabetes mellitus
Thyroid disease
Irritable bowel syndrome
Idiopathic dilated cardiomyopathy
Primary biliary cirrhosis
Rheumatoid arthritis
Sjgrens syndrome
Infertility
Osteoporosis
IgA deficiency
Epilepsy (with cerebral calcifications)
Downs syndrome
70
37
Up to 7
5
36
3
3
3
23
3
2.5
2.3
2
Complications
Bone disease in up to 40%
(osteoporosis and osteomalacia).
Increased risk of gastrointestinal
malignancy (enteropathyassociated T-cell lymphoma,
squamous cell carcinoma of the
pharynx and oesophagus, and
small intestinal adenocarcinoma).
Disease associations
Associated diseases are shown in
Table 33.
FURTHER READING
Al-Toma A, Verbeek WH and Mulder CJ.
Update on the management of
refractory coeliac disease. J.
Gastrointest. Liver Dis. 2007; 16: 5763.
Prognosis
Mortality
Mortality is increased in coeliac
disease, chiefly due to an excess of
malignant disease. Adoption of a
gluten-free diet appears to protect
against this complication and results
in a normal lifespan.
Aetiology/pathophysiology/
pathology
This is an acute inflammatory
process of the pancreas with variable
involvement of other regional tissues
or remote organ systems. Once the
process has started, the degree of
pancreatic necrosis is variable and
in part related to proteolytic
autodigestion of the gland.
The most common causes of acute
pancreatitis in the UK are gallstones
(3050%) and alcohol (1040%), but
a significant number of cases do not
have an immediately obvious cause
(15%).
Clinical presentation
Common
Abdominal pain, usually epigastric
and radiating through to the back.
Vomiting.
Hypovolaemia, circulatory
collapse, hypoxia.
75
GAH_C02
12/9/10
9:03
Page 76
Uncommon
Jaundice suggests the presence of an
associated cholangitis and raises the
probability of gallstones.
Rare
No pain (consider hypothermia).
Physical signs
Common
In mild acute pancreatitis there
may be few physical signs.
Otherwise expect abdominal/
epigastric tenderness or infrequent
or absent bowel sounds.
Assessment of cause
Glasgow/Ranson criteria
Three or more positive criteria,
based on initial admission score and
subsequent repeat tests over 48 hours,
constitutes severe disease.
Uncommon
In patients with more severe
disease there will be clinical
evidence of hypovolaemia and
systemic inflammation. Other
features may include:
mental state (the patient may be
agitated and delirious);
tachycardia;
hypotension;
fever;
peripheral cyanosis;
Differential diagnosis
This includes perforated peptic
ulcer, intestinal ischaemia/infarction,
ectopic pregnancy, aortic dissection,
myocardial infarction (see
Section 1.4.4).
peritonism.
Rare
Cullens sign (periumbilical bruising)
and Grey Turners sign (flank
bruising) are both associated with
severe haemorrhagic pancreatitis.
Investigation/staging
Diagnosis with serum amylase
Serum amylase is diagnostic of
pancreatitis if more than three times
the upper limit of normal for the
laboratory. Alternatives include
serum lipase and possibly urinary
trypsinogen.
Assessment of severity
Severity can be assessed using the
Glasgow/Ranson criteria.
76
Fig. 34 Pancreatic pseudocyst complicating acute pancreatitis. The stomach is stretched over the large
pseudocyst (arrow). (Courtesy of Dr N.D. Derbyshire, Royal Berkshire Hospital.)
GAH_C02
12/9/10
9:03
Page 77
TABLE 34 CONTRAST-ENHANCED CT
GRADING OF
ACUTE PANCREATITIS
Grade
CT morphology
Normal
Treatment
Emergency
Resuscitation Intravenous fluids
to restore circulating volmue (may
require central venous pressure
monitoring) and oxygen. Patients
with severe pancreatitis (as defined
above) should be managed in either
a high-dependency unit or an
intensive care unit.
Short-term
Endoscopic retrograde
cholangiopancreatography
(ERCP) If gallstones are present
on ultrasound or if the patient has
clinical features of cholangitis (fever,
jaundice), early ERCP (ie within the
first 24 hours) should be considered
on the principle that early relief
of biliary obstruction will reduce
complications. If this is not
Fig. 35 Drainage of a pancreatic pseudocyst into the stomach showing the internal transgastric drain in
situ. (Courtesy of Dr N.D. Derbyshire, Royal Berkshire Hospital.)
77
GAH_C02
12/9/10
9:03
Page 78
Long-term
Management of the appropriate risk
factor helps to prevent recurrent
attacks:
abstinence from alcohol;
early cholecystectomy if gallstones
are confirmed to be the underlying
cause;
control lipids/calcium.
Complications
TABLE 35 PROGNOSIS
Scoring system
Glasgow/Ranson criteria1
<2
35
>6
APACHE II 2
<9
>13
Mortality (%)
5
10
60
low
high
Common
Pancreatic pseudocyst/abscess
(5%): persistent pain and/or fever
suggests the development of a
pancreatic pseudocyst or abscess,
as does a persistently raised
amylase.
Paralytic ileus.
Hypovolaemic shock.
Renal failure.
Hypocalcaemia.
Hypoxia.
Uncommon
Prevention
Primary
Other than a reduction in alcohol
consumption there is little scope
for primary prevention of acute
pancreatitis.
Secondary
Cholecystectomy.
Ascites.
FURTHER READING
Prognosis
Thirty per cent of patients have
recurrent attacks, which are more
likely in pancreatitis related to
alcohol consumption. Overall
78
Aetiology/pathophysiology/
pathology
Chronic pancreatitis is defined as a
progressive inflammatory condition
of the pancreas characterised by
irreversible changes that typically
cause pain and/or permanent loss
of both endocrine and exocrine
function. This evolution usually
occurs over a period of several years.
Clinically, this helps to distinguish
between acute first-onset
pancreatitis, recurrent acute
pancreatitis and chronic pancreatitis.
However, it is often difficult to
classify pancreatitis: histology is not
routinely used, but it does remain
the gold standard for the early stage
of chronic pancreatitis, where there
is loss of normal acinar cells, fibrosis
and lymphocytic infiltrate.
Rare
External pancreatic fistulae may
follow percutaneous drainage of
pseudocyst.
GAH_C02
12/9/10
9:03
Page 79
Epidemiology
Rare. Estimated incidence varies
between 1.6 and 23 per 100,000,
with prevalence about four times
higher.
Clinical presentation
Physical signs
Common
There are no specific physical signs
until there has been sufficient
destruction of the gland to cause
pancreatic failure (either exocrine
or endocrine).
Common
Abdominal pain, typically epigastric
radiating through to the back. It is
often precipitated by eating fatty
foods or drinking alcohol.
Uncommon
Erythema ab igne may be evident
on the anterior abdominal wall in
patients with chronic pancreatic
pain.
Uncommon
Exocrine pancreatic insufficiency:
steatorrhoea and weight loss.
Endocrine pancreatic
insufficiency: diabetes.
Rare
Jaundice: due to either fibrosis
encroaching on the common bile
Investigation/staging
Serum amylase is often normal or
at most only modestly elevated
and therefore only of value during
attacks of acute abdominal pain
to exclude acute-on-chronic
pancreatitis (although serum
amylase level may not reach
diagnostic levels).
Fig. 36 Chronic pancreatitis shown on ERCP: (a) dilated pancreatic duct with loss of side branches in severe disease compared with (b) minimal duct changes.
79
GAH_C02
12/9/10
9:03
Page 80
Others
Pancreatic diabetes has the same
complication rate as any other type
of diabetes and therefore requires
global assessment: although
hyperglycaemia may be relatively
mild, early treatment with insulin is
often useful. Ensure abstinence from
alcohol.
Common
Malabsorption and diabetes.
Differential diagnosis
Treatment
Pancreatic enzyme replacement
Preparations such as Creon and
Pancrex often improve both the pain
and the malabsorption associated
with chronic pancreatitis. Some
patients have a partial response
and may require addition of acid
suppression to reduce enzyme
destruction by the stomach.
Analgesia
Where pain is the dominant
feature, opiate analgesia and local
approaches such as coeliac axis
block may be necessary. EUS can
be employed to guide coeliac plexus
blockade.
80
Uncommon
Common bile duct obstruction.
Antioxidants
Complications
Tests of endocrine pancreatic
function
FURTHER READING
Rare
Pancreatic carcinoma.
Prognosis
Morbidity
Although diabetes and
malabsorption can be treated,
chronic pain is a major source of
morbidity with associated loss of
employment, depression and opiate
dependence.
Mortality
Survival is reduced in all causes of
chronic pancreatitis. Outcomes are
often worse in alcoholic chronic
pancreatitis, with death in this group
being due to many different causes.
Prevention
Secondary
Abstinence from alcohol along with
medical management as outlined
above will usually lead to clinical
stabilisation.
Epidemiology
Pancreatic carcinoma is the fourth
commonest gastointestinal tumour.
Its incidence is increasing in the
Western world, in the range of
510 per 100,000. Male to female
ratio is 1.3:1. It is rare in patients
under 45 years old.
Clinical presentation
Common
Painless cholestatic jaundice
associated with varying degrees
of pruritus, pale stools and dark
urine due to common bile duct
obstruction.
Weight loss.
Abdominal pain.
Uncommon
Vomiting (from duodenal
obstruction).
Malignant ascites.
Unexplained exocrine pancreatic
insufficiency.
GAH_C02
12/9/10
9:03
Page 81
Rare
Venous thrombosis
(thrombophlebitis migrans).
Diabetes.
Physical signs
Common
Jaundice and cachexia.
Uncommon
Palpable gallbladder (Courvoisiers
sign).
Palpable mass.
Ascites.
Investigation/staging
Blood tests
Routine blood tests show nonspecific changes related to biliary
obstruction. The pancreaticobiliary
tumour marker CA19-9 may be
elevated but is not specific to
pancreatic tumours.
Non-invasive imaging
Abdominal ultrasound May show
a dilated biliary tree. A pancreatic
mass may be demonstrated, but the
absence of a mass on ultrasound
does not exclude a pancreatic
malignancy. Dilatation of both
the common bile duct and the
pancreatic duct is highly suggestive
of a carcinoma of the pancreatic
head (double duct sign).
Fig. 37 CT scan showing carcinoma of the head of the pancreas with distal pancreatic duct dilatation.
(Courtesy of Dr N.D. Derbyshire, Royal Berkshire Hospital.)
Invasive imaging
Endoscopic retrograde
cholangiopancreatography (ERCP)
Duodenoscopy allows assessment
of the ampulla of Vater and
identification and biopsy of a lesion
if present. ERCP allows diagnosis
and placement of an endobiliary
stent to allow relief from biliary
obstruction in patients (the
majority) who are unsuitable
for surgical resection. Carries a
significant morbidity and mortality.
Percutaneous transhepatic
cholangiography (PTC) For cases
where ERCP has failed or is not
possible, eg previous surgery such
as Polya gastrectomy or Roux-en-Y
biliary reconstruction; also allows
placement of an endobiliary stent.
Endoscopic ultrasound (EUS) CT
and transabdominal ultrasound can
miss lesions <2 cm in size. EUS is
particularly good at detecting these
Differential diagnosis
Of acute cholestasis:
choledocholithiasis, intrahepatic
cholestasis (eg drug reaction).
Of pancreatic mass: ampullary
carcinoma (tumour arising from
the ampulla of Vater), which has a
better prognosis.
81
GAH_C02
12/9/10
9:03
Page 82
Treatment
This depends on suitability
for surgery. Patients who have
resectable disease and who will
be operated on in a timely fashion
may not require stenting. Routine
preoperative biliary decompression
has not been shown to be beneficial.
Short-term
Those with extremely symptomatic
jaundice may require stenting prior
to surgery, but the route of delivery
and type of stent is controversial.
The British Society of
Gastroenterology guidelines suggest
plastic stenting via ERCP, although
many centres prefer metal stenting
via PTC as there is a lower risk of
pancreatitis and therefore less risk
of unnecessary delay.
82
Prognosis
Morbidity
Most patients with pancreatic
cancer have incurable disease at
presentation and will experience
pain in addition to progressive
anorexia and weight loss.
2.4.4 Neuroendocrine
tumours
Aetiology/pathophysiology/
pathology
Tumours arising from the
specialised neuroendocrine tissue of
the pancreas or intestine. They are
rare but important differentials for
a variety of clinical syndromes
including pancreatic mass lesions.
Mortality
Investigation/staging
Stool weight
This is performed on a normal
diet and then repeated fasting to
distinguish secretory from osmotic
diarrhoea.
FURTHER READING
Choti MA. Adjuvant therapy for
pancreatic cancer: the debate
continues. N. Engl. J. Med. 2004;
350: 124951.
Pancreatic Section of the British
Society of Gastroenterology, Pancreatic
Society of Great Britain and Ireland,
Association of Upper Gastrointestinal
Surgeons of Great Britain and Ireland,
Royal College of Pathologists and
Special Interest Group for GastroIntestinal Radiology. Guidelines for
the management of patients with
pancreatic cancer, periampullary and
ampullary carcinomas. Gut 2005; 54
(Suppl. 5): v1v16. Full text available at
http://www.bsg.org.uk/
Blood tests
Serum chromogranin A has an
uncertain role but is produced by
all cells derived from the neural
crest and may be raised in any
neuroendocrine tumour. Most
neuroendocrine hormones can now
be identified on a fasting serum
sample. In the case of gastrin it is
GAH_C02
12/9/10
9:03
Page 83
TABLE 36 NEUROENDOCRINE
SYMPTOM COMPLEX
2.5.1 Choledocholithiasis
Tumour type
Symptoms
Insulinoma
Gastrinoma (Zollinger
Ellison syndrome)
Glucagonoma
VIPoma (WermerMorrison
syndrome)
Somatostatinoma
Non-functioning
Pancreatic mass
Pancreatic imaging
VIPoma: octreotide.
Treatment
Long-term or according to stage
Surgical resection is probably the
best treatment if a focal tumour can
be identified and the patient is fit
enough. Medical treatment depends
on the secreted hormone.
Epidemiology
Overall prevalence is 10%. Incidence
increases with age and is twice as
high in women as in men.
Clinical presentation
Glucagonoma: octreotide.
Common
Prognosis
Octreotide scan
Radiolabelled somatostatin binds to
receptors on many neuroendocrine
tumour cells and can help to localise
primary and secondary tumour
deposits.
Aetiology/pathophysiology/
pathology
FURTHER READING
Kulke MH. New developments in
the treatment of gastrointestinal
neuroendocrine tumours. Curr. Oncol.
Rep. 2007; 9: 17783.
Ramage JK, Davies AHG, Ardill J,
et al. (on behalf of UKNETwork
for neuroendocrine tumours).
Guidelines for the management
of gastroenteropancreatic
neuroendocrine (including carcinoid)
tumours. Gut 2005; 54 (Suppl. 4):
iv1iv16. Full text available at
http://www.bsg.org.uk/
Uncommon
Obstructive jaundice without
symptoms.
Gallstone ileus.
83
GAH_C02
12/9/10
9:03
Page 84
Physical signs
Common
There may be no signs, although
jaundice may be present with right
upper quadrant tenderness. In acute
cholecystitis look for Murphys sign.
Rare
The presence of splenomegaly
suggests haemolytic anaemia with
secondary pigmented common bile
duct (CBD) stones.
Investigations
Fig. 38 ERCP showing a stone in the CBD.
Blood tests
FBC and reticulocyte count: an
elevated white cell count occurs
with cholangitis; macrocytic
anaemia and elevated reticulocyte
count suggests haemolysis.
Liver biochemistry: classically
elevated bilirubin and ALP/GGT;
rarely in acute biliary obstruction,
aspartate transaminase (AST)/
alanine transaminase (ALT) may
be >1000 U/L.
Ultrasound
The preferred investigation for
detecting stones in the gallbladder,
but remember that the sensitivity for
stones in the CBD is only 70% and
the only sign may be duct dilatation.
84
Endoscopic retrograde
cholangiopancreatography
Endoscopic retrograde
cholangiopancreatography (ERCP)
can both confirm that a stone is
causing biliary obstruction (Fig. 38)
and be employed therapeutically to
remove stones. It will also identify
any distal CBD stricture, benign or
malignant, that may have resulted in
proximal stone formation. However,
ERCP does carry significant risks
and so magnetic resonance
cholangiopancreatography (MRCP)
(see below) should be considered
first (if available) in patients who
do not require immediate/urgent
therapeutic intervention or if
there is diagnostic uncertainty.
Magnetic resonance
cholangiopancreatography
This is a non-invasive method of
imaging the CBD and pancreatic
duct without the need for contrast
Differential diagnosis
Other causes of biliary obstruction
such as tumour or congenital
abnormalities such as choledochal
cysts.
Treatment
Emergency
Emergency early ERCP (within
72 hours) with removal of CBD
stones is indicated in patients with
acute pancreatitis associated with
obstructive jaundice (see Section
1.4.5). An alternative approach is
laparoscopic exploration of the
GAH_C02
12/9/10
9:03
Page 85
FURTHER READING
Beckingham IJ. ABC of diseases of liver,
pancreas and biliary system: gallstone
disease. BMJ 2001; 322: 914.
Johnson CD. ABC of the upper
gastrointestinal tract: upper
abdominal pain gall bladder.
BMJ 2001; 323: 11703.
Fig. 39 Plain abdominal radiograph showing a plastic stent within the CBD.
Short-term
Endoscopic removal of stones
A sphincterotomy or balloon
sphincteroplasty (cutting or dilating
the sphincter of Oddi with a balloon)
is performed and the CBD trawled
with either a balloon or basket
to remove the stones. The
sphincterotomy allows any retained
material to pass. There is a significant
risk of acute pancreatitis, bleeding
or duodenal perforation, with a
0.51% mortality. Larger stones may
require crushing with a mechanical
lithotriptor or, alternatively, a stent
can be inserted to allow bile
drainage and a further attempt at
removal at a later date. Stenting
often causes the stones to shrink
over time. Occasionally a nasobiliary
drain is required to provide
temporary biliary decompression.
Long-term
Interval laparoscopic
cholecystectomy in patients for
Complications
Cholangitis and secondary
septicaemia are common. Prolonged
asymptomatic biliary obstruction
can rarely lead to secondary biliary
cirrhosis.
Prognosis
Good if CBD stones are removed.
Disease associations
Haemolytic anaemia (eg sickle
cell) or spherocytosis leading to
pigmented large or intrahepatic
stones.
Ileal disease/resection, which
interrupts enterohepatic
circulation of bile acids.
Epidemiology
Females account for 90% of cases
and most present between the ages
85
GAH_C02
12/9/10
9:03
Page 86
Clinical presentation
Common
Asymptomatic (diagnosed
as a result of investigation for
abnormal liver function tests).
Itching.
Lethargy.
Anti-mitochondrial antibody
This is present in 95% of cases and
is specific for PBC. Individuals with
anti-mitochondrial antibody (AMA)
and normal liver histology will
eventually develop PBC. Patients
with AMA-negative biopsy-proven
PBC, although rare, behave in the
same clinical manner as AMApositive patients. Anti-nuclear
antibodies and/or smooth muscle
antibodies are more frequently
positive in AMA-negative PBC.
Uncommon
Jaundice.
Haematemesis (from varices).
Abdominal distension (ascites).
Confusion (hepatic
encephalopathy).
Hepatocellular carcinoma.
Immunoglobulins
Physical signs
Common
Liver biopsy
Uncommon
Late signs of portal hypertension
(ascites and hepatic encephalopathy).
Investigations
Liver biochemistry
High alkaline phosphatase and mild
increase in alanine transaminase.
Rising bilirubin is a marker of poor
prognosis. Falling albumin and
rising prothrombin time only occur
at a very late stage in the disease as
it is a biliary cirrhosis.
Treatment
Short-term
Ursodeoxycholic acid Its role is
controversial but it appears to delay
time to transplantation and death in
late-stage disease. It may improve
itching. Treatment at a dose of
1015 mg/kg should be directed to
symptomatic patients.
Other immunosuppressives
Steroids, azathioprine, ciclosporin
and methotrexate have not
convincingly been shown to be
effective.
Itching Responds to colestyramine.
If persistent, other drugs worth
trying include rifampicin,
benzodiazepines, ondansetron,
serotonin antagonists and naltrexone
(opiate antagonist).
Long-term
Liver transplantation Patients who
develop signs of decompensated liver
disease or in whom bilirubin is
greater than 100 mol/L should be
referred to a liver unit if
appropriate. Recurrence in hepatic
grafts occurs, but this does not have
an adverse effect on outcome in the
first 510 years.
Complications
In PBC the changes in the liver
are focal so a liver biopsy is
not useful for staging liver disease.
Furthermore, diagnosis does not
usually require liver biopsy because of
the specificity of AMA for this disease.
Differential diagnosis
Large bile duct obstruction.
Sclerosing cholangitis.
86
Prognosis
Variable and unpredictable. Some
asymptomatic patients may have a
normal life expectancy. Symptoms
generally develop within 27 years,
with subsequent life expectancy
varying from 2 to 10 years.
GAH_C02
12/9/10
9:03
Page 87
Fig. 40 Liver biopsy of a patient with primary biliary cirrhosis showing (a) portal tract with lymphocytic infiltration and loss of bile ducts, (b) granuloma and
(c) progression to biliary cirrhosis.
Disease associations
Other autoimmune conditions:
rheumatoid arthritis, CREST
syndrome (calcinosis, Raynauds
disease, esophagus (hypomotility),
sclerodactyly, telangiectasia),
hypothyroidism, sicca syndrome
(dry mouth and eyes) and coeliac
disease.
FURTHER READING
Charatcharoenwitthaya P and Lindor
KD. Current concepts in the
pathogenesis of primary biliary
cirrhosis. Ann. Hepatol. 2005; 4: 16175.
Kaplan MM and Gershwin ME. Primary
biliary cirrhosis. N. Engl. J. Med. 2005;
353: 126173.
Epidemiology
Prevalence is 6 per 100,000: 70%
are male and the average age at
diagnosis is 40 years.
Clinical presentation
Fatigue, intermittent jaundice,
pruritus, right upper quadrant
pain, or no symptoms but abnormal
liver biochemistry (often noted in
patients with ulcerative colitis or
Crohns disease).
87
GAH_C02
12/9/10
9:04
Page 88
Physical signs
There are no signs in about 50% of
symptomatic patients. Jaundice and
hepatomegaly or splenomegaly may
be present.
Investigations
Liver biochemistry
High alkaline phosphatase/glutamyltransferase. Mild elevations
in serum transaminases (aspartate
transaminase/alanine transaminase).
Bilirubin may be raised. A low
albumin and raised prothrombin
time are only found in late-stage
disease (biliary cirrhosis).
Cholangiography
Percutaneous transhepatic
cholangiography or ERCP show
multiple irregular stricturing and
dilatation (beading) of intrahepatic
ducts (Fig. 41), with or without
extrahepatic stricture.
Liver biopsy
May be normal. Periductal onion
skin fibrosis and inflammation with
expansion of portal tracts, bile duct
proliferation and portal oedema.
Late progressive fibrosis with loss
of bile ducts (Fig. 42).
Fig. 41 ERCP showing classical beading of the intrahepatic bile ducts in PSC.
Differential diagnosis
Secondary sclerosing cholangitis
due to cytomegalovirus or
Cryptosporidium infection in
AIDS.
Previous bile duct surgery.
Bile duct stones causing cholangitis.
Treatment
There is no curative therapy.
Fig. 42 Liver biopsy showing (a) normal portal tract (bile duct, hepatic artery and portal vein) and (b) periductal sclerosis, onion skin fibrosis typical of PSC.
88
GAH_C02
12/9/10
9:04
Page 89
Management of complications
Disease associations
Pregnancy
Intrahepatic cholestasis of
pregnancy (ICP) affects about
0.7% of pregnancies in the UK
and is associated with prematurity,
fetal distress and intrauterine death.
It is characterised by pruritus,
mostly in the third trimester, and
diagnosis is based on the presence
of itch in association with elevated
levels of serum bile acids and in
the absence of other skin diseases.
Current medical management
is with ursodeoxycholic acid, a
hydrophilic bile acid that alters
the composition of the bile acid
pool in maternal blood. When
ICP is diagnosed, ursodeoxycholic
acid coupled with close
maternalfetal surveillance
is indicated.
Ursodeoxycholic acid
Improves liver biochemistry but
probably has no effect on histology
or survival. Steroids, azathioprine,
methotrexate and ciclosporin have
not been shown to have any effect
on disease outcome.
Liver transplantation
Indicated for end-stage biliary
cirrhosis. Cholangiocarcinoma
is a contraindication.
Complications
These include cholangitis, common
bile duct or intrahepatic stones,
extrahepatic biliary strictures, biliary
cirrhosis with portal hypertension,
cholangiocarcinoma (occurs in
1030%, more commonly if the
patient has ulcerative colitis) and
colorectal carcinoma (25% lifetime
risk, especially if the patient has
ulcerative colitis). Most of these
complications present as increasing
jaundice.
It can be difficult to
differentiate a benign biliary
stricture from a cholangiocarcinoma,
even after cholangiography and
cytology of brushings from the
stricture.
Prognosis
This is variable. In symptomatic
patients the median survival
from presentation to death or
transplantation is 12 years; 75%
of asymptomatic patients are alive
at 15 years.
FURTHER READING
Maggs JR and Chapman RW. Sclerosing
cholangitis. Curr. Opin. Gastroenterol.
2007; 23: 31016.
Olsson R, Boberg KM, de Muckadell OS,
et al. High-dose ursodeoxycholic acid
in primary sclerosing cholangitis:
a 5-year multicenter, randomized,
controlled study. Gastroenterology
2005; 129: 146472.
Inherited
Sepsis
Jaundice associated with
cholestatic liver biochemistry
(elevated alkaline phosphatase and
-glutamyltransferase) is common in
patients with extrabiliary bacterial
infections, particularly on the
intensive care unit. Differential
diagnosis is from cholestasis due
to TPN, gallstones and drugs.
Treatment is of the underlying
condition.
2.5.5 Cholangiocarcinoma
Aetiology/pathophysiology/
pathology
Chronic inflammation and bile
duct stasis are associated with
increased risk of developing
cholangiocarcinoma, which is a
malignant adenocarcinoma of the
biliary tree with three main
distributions.
1. Intrahepatic or peripheral
tumours arising from bile ducts
within the liver, usually mass
lesions.
2. Extrahepatic tumours that are
classified as proximal (near the
89
GAH_C02
12/9/10
9:04
Page 90
Epidemiology
Cholangiocarcinomas comprise
510% of malignant hepatic
tumours and are more common
with increasing age (most patients
>60 years). The incidence is
increasing in the Western world
(cause unknown). Intrahepatic
cholangiocarcinoma may be
mistaken for a liver mass and
therefore be under-reported.
Clinical presentation
The patient is often asymptomatic
until a late stage, when symptoms
include biliary obstruction, fever,
weight loss and vague abdominal
pain. Some patients describe itching
before jaundice becomes clinically
apparent.
Physical signs
Jaundice, with or without
hepatomegaly.
Weight loss.
Biliary obstruction is usually
proximal to the cystic duct,
so the gallbladder is not usually
palpable (negative Courvoisiers
sign).
Ultrasound/CT
Liver biochemistry
Elevated bilirubin/alkaline
phosphatase and glutamyltransferase.
Endoscopic retrograde
cholangiopancreatography
Investigations
Tumour markers
CA19-9 rises, but does so in many
causes of jaundice (benign and
malignant) giving a low sensitivity
90
Fig. 43 ERCP showing a cholangiocarcinoma with dilatation of the CBD above the stricture.
Percutaneous transhepatic
cholangiography
In the presence of a lower common
bile duct (CBD) stricture it may not
be possible to cannulate the papilla
endoscopically and the biliary tree
has to be accessed percutaneously
using percutaneous transhepatic
cholangiography (PTC) (Fig. 44).
PTC is also particularly useful in
patients with proximal strictures
or Klatskin tumours.
Endoscopic ultrasound
Has been used to take tissue
samples by fine-needle aspiration.
The use of miniprobes allows further
assessment of biliary strictures by
intraductal ultrasound in some
centres.
Differential diagnosis
Extrahepatic tumours must
be differentiated from benign
strictures, eg chronic pancreatitis,
GAH_C02
12/9/10
9:04
Page 91
Long-term
Fig. 44 PTC showing a stricture in the CBD.
Treatment
Short-term
Relief of biliary obstruction with a
stent placed percutaneously (Fig. 45)
Fig. 45 (a) A high CBD stricture with dilated intrahepatic ducts above. A percutaneously inserted guidewire can be seen crossing the stricture and passing out of
the biliary tree into the duodenum. (b) A metal stent has been placed through the stricture allowing contrast to pass into the duodenum.
91
GAH_C02
12/9/10
9:04
Page 92
Complications
Secondary bacterial cholangitis, with
or without a blocked stent.
Prognosis
This is poor, with an overall survival
rate of 4053% at 1 year and
10 19% at 2 years.
92
Disease associations
Well-recognised associations are
primary sclerosing cholangitis,
parasitic infections with liver
flukes such as Clonorchis and
Opisthorchis (South-east Asia)
and recurrent bacterial cholangitis
with hepatolithiasis. Exposure
to thorium dioxide (thorotrast),
1-antitrypsin deficiency and
choledochal cysts have also been
described in association with
cholangiocarcinoma.
Aetiology/pathophysiology/
pathology
FURTHER READING
Khan SA, Davidson BR, Goldin R, et al.
Guidelines for the diagnosis and
treatment of cholangiocarcinoma:
consensus document. Gut 2002; 51
(Suppl. 6): vi1vi9. Full text available
at http://www.bsg.org.uk/
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD. Cholangiocarcinoma.
Lancet 2005; 366: 130314.
GAH_C02
12/9/10
9:04
Page 93
Prevention
TABLE 37 CAUSES
Type of agent
Pathogen
Comment
Viruses
Rotavirus
Norwalk
Preformed toxins
Staphylococcus
Bacillus cereus
Intestinal production
of enterotoxins
Vibrio cholerae
Vibrio parahaemolyticus
Invasive bacterial
infection
E. coli 0157:H7
Salmonella, Shigella,
Campylobacter
Parasites
Giardia intestinalis
Entamoeba histolytica
Epidemiology
Worldwide outbreaks, although
poorer parts of the world have
higher rates of endemic infection.
Investigation
Stool and vomitus should
be collected and analysed for
pathogens by microscopy, culture
and toxin testing. Food poisoning
is a notifiable illness, for obvious
public health reasons.
Treatment
Epidemiology
Travellers to endemic areas in
the tropics, subtropics and poor
countries with inadequate sanitation
and food hygeine practices are most
affected. Salmonella infection is
endemic in poultry in the UK, and
undercooked or raw eggs and
chicken are a common cause of
infection. E. coli strain 0157:H7
is endemic in cattle and causes
outbreaks associated with ingestion
of contaminated beef.
Emergency
Clinical presentation
Vomiting and diarhoea following
exposure are the typical features.
The main danger of acute
gastroenteritis is dehydration and
its consequences, which can include
life-threatening circulatory collapse,
especially in children and in the old
and infirm.
Physical signs
Dehydration is the most likely sign.
Rectal examination may reveal
Complications
Reactive arthritis may develop
after a self-limited episode of
food poisoning. GuillainBarr
syndrome may follow infection
with Campylobacter species.
Clinical presentation
The incubation period is 35 days.
Dysentery typically causes severe,
cramping abdominal pain and
diarrhoea, which may be bloody.
There is frequently associated
malaise, headache and myalgia.
Infection with E. coli strain 0157:H7
may be associated with severe renal
dysfunction and haemolysis, and
may be rapidly fatal. Bacterial
dysentery may be indistinguishable
93
GAH_C02
12/9/10
9:04
Page 94
Sigmoidoscopic and
histological appearances
in gastrointestinal infections
and idiopathic IBD may be
indistinguishable, and the two
conditions can also coexist.
Complications
Bacterial dysentery may cause
Reiters syndrome (uveitis or
conjunctivitis, urethritis and
arthritis). GuillainBarr syndrome
may follow infection with
Campylobacter species. Salmonella
infection may become systemic
(eg causing osteomyelitis or septic
arthritis), and a chronic carrier
state associated with colonisation
of the biliary tree is sometimes
established.
Treatment
Fluoroquinolones such as
ciprofloxacin are usually highly
effective. Haemolyticuraemic
syndrome caused by E. coli 0157:H7
infection requires high-intensity
supportive treatment.
2.6.3 Antibiotic-associated
diarrhoea
Aetiology/pathophysiology/
pathology
Use of antibiotics alters the enteric
bacterial population and frequently
causes diarrhoea. In some cases this
94
is caused by overgrowth of
enterotoxin-producing Clostridium
difficile. Most antibiotics are
implicated, including clindamycin,
with the widespread use of thirdgeneration cephalosporins and
broad-spectrum penicillins
responsible for many cases.
Clinical presentation
Diarrhoea may be mild, with
frequent watery stools, or more
severe, with passage of blood and
mucus and a marked systemic
inflammatory response (fever,
tachycardia, hypotension). The
most severe consequence of
toxigenic C. difficile infection,
pseudomembranous colitis, may
lead to intestinal perforation and
is life-threatening.
Investigations
C. difficile can be cultured from the
stool and its enterotoxins can be
detected by a sensitive and rapid
enzyme-linked immunosorbent assay
(ELISA). Sigmoidoscopy reveals
punctate yellow-white plaques
adhering to inflamed mucosa in
pseudomembranous colitis.
FURTHER READING
Bricker E, Garg R, Nelson R, et al.
Antibiotic treatment for Clostridium
difficile-associated diarrhea in adults.
Cochrane Database Syst Rev 2005; (1):
CD004610.
Hurley BW and Nguyen CC. The
spectrum of pseudomembranous
enterocolitis and antibiotic-associated
diarrhea. Arch. Intern. Med. 2002; 162:
217784.
Clinical presentation
Giardiasis is spread by the fecaloral
route and by ingesting contaminated
water. The organism is relatively
resistant to chlorine. Infection
typically causes nausea and
diarrhoea with excessive flatus after
an incubation period of 14 weeks.
Malabsorption may occur, with pale,
bulky, offensive stools and weight
loss. Symptoms may persist for
months.
Pinworm infection is spread by the
fecaloral route from human to
human. It is particularly prevalent
among children and may cause
GAH_C02
12/9/10
9:04
Page 95
Investigations
Complications
Treatment
Metronidazole or tinidazole are
highly effective for giardiasis, while
pinworm infections are treated with
mebendazole or albendazole.
Household contacts should be
treated.
Clinical presentation
The incubation period for amoebic
dysentery is 14 weeks. Symptoms
range from mild diarrhoea to
severe bloody diarrhoea (colonic
ulceration). Amoebic liver abscess
may present many months after
infection with abdominal pain,
fever and abnormal liver
function tests.
Investigations
Dysentery is diagnosed by
examination of the stool, which may
demonstrate live parasites, or by
rectal biopsy or serology. Amoebic
abscesses are visualised by imaging,
Treatment
Metronidazole is effective in
treating amoebic dysentery.
Liver abscesses should be treated
with metronidazole followed by
diloxanide to eliminate carriage
of the organism.
Gastroenteritits caused
by unusual organisms,
oropharyngeal candidiasis, and severe
and persistent herpesvirus infection
raise the possibility of HIV infection.
95
GAH_C02
12/9/10
9:04
Page 96
Investigations
Blood tests
Fig. 47 Histological specimen from Crohns colitis showing intense inflammation and granuloma.
Epidemiology
Incidence is 68 per 100,000 and
prevalence is 2656 per 100,000 in
northern Europe, the USA and
Australia. Slightly more common
in females. There is a bimodal age
incidence: 1540 years is most
common, with a second peak at
around 70 years of age. Ten per
cent of patients have a first-degree
relative with the disease. The
risk for siblings is 30-fold increased
compared with the general
population. Smoking increases
relative risk three-fold.
96
Clinical presentation
Other tests
Common
Diarrhoea, abdominal pain and
weight loss (often >10% body mass)
are all expected, with Crohns
disease the presumed diagnosis in a
young patient with this triad. May
be associated with general malaise,
lassitude, fever and anorexia. A
careful history may reveal a lengthy
preceding history of bowel upset, a
previous diagnosis of irritable bowel
syndrome, or previous perianal
disease (fissure or abscess).
Rare
Sigmoidoscopy/colonoscopy can
show colonic or ileal inflammation
(may be patchy), granulomas on
biopsy and is the investigation of
choice. Small bowel follow-through
can show segmental inflammation,
strictures and fistulae (Fig. 48). MRI
scanning is particularly useful for
assessing complex perianal disease,
including fistulae.
Differential diagnosis
Physical signs
Common
There may be few physical signs, or
the patient may be thin and unwell
with clubbing, aphthous ulceration,
abdominal tenderness, and perianal
skin tags, ulceration or fistulae.
Uncommon
Abdominal mass.
Treatment
Rare
Emergency
GAH_C02
12/9/10
9:04
Page 97
Fig. 48 Barium follow-through showing several tight strictures in the terminal ileum in a patient with
Crohns disease.
Short-term
Corticosteroids In severe disease
start hydrocortisone 100 mg iv qid.
Following clinical response, or if the
attack is less severe, commence oral
prednisolone at 3040 mg daily and
taper down by approximately 5 mg
per fortnight depending on clinical
progress; 70% will be in remission
in 34 months. Budesonide, a
topically acting steroid with high
potency and extensive first-pass
metabolism, is equivalent to
prednisolone in inducing remission
in terminal ileal disease and has
fewer side effects, but is much more
expensive and relapse rates within
1 year are disappointingly high.
5-Aminosalicylic acids These
compounds have only marginal
benefit in acute disease.
Dietary Elemental and polymeric
diets containing low-molecularweight nutrients may induce
remission in up to 70% of patients
(particularly in small bowel disease).
Long-term
About 50% of Crohns disease
patients will have relapsed 1 year
after initial treatment.
5-Aminosalicylic acids Have at
best a modest effect in maintaining
remission, with the postsurgical
subgroup benefiting most.
Azathioprine This
immunosuppressant has been
shown to induce remission in
steroid-resistant and steroiddependent patients, to reduce
relapse rates (including post
surgery), and to have steroid-sparing
effects. It takes 612 weeks to
achieve its effects. Side effects
include bone marrow suppression,
liver dysfunction (dose dependent)
and pancreatitis (idiosyncratic).
Patients should have FBC checked
Complications
Common
Intestinal obstruction Usually
subacute. May be due to active
disease causing oedema and
narrowing, or to chronic fibrotic
stricture. The former usually
responds to steroids.
97
GAH_C02
12/9/10
9:04
Page 98
FURTHER READING
Fig. 49 Terminal ileum resected from a patient with Crohns disease showing linear ulceration and
pseudopolyps.
Prognosis
Malabsorption Vitamin B12
deficiency and bile salt diarrhoea
are caused by terminal ileal disease.
Extensive involvement of the small
bowel or surgical resections result
in generalised malabsorption
(short bowel syndrome). Bacterial
overgrowth secondary to
enteroenteric fistulae or strictures
results in fat malabsorption.
Perforations Contained perforations
result in abdominal, pelvic and
ischiorectal abscesses and require
drainage.
Uncommon/rare
Chronic blood loss causing
iron-deficiency anaemia.
Massive rectal bleeding, almost
always secondary to colonic
disease.
Toxic megacolon can occur, but is
less common than in ulcerative
colitis.
98
Morbidity
Some patients experience
considerable morbidity from
general ill-health, pain, malnutrition,
fistulous disease, abscess formation,
repeated surgery or steroid side
effects, but most are maintained
relatively symptom-free.
Mortality
Overall mortality is twice that
for the general population. Those
diagnosed with the disease before
the age of 20 have more than
10 times the standardised
mortality ratio.
Prevention
Cessation of smoking is of benefit in
active disease and reduces the risk of
relapse.
Disease associations
Weak association with primary
sclerosing cholangitis, arthralgia and
arthritis; also with HLA-B27.
GAH_C02
12/9/10
9:04
Page 99
Uncommon
Toxic megacolon, arthritis, iritis and
skin rashes (erythema nodosum,
pyoderma gangrenosum).
Investigations/staging
Fig. 50 Histology of ulcerative colitis showing inflammatory infiltrate within the mucosa.
Clinical presentation
Epidemiology
Common
Barium enema
Physical signs
Colonoscopy
The investigation of choice in
ulcerative colitis: may show
inflammation extending from the
rectum to the proximal extent of
disease (Fig. 52). In severe disease
this should be limited to flexible
sigmoidoscopy due to the increased
risk of perforation.
Differential diagnosis
Fig. 51 Barium enema showing ulcerative colitis extending to the splenic flexure.
99
GAH_C02
12/9/10
9:04
Page 100
Complications
Common complications include
malnutrition, steroid-induced side
effects, arthralgias, arthritis, skin
rash. Less common are uveitis, toxic
megacolon and perforation or sepsis.
Malignancy (colorectal carcinoma)
is rare.
Prognosis
Fig. 52 Endoscopic appearance of (a) normal colon and (b) inflamed colon.
Treatment
Emergency
Patients who are very ill will require
emergency admission to hospital for
resuscitation followed by treatment
as described in Sections 1.4.2 and
1.4.4.
Short-term
In mild to moderate disease,
high-dose 5-aminosalicylic acid
compounds (4 g/day) may induce
remission. The addition of topical
preparations can result in more
rapid resolution of rectal bleeding
and are the first-line treatment of
choice in proctitis and colitis not
100
Long-term
5-Aminosalicylic acid compounds
can maintain remission in most
patients. In patients who have
frequent relapses or become steroid
dependent, immunosuppression
Morbidity
About 25% of patients experience
only one attack, 40% are in
remission in any one year, and a
minority have unremitting disease.
About 30% of patients ultimately
undergo colectomy. The longer a
patient remains in remission, the
better the chance of remaining in
remission.
Mortality
Overall mortality is not increased
compared with healthy controls,
possibly due to a lower incidence
of smoking.
Prevention
Secondary prevention is with
5-aminosalicylic acid compounds
and azathioprine.
GAH_C02
12/9/10
9:04
Page 101
Disease associations
Physical signs
Prognosis
FURTHER READING
Carter MJ, Lobo AJ and Travis SPL (on
behalf of the IBD Section of the British
Society of Gastroenterology).
Guidelines for the management of
inflammatory bowel disease in adults.
Gut 2004; 53 (Suppl. 5): v1v16. Full text
available at http://www.bsg.org.uk/
Podolsky DK. Inflammatory bowel
disease. N. Engl. J. Med. 2002; 347:
41729.
Stein RB and Hanauer SB. Medical
therapy for inflammatory bowel
disease. Gastroenterol. Clin. North Am.
1999; 28: 297321.
Disease associations
Investigations/staging
Serum inflammatory markers,
macroscopic appearance at
colonoscopy and barium enema
are usually normal. Coeliac
antibodies should be checked
and duodenal biopsies arranged
if these are positive. Microscopic
changes in the colon (raised
intraepithelial lymphocytes or a
thick subendothelial collagen band)
are diagnostic, but there may be a
40% false-negative rate if only leftsided biopsies are taken, so samples
should also be taken from the
ascending colon.
Epidemiology
Occurs typically in middle-aged and
elderly women. More common than
originally thought, with combined
incidence of about 810 per
100,000.
Clinical presentation
Most commonly with persistent
watery diarrhoea. Less commonly
weight loss and abdominal pain may
be seen in cases with coexisting
coeliac disease.
Treatment
The condition may be self-limiting.
Antidiarrhoeal agents (eg
loperamide) may be sufficient in
mild disease. 5-Aminosalicylic acid
compounds may be of benefit in
mild to moderate disease, with
improvement seen in up to 50% of
cases. Bismuth subsalicylate has
been advocated, but trial data are
limited and there remain concerns
over potential toxic side effects. In
resistant cases budesonide (a potent
corticosteroid with high first-pass
metabolism and thus low systemic
side-effect profile) seems to be
more efficacious than conventional
corticosteroid therapy with
prednisolone. Colestyramine
may be of value, with some
case series reporting incidence
of concomitant bile salt
malabsorption as high as 60%.
There are no good data for any
of the mentioned drugs in
maintenance of remission.
FURTHER READING
Chande N, McDonald JW and
MacDonald JK. Interventions for
treating lymphocytic colitis. Cochrane
Database Syst Rev 2007; Jan 24:
CD006096.
Stroehlein R. Microscopic colitis. Curr.
Opin. Gastroenterol. 2004; 20: 2731.
Aetiology/pathophysiology/
pathology
The hallmark of the functional
gastrointestinal disorders is altered
(usually increased) visceral pain
sensitivity. This may be associated
with increased release of 5hydroxytryptamine (5HT, serotonin)
from enterochromaffin cells in the
gut, but central (psychosocial,
neurohumoral) factors may be
important, and it has also been
suggested that alterations in the
intestinal bacterial flora may be
involved. This is supported by the
high incidence of patients presenting
with irritable bowel syndrome
following culture-positive
gastroenteritis, use of broadspectrum antibiotics or pelvic
surgery. The role of stress is
uncertain, but there is a higher
101
GAH_C02
12/9/10
9:04
Page 102
TABLE 38 THE
Classification
Examples
Oesophageal disorders
Globus
Functional heartburn
Functional dysphagia
Gastroduodenal disorders
Functional dyspepsia
Functional vomiting
Bowel disorders
Biliary disorders
Anorectal disorders
Epidemiology
The prevalence of the functional
bowel disorders depends entirely on
definition. It is estimated that only
10 50% of patients with functional
gut symptoms consult medical
practitioners, yet this represents as
much as 5% of all general practice
consultations in the UK and up to
40% of gastroenterology referrals.
There is a female to male
predominance of 23:1. About 75%
of patients diagnosed with irritable
bowel syndrome will continue to
have chronic disease.
Clinical presentation
Common
The agreed definition of irritable
bowel syndrome is as follows: At
least 12 weeks, which need not be
consecutive, in the preceding 12
months of abdominal discomfort or
pain that has two of the following
three features: relieved with
defecation; and/or onset associated
with a change in frequency of stool;
and/or onset associated with a
change in form (appearance)
of stool.
102
dysphagia;
anorexia and/or weight loss;
mouth ulcers;
nocturnal diarrhoea;
rectal bleeding.
Physical signs
There are no characteristic physical
signs.
Differential diagnosis
The following should always
be considered: coeliac disease,
hypolactasia, inflammatory bowel
disease, giardiasis, depressive illness,
gastrointestinal malignancy and
thyroid disease (hyperthyroidism
and hypothyroidism). The diffential
diagnosis for chronic diarrhoea is
described in Section 1.1.3.
Treatment
Prognosis
Investigation
The extent of clinical investigation
must be tailored to the individual
patient. A detailed history (including
a good dietary history) is central to
GAH_C02
12/9/10
9:04
Page 103
FURTHER READING
Carter MJ, Lobo AJ and Travis SPL
(on behalf of the IBD Section of the
British Society of Gastroenterology).
Guidelines for the management of
inflammatory bowel disease in adults.
Gut 2004; 53 (Suppl. 5): v1v16. Full text
available at http://www.bsg.org.uk/
TABLE 39 TREATMENTS
Main symptom
Treatments
Diarrhoea
Constipation
Pain/bloating
Clinical presentation
Most commonly an incidental
finding at colonoscopy, but
sometimes can present with iron-
BOWEL SYNDROME
Hamartomatous polyps
Polyps found during
colonoscopy for investigation of
iron-deficieny anaemia may not be the
cause but merely an incidental finding.
Differential diagnosis
Not all colonic polyps carry a
significantly increased risk of
colorectal cancer.
Hyperplastic polyps
These are diminutive polyps, usually
less than 5 mm in diameter, found in
the distal colon and rectum. They
are not neoplastic and carry no
significant risk of colorectal cancer.
Hyperplastic polyps found beyond
the splenic flexure should be
followed up as they may be serrated
Inflammatory pseudopolyps
Representing islands of regenerative
mucosa in a chronically inflamed
bowel, these are seen in Crohns
disease and ulcerative colitis. They
carry no malignant potential.
Treatment
Colonoscopic polypectomy is
recommended for all adenomatous
polyps. Further surveillance for
these patients is discussed in
Section 2.9.2.
103
GAH_C02
12/9/10
9:04
Page 104
Complications
Colorectal carcinoma.
FURTHER READING
Levine JS and Ahnen DJ. Clinical
practice: adenomatous polyps of the
colon. N. Engl. J. Med. 2006; 355: 25517.
Aetiology/pathophysiology/
pathology
There are several conditions that
are recognised to predispose to
colorectal cancer.
Ulcerative colitis
Patients with a 10-year history of
colitis extending proximal to the
splenic flexure are at increased risk
of colorectal carcinoma. They should
be offered surveillance colonoscopy
with random pancolonic biopsies
to detect dysplastic change (see
Prevention).
Family history
There is a family history in 14%
of new cases of colorectal cancer.
Lifetime risk can be calculated
based on family history and
surveillance recommended
accordingly (Table 40).
104
Fig. 53 The colonic adenomacarcinoma sequence. DCC (deleted in colon cancer), APC, MLH1 and MSH2
are genes.
Epidemiology
Familial adenomatous
polyposis (FAP): autosomal
dominant; hundreds of
adenomatous polyps are
seen throughout the colon
and evident from an early age;
the risk of neoplasia is such
that prophylactic colectomy is
performed before the age of 20.
Clinical presentation
Common
Change in bowel habit: new-onset
constipation or spurious diarrhoea.
Iron-deficiency anaemia.
Hereditary non-polyposis
colon cancer (HNPCC): this
is inherited in an autosomal
dominant fashion and is due to
mutations in DNA mismatch
repair genes; individuals at risk
are offered colonoscopic
screening.
TABLE 40 FAMILY
CANCER. THERE IS
Rectal bleeding.
Uncommon
Large bowel obstruction:
constipation, pain and vomiting.
Evidence of metastatic disease
(ascites).
AT A RISK OF
IN
12
OR GREATER
Lifetime risk
None
One first-degree relative >45 years
One first-degree and one second-degree relative
One first-degree relative <45 years
Two first-degree relatives (any age)
Dominant inheritance (eg HNPCC)
1 in 40
1 in 17
1 in 12
1 in 10
1 in 6
1 in 2
GAH_C02
12/9/10
9:04
Page 105
Weight loss.
Abdominal pain.
Anorexia.
Physical signs
Common
In most cases there will be no
diagnostic physical signs.
Uncommon
Palpable abdominal mass.
Signs of iron deficiency: pallor,
koilonychia, glossitis.
Signs of metastatic disease:
hepatomegaly, ascites.
Fig. 54 Dukes staging for colorectal carcinoma. This was originally used for the staging of rectal cancer
but is now widely adopted for colorectal cancer in general. Stage D was not originally described by Dukes.
Investigation/staging
Dukes staging of colonic carcinoma
(Fig. 54).
Blood tests
FBC, iron indices: may demonstrate
iron-deficiency anaemia.
Tumour markers
Carcinoembryonic antigen (CEA) is
not useful for diagnosis but may be
useful in monitoring the patients
response to treatment and for the
identification of disease relapse.
Fig. 55 Barium enema showing an apple-core lesion of colonic carcinoma in the transverse colon.
Colonoscopy
Barium enema
105
GAH_C02
12/9/10
9:04
Page 106
Differential diagnosis
Diagnoses listed in Table 41 should
be considered.
Treatment
Emergency
TABLE 41 DIFFERENTIAL
Presentation
Diagnoses to consider
Diverticular disease
Irritable bowel syndrome
Inflammatory bowel disease
Gastroenteritis
Thyroid disease
Iron-deficiency anaemia
Rectal bleeding
Short-term
Surgery This is required in most
cases of colorectal cancer. The extent
of bowel resection depends on the
site of the tumour: attempts are
made to resect at least 5 cm of
normal bowel either side of it.
Palliative approaches Although
surgery is the usual treatment for
patients with impending colonic
obstruction, stenting of tumours
with self-expanding metal stents
offers an alternative approach for
the palliative relief of obstruction.
Complications
Large bowel obstruction and
metastatic disease are common.
Prognosis
Mortality
Prognosis following surgery depends
on the histological grade of the
106
OF COLORECTAL CANCER
Dukes stage
A
B
C
Distant metastases
95100
6575
3040
<1
Prevention
Identifying asymptomatic
individuals with premalignant or
early malignant disease offers the
opportunity to reduce the associated
mortality of colorectal carcinoma.
This is loosely referred to as
screening, although it may be
useful to distinguish targeted
screening on the basis of a preexisting disease (surveillance,
eg ulcerative colitis) or positive
family history (case finding) from
population screening of individuals
of average risk.
Surveillance
Indications for surveillance include:
previous diagnosis of colorectal
cancer;
Case finding
Appropriate in those with a
significant positive family history
(see Table 40).
Population screening
Despite continuing controversy,
population screening for colorectal
cancer is shortly to be introduced in
GAH_C02
12/9/10
9:04
Page 107
Epidemiology
The prevalence of diverticular
disease of the colon increases
with age: it is present in 50%
of the population over the age
of 50 years.
Clinical presentation
Common
FURTHER READING
Cairns S and Scholefield JH, eds.
(Developed on behalf of the British
Society of Gastroenterology and the
Association of Coloproctology of Great
Britain and Ireland). Guidelines for
colorectal cancer screening in high
risk groups. Gut 2002; 51 (Suppl. 5):
v1v2. Full text available at
http://www.bsg.org.uk/
Weitz J, Koch M, Debus J, et al. Colorectal
cancer. Lancet 2005; 365: 15365.
Uncommon
Diverticular abscess.
Colovesical fistula.
Colonic stricture: after repeated
episodes of inflammation,
resulting in subacute colonic
obstruction.
Investigation
Barium enema/colonoscopy
Diverticular change may be
demonstrated by either barium
enema or colonoscopy.
Abdominal CT
CT is the best way to demonstrate
abscess formation (Fig. 56).
Colovesical fistulae require a high
index of suspicion (recurrent urinary
tract infections, pneumaturia, etc.)
but may be identified on barium
contrast radiology (Fig. 57).
Differential diagnosis
This includes colonic carcinoma,
colonic ischaemia, inflammatory
bowel disease and irritable bowel
syndrome.
Treatment
Short-term
The management of diverticular
disease is determined by the extent
of symptoms or presence of
complications. Acute diverticulitis
requires intravenous fluids,
antibiotics and analgesics, with
diverticular abscess often requiring
drainage in addition; bleeding will
usually settle with supportive
treatment.
Long-term
Avoidance of constipation (high-fibre
diet, bulking laxatives such as
Normacol, and good fluid intake)
is recommended in the belief
that this may reduce the risk of
complications. Surgery is reserved
for complicated diverticular disease
(ie bleeding, abscess, stricture).
Physical signs
There are no specific physical signs
of diverticular change itself. In acute
diverticulitis or in the presence of a
diverticular abscess there may be left
iliac fossa tenderness or a palpable
mass.
Prognosis
Many patients experience recurrent
diverticulitis or bleeding, but
diverticular change is not a
progressive pathology and there is no
increased risk of colonic neoplasia.
107
GAH_C02
12/9/10
9:04
Page 108
Fig. 56 Diverticular disease: (a) CT scan showing a loop of bowel (lumen in black) with diverticula; (b) adjacent collection (identified by tip of white marker line)
due to a perforated diverticulum adjacent to the bladder.
Clinical presentation
Common
Ischaemic colitis Bloody diarrhoea,
usually of sudden onset and
associated with abdominal pain.
FURTHER READING
Stollman N and Raskin JB. Diverticular
disease of the colon. Lancet 2004; 363:
6319.
108
Epidemiology
Vascular disease in general is
increasing in most developed
countries. Risk factors include age,
male sex, family history, smoking,
diabetes, hypertension,
Uncommon
Mesenteric angina: recurrent
postprandial abdominal pain and
weight loss.
Physical signs
Other features of atheroma: arcus,
xanthelasma.
GAH_C02
12/9/10
9:04
Page 109
Investigation
Radiological
Plain abdominal radiograph:
may show aortic calcification
and colonic mucosal oedema,
often with thumb-printing,
which may be of relatively
limited distribution compared
with other forms of colitis
(eg distal transverse colon
and splenic flexure).
CT or MRI angiography: the
presence of significant stenosis
or occlusion of two out of three
(coeliac axis, superior mesenteric
artery and inferior mesenteric
artery) vessels is suggestive of
significant disease; the superior
mesenteric artery needs to be
involved to justify intervention.
Mesenteric angiography: confirms
the radiological diagnosis
and may allow therapeutic
intervention to be performed
(eg angioplasty or stenting).
Complications
Intestinal strictures and obstruction.
Prognosis
Excess mortality is associated with
other features of vascular disease
(ischaemic heart disease, stroke,
renal failure, etc.). Acute intestinal
infarction carries a high mortality
rate and significant long-term
morbidity, often requiring parenteral
nutrition.
FURTHER READING
Green BT and Tendler DA. Ischemic
colitis: a clinical review. South. Med. J.
2005; 98: 21722.
Treatment
Acute intestinal infarction often
requires emergency surgery for
bowel resection. Lesser degrees of
Clinical presentation
Common
Epidemiology
Differential diagnosis
2.10.1.1 Hepatitis A
Aetiology/pathology
Other
Physical signs
Features of an acute hepatitis
(tender mild hepatomegaly, jaundice)
are common. Splenomegaly is seen
in 15% of cases.
109
GAH_C02
12/9/10
9:04
Page 110
TABLE 43 ANORECTAL
Condition
Aetiology,
pathophysiology,
pathology
DISEASES
Clinical presentation
Investigation
Treatment
Proctoscopy
Flexible sigmoidoscopy:
necessary to exclude other
causes of rectal bleeding (eg
proctitis, rectal cancer, polyps)
In some circumstances
investigation of the more
proximal colon by barium
enema or colonoscopy may
be necessary
Anal fissure
Sigmoidoscopy and
examination under
anaesthetic
Fistula in ano1
1. Fistula in ano may cause faecal incontinence if it passes through the anal sphincter; Crohns disease should always be considered in
patients with recurrent or complex perianal fistulae.
GTN, glyceryl trinitrate.
110
GAH_C02
12/9/10
9:04
Page 111
Fig. 58 Histology of acute viral hepatitis. (a) Unlike cirrhosis the normal hepatic architecture is preserved. (b) Higher power showing mixed (neutrophil and
polymorphonucleocyte) portal tract inflammation and infiltration of the lobule; other findings are hepatocyte necrosis and ballooning of hepatocytes. (c) Hepatitis
B infection with positive immunohistochemical staining for HBsAg in hepatocytes.
Investigation
Liver biochemistry: high serum
transaminases (peak usually
>1000 U/L), with or without
raised serum bilirubin; alkaline
phosphatase raised in cholestatic
phase; normal albumin.
Serology: the presence of hepatitis
A IgM indicates a recent infection
(Fig. 59).
Differential diagnosis
See Table 44.
111
GAH_C02
12/9/10
9:04
Page 112
TABLE 44 DIFFERENTIAL
Common
Uncommon
Viral hepatitis
Halothane
Hepatitis A
Nitrofurantoin
Hepatitis B ( hepatitis D)
Liver infiltration (adenocarcinoma/lymphoma)
Hepatitis E
Venous hepatic outflow obstruction
Seronegative hepatitis
Pregnancy-associated liver disease
Drugs
Wilsons disease
Paracetamol
NSAIDs
Flucloxacillin/Augmentin (co-amoxiclav)
Dextropropoxyphene
Alcoholic hepatitis
Autoimmune chronic active hepatitis
Ischaemic hepatitis (eg heart failure, septic shock)
Prevention
In those with a typical
hepatitis who are seronegative
for hepatitis A and B, be sure to
specifically request hepatitis E testing.
Passive immunisation
Pooled serum immunoglobulin can
be given to close contacts of a case
of hepatitis A within 2 weeks of
exposure.
Treatment
This is supportive, with intravenous
fluids if vomiting. Rare cases of
acute liver failure need special
management.
Complications
Active immunisation
Formalin-inactivated vaccine is
indicated for travellers to high-risk
areas, homosexuals, intravenous
drug users and those with chronic
liver disease. It provides protection
for 510 years.
112
FURTHER READING
Kemmer NM and Miskovsky EP.
Hepatitis A. Infect. Dis. Clin. North Am.
2000; 14: 60515.
Prognosis
Cytomegalovirus
Cytomegalovirus (CMV) can
cause an acute hepatitis, most
commonly in those who are
immunosuppressed. Patients may
be asymptomatic, with hepatitis
recognised solely from elevation of
serum transaminases, but symptoms
can range from fever and malaise to
a devastating illness with jaundice
and other features of CMV infection
including pharyngitis, oesophagitis,
gastroenteritis, pneumonitis,
retinitis and bone marrow
suppression. Diagnosis is by
demonstrating CMV on tissue
biopsy, detection of CMV by PCR
GAH_C02
12/9/10
9:04
Page 113
2.10.2.1 Hepatitis B
EpsteinBarr virus
Other
Other rare causes of viral
hepatitis include herpes simplex,
adenovirus and rubella in the
immunosuppressed. Parvovirus
also rarely causes hepatitis in
association with pancytopenia.
Note that hepatitis C is not a cause
of acute liver disease, but is the
commonest cause of chronic
hepatitis in the world.
FURTHER READING
Aggarwal R and Krawczynski K.
Hepatitis E: an overview and recent
advances in clinical and laboratory
research. J. Gastroenterol. Hepatol.
2000; 15: 920.
Aetiology/pathophysiology/
pathology
Epidemiology
Horizontal transmission is via
parenteral transmission and sexual
contact, and probably by close
contact in young children. Vertical
transmission accounts for the high
rates of infection worldwide. The
prevalence is falling, although
worldwide there are still 350 million
chronic carriers.
Clinical presentation
Common
Most infected individuals are
asymptomatic. Some will have fever,
malaise, nausea and right upper
quadrant pain. Up to 4 months after
exposure there may be self-limiting
jaundice, which rarely lasts more
than 1 month (Fig. 60).
Rare
A cholestatic phase and relapses
are uncommon (unlike hepatitis A).
The presence of immune complexes
containing hepatitis B antigens leads
to extrahepatic manifestations, eg
polyarteritis, glomerulonephritis
and myocarditis.
Physical signs
The acute phase may produce
signs of an acute hepatitis. Signs of
chronic liver disease develop later in
some cases (see Section 1.2.2).
Investigation
Liver biochemistry
High serum transaminases and an
elevated bilirubin may be seen in the
acute phase.
Evidence of infection
Serological markers of HBV infection
are shown in Table 45. During the
acute phase of illness HBV DNA
can be detected in the blood; this is
cleared by 2 months in >90% of cases.
113
GAH_C02
12/9/10
9:04
Page 114
TABLE 45 SEROLOGICAL
Acute hepatitis B
Resolved acute infection
Vaccination
MARKERS OF HEPATITIS
INFECTION
HBsAg
HBeAg
HBsAb
HBcAb (IgG)
+/
Treatment
Neonates
Others
2.10.2.2 Hepatitis C
Complications
Chronicity
Persistence of HBsAg in serum for
longer than 6 months suggests
chronicity. Overall, 10% of adults
and 90% of neonates or those who
become infected in infancy will
become chronic carriers. The carrier
rate in the UK is 0.1% compared
with 1015% in Africa. Chronicity is
less common if the acute attack is
more severe, ie associated with
jaundice.
TABLE 46 INDICATIONS
Prognosis
Good unless acute liver failure ensues.
Prevention
Vaccination along with strategies to
prevent exposure.
114
Aetiology/pathophysiology/
pathology
Hepatitis C virus (HCV) is an
RNA virus that is parenterally
transmitted, most commonly
by percutaneous exposure to
contaminated blood. Sexual
transmission is possible, but not
common. HCV infection occurs
in 28% of infants born to HCVinfected mothers. Most of those
infected develop hepatitis
14160 days after exposure.
Epidemiology
In the UK, 0.10.5% of the
population have been infected, but
in some countries the prevalence is
much higher, eg up to 20% in Egypt.
Clinical presentation
Most cases are asymptomatic:
perhaps 20% develop a mild acute
hepatitic illness, but jaundice is rare
and symptoms are less severe than
with hepatitis A or hepatitis B. In
the long term, 85% of patients fail to
clear the virus and have persistent
viraemia. Many of these develop
slowly progressive chronic liver
disease, and over the course of
2040 years progress from acute
to chronic persistent hepatitis,
to chronic active hepatitis, to
cirrhosis (in 10%) and eventually
hepatocellular carcinoma (14%).
GAH_C02
12/9/10
9:04
Page 115
Physical signs
Investigation
Liver biochemistry
Prevention
FURTHER READING
Cramp M and Rosenberg W. Guidance
on the Treatment of Hepatitis C
Incorporating the Use of Pegylated
Interferons. London, British Society for
Gastroenterology, 2003. Full text
available at http://www.bsg.org.uk/
Evidence of infection
HCV infection is usually diagnosed
by testing for HCV antibodies.
If positive this is followed by
testing for HCV RNA, providing an
independent method of confirming
infection and determining whether
it is persistent.
Treatment
Pegylated interferon alfa with
ribavarin are effective but
expensive and often difficult for
patients to tolerate because of
side effects. They should only be
administered by specialists in
accordance with recognised
protocols.
Clinical presentation
Increasing jaundice and confusion,
ie encephalopathy, often following
known precipitant, eg paracetamol
overdose.
Physical signs
Poland GA and Jacobson RM. Clinical
practice: prevention of hepatitis B with
the hepatitis B vaccine. N. Engl. J. Med.
2004; 351: 28328.
Liver biopsy
The acute hepatitis induced by
HCV is generally less severe than
with the other hepatitis viruses. In
patients with persistent infection the
histological findings can fluctuate,
but scoring systems that typically
quantitate necrosis, inflammation
and fibrosis remain the best
predictors of outcome and are
often used to decide whether to
offer antiviral treatment.
Complications
Common complications include the
following.
Cerebral oedema: occurs in
4070% of patients who develop
grade III/IV hepatic
encephalopathy.
115
GAH_C02
12/9/10
9:04
Page 116
Prognosis
Overall with medical treatment
1040% of patients survive, with
outcome best for paracetamol
overdose and hepatitis A and worst
for non-A non-B hepatitis and
idiosyncratic drug reactions. The
time to onset of encephalopathy is
also a prognostic factor: 35% of
patients with hyperacute failure
survive compared with only 15%
of those with subacute failure.
With such figures, selection for
transplantation is important and
the 1-year survival after super-urgent
liver transplantation probably now
exceeds 6575%.
Prevention
Treatment of paracetamol
overdose with N-acetylcysteine
within 16 hours of overdose can
prevent liver failure.
FURTHER READING
Khan SA, Shah N, Williams R and Jalan
R. Acute liver failure: a review. Clin.
Liver Dis. 2006; 10: 23958.
Fig. 61 Metabolic pathways involved in alcohol metabolism; 85% of alcohol is metabolised via the ADH
pathway. ADH, alcohol dehydrogenase; ALDH2, acetaldehyde dehydrogenase 2; P450-II-E1, cytochrome
P450-II-E1.
Aetiology/pathophysiology/
pathology
Ethanol is primarily oxidised in the
liver (Fig. 61). Men who drink more
than 52 units or 420 g (1 unit of
alcohol is 10 mL by volume, or
8 g by weight, of pure alcohol) per
week and women who drink more
than 35 units (280 g) per week are
at increased risk of alcohol-related
liver disease (ALD). The three most
widely recognised forms of ALD are
alcoholic fatty liver (steatosis), acute
alcoholic hepatitis and alcoholic
cirrhosis. The histology of alcoholic
liver diseases is shown in Fig. 62.
Epidemiology
116
Clinical presentation
Minor alcoholic hepatitis may
be asymptomatic, with elevated
serum transaminases as the only
abnormality, and many people are
diagnosed when they have routine
liver function tests as part of a
medical check-up. Severe alcoholic
hepatitis presents with hepatic
encephalopathy, jaundice, renal
failure or coagulopathy. Other
than those who present with
decompensated liver disease,
patients tend to have non-specific
features such as nausea, vomiting,
abdominal discomfort or diarrhoea.
They may also present with other
sequelae of alcoholism such as
pneumonia, rib fractures, head
injury, pancreatitis, neuropathy
or heart failure.
Physical signs
This depends on the severity.
Mild/moderate alcoholic hepatitis
causes tender hepatomegaly,
with jaundice in 1015%.
Severe alcoholic hepatitis
causes jaundice, ascites, hepatic
encephalopathy and rarely a hepatic
bruit. Parotid gland enlargement
and testicular atrophy are
sometimes seen.
GAH_C02
12/9/10
9:04
Page 117
Fig. 62 Acute alcoholic hepatitis. (a) Pericellular fibrosis around individual hepatocytes giving a chicken-wire appearance. (b) Mallorys hyaline within
hepatocytes. (c) Megamitochondria and fat within hepatocytes. Other features are predominantly neutrophil infiltration around portal tracts and fibrosis around
the hepatic vein. More extensive fibrosis or established cirrhosis may also be present.
Investigation
Assessment of severity
FBC: there is often a leucocytosis
(more common with viral
hepatitis) and a macrocytosis. An
initial low platelet count is seen
with acute alcohol use in the
absence of portal hypertension.
Low-grade haemolysis is common.
Prothrombin time is an important
prognostic marker.
Liver function tests reveal
aspartate transaminase (AST,
usually >300 U/L) greater than
alanine transaminase (ALT) in
alcoholic liver disease. Alkaline
phosphatase is often elevated,
Differential diagnosis
Assessment of chronic liver disease
Alcoholic hepatitis can coexist with
other chronic liver diseases, eg
haemochromatosis, hepatitis C
and hepatitis B, which should
be screened for as appropriate
(see Sections 1.1.7 and 1.2.2).
Treatment
This will depend on the presentation
(see Sections 1.1.7, 1.2.2, 1.4.3 and
1.4.6) but with specific regard to
117
GAH_C02
12/9/10
9:04
Page 118
Short-term
Corticosteroids should be considered
in severe alcoholic hepatitis as long
as there is no evidence of infection
or renal failure.
Long-term
Abstinence: psychological input
and counselling both reduce
readmission rates.
Drugs: acamprosate and
naltrexone (12 months) may
reduce alcohol dependence.
Disulfiram should probably be
avoided because of side effects.
Complications
Ascites, hepatic encephalopathy,
septicaemia, hepatorenal failure
and chronic liver disease.
Prognosis
Patients admitted to hospital with
alcoholic hepatitis have an overall
15% mortality at 30 days, but those
with severe disease (hepatic
encephalopathy, jaundice, renal
failure or coagulopathy) have a
mortality closer to 1 in 2. There are
a number of ways of quantifying
an individual patients chance of
surviving: the Maddrey discriminant
function involves a formula
including the prothrombin time and
serum bilirubin, with those scoring
highly (worse) often considered
for a trial of steroids; the Glasgow
Alcoholic Hepatitis Score (GAHS)
depends on five variables (age, white
blood cell count, urea, prothrombin
ratio and serum bilirubin) and
appears to perform slightly better.
Overall survival at 5 years is 60%
if the patient remains abstinent,
falling to 40% if the patient
continues to drink.
The development of complications of
cirrhosis reduces life expectancy: a
118
Prevention
Disease associations
These include hypertension,
alcoholic cardiomyopathy, chronic
pancreatitis, duodenal ulceration,
peripheral sensory neuropathy,
cerebellar atrophy, cerebral atrophy,
Wernickes encephalopathy and
Korsakoffs dementia.
FURTHER READING
Bathgate AJ (on behalf of the UK Liver
Transplant Units Working Party).
Recommendations for alcohol-related
liver disease. Lancet 2006; 367: 20456.
GAH_C02
12/9/10
9:04
Page 119
TABLE 47 CLINICAL
++
+++
Acute cholestasis
+++
+++
++
++
Hepatic fibrosis
N
No liver disease (enzyme induction)
N
/+
Fatty liver
Steatohepatitis
Granuloma
++
++
N
Paracetamol
NSAIDs
Isoniazid
Halothane
Oestrogens
Flucloxacillin
Chlorpromazine
Dextropropoxyphene
Tetracycline
Amiodarone
Carbamazepine
Allopurinol
Methotrexate
Rifampicin
ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; GGT,
-glutamyltransferase; N, normal liver biochemistry.
Fig. 63 Bile duct damage due to clavulinic acidamoxicillin. The bile duct epithelium is irregular and
infiltrated with lymphocytes.
Epidemiology
The incidence of hepatic drug toxicity
is under-reported; it is thought to
be 1 in 10,000100,000. Prevalence
increases with age, with drugs
being responsible for 40% of acute
hepatitis in those aged >50 years.
Drugs most commonly implicated in
causing drug toxicity include:
clavulanic acidamoxicillin
(Augmentin);
flucloxacillin;
amiodarone;
statins;
thiopurines, eg azathioprine;
NSAIDs;
paracetamol/dextropropoxyphene;
herbal remedies.
Investigations
FBC may show an eosinophilia.
The pattern of liver biochemistry is
shown in Table 47. Liver injury is
defined as an ALT value more than
three times the upper limit of the
normal range, an ALP value more
than twice the upper limit of
normal, or a total bilirubin level
more than twice the upper limit
of normal if associated with any
elevation of ALT or ALP. Liver injury
119
GAH_C02
12/9/10
9:04
Page 120
Disease associations
Differential diagnosis
Clinical presentation
Narcotics/anxiolytics:
accumulation results in hepatic
encephalopathy.
Codeine: causes constipation and
secondary hepatic encephalopathy.
NSAIDs: may cause haemorrhage
from oesophageal varices and
precipitate hepatorenal failure.
Treatment
Gentamicin/radiocontrast agents:
may precipitate hepatorenal
failure.
Complications
Acute liver failure
This is more likely in elderly people.
It occurs in about 20% who are
jaundiced. Overall 1520% of acute
liver failure is due to drugs.
Frequently reported with
antituberculous medication.
Chronic cholestasis
120
Prognosis
FURTHER READING
Epidemiology
Incidence varies with geographic
region, age and sex. The commonest
cause of chronic hepatitis in the
world is hepatitis C; in the UK the
commonest cause of cirrhosis is
alcohol, followed by hepatitis C.
Clinical presentation
Common
GAH_C02
12/9/10
9:04
Page 121
Fig. 64 (a) Normal liver; (b) cirrhotic liver containing a benign cyst.
Treatment
See Sections 1.1.7, 1.2.2, 1.4.3 and
1.4.6 for discussion of the various
clinical presentations that can arise
in patients with chronic liver
disease.
Specific measures
Progressive liver disease can
sometimes be arrested where the
cause is known (Table 49).
Fig. 65 Histological appearance of cirrhosis. There is loss of the normal architecture which is replaced by
nodules.
Hepatic decompensation:
jaundice, ascites, hepatic
encephalopathy, variceal
haemorrhage.
Physical signs
See Section 1.2.2.
Investigations/staging
See Sections 1.1.7 and 1.2.2 for
discussion. Aside from the issues
discussed in these scenarios, note
that osteoporosis and more rarely
osteomalacia are important
complications of chronic liver
disease and associated with
significant morbidity through
fractures resulting in pain, deformity
and immobility. Patients with
chronic liver disease should have
their bone density measured, in
addition to vitamin D and
testosterone levels.
Wilsons disease
Wilsons disease may present
as asymptomatic liver disease
with predominant neurological
abnormalities, as chronic liver disease
with cholestatic features in early
adulthood, or as fulminant liver failure
in younger patients. A clue to Wilsons
disease in these patients is the
presence of significant red cell
haemolysis. Always consider the
diagnosis in patients under the age
of 40 years with unexplained liver
disease: prompt treatment can be
life-saving.
General measures
Treatment is aimed at managing and
preventing complications.
121
GAH_C02
12/9/10
9:04
Page 122
TABLE 48 IMPORTANT
Genetic haemochromatosis
1-Antitrypsin deficiency
Wilsons disease
Ascites: diuretics, eg
spironolactone, furosemide,
amiloride.
Portal hypertension: non-selective
beta-blocker (propranolol).
Bone disease: for
osteoporosis/osteomalacia,
treatments include calcium,
bisphosphonates (eg cyclical
etidronate, alendronate,
risedronate), calcitonin and
combined vitamin D/calcium.
To maintain general health:
nutrition.
Complications
TABLE 49 SPECIFIC
Treatment
Abstinence
Genetic haemochromatosis
1-Antitrypsin deficiency
Wilsons disease
122
Common
Coagulopathy Caused by decreased
synthesis of coagulation factors II, V,
VII and IX with worsening liver
function, or as a result of chronic
cholestasis and reduced levels of
vitamin K. It is aggravated by
thrombocytopenia caused by
hypersplenism due to portal
hypertension.
Encephalopathy The cause is
multifactorial and ill-understood.
Abnormal amino acid synthesis and
increased ammonia production may
play a role, as may abnormal enteric
bacterial metabolism and reduced
hepatic clearance of neurotoxic
substances due to portal
hypertension and shunting. Resting
electroencephalogram shows slowed
alpha-wave frequency. Treatments
for encephalopathy are inadequate,
but see Section 1.4.6 for discussion.
GAH_C02
12/9/10
9:04
Page 123
Prognosis
Morbidity
There is significant morbidity from
malaise, malnutrition, sepsis and
bleeding. Figure 67 shows the
natural history of hepatitis C
infection.
Mortality
Life expectancy is severely reduced,
but varies depending on the cause
Fig. 66 Haemochromatosis: iron deposition in hepatocytes shown as blue staining with Perls stain.
Fig. 67 Natural history of hepatitis C infection: (a) rate of progression to cirrhosis; (b) different rates of disease progression and factors associated with rapid
progression.
123
GAH_C02
12/9/10
9:04
Page 124
TABLE 50 CHILDSPUGH
Parameter
Bilirubin (mol/L)1
Albumin (g/L)
PT (seconds prolonged)
Encephalopathy
Ascites
Aetiology/pathophysiology/
pathology
Score
1
<34
>35
<4
None
None
3450
2835
46
Mild
Mild
>50
<28
>6
Marked
Marked
Clinical presentation
Common
Abscess: fever, pain and tenderness.
Class A
Class B
Class C
Total score
1-year survival
56
79
1015
100%
80%
50%
Uncommon/rare
Weight loss, abdominal pain,
increased ascites secondary to portal
vein thrombosis, and bleeding or
tumour rupture.
FURTHER READING
Gins P, Cardenas A, Arroyo V and
Rodes J. Management of cirrhosis and
ascites. N. Engl. J. Med. 2004; 350:
164654.
Gins P, Guevara M, Arroyo V and
Rodes J. Hepatorenal syndrome. Lancet
2003; 362: 181927.
Grant A, Neuberger J, Day C and
Saxseena S (on behalf the British
Society of Gastroenterology and the
British Association for the Study of the
Liver). Guidelines on the Use of Liver
Biopsy in Clinical Practice. London:
British Society for Gastroenterology,
2004. Full text available at
http://www.bsg.org.uk/
Fig. 68 CT scan showing multiple hepatic cysts in a patient with autosomal dominant polycystic kidney
disease. The scan also shows ascites and absence of kidneys following bilateral nephrectomy.
124
GAH_C02
12/9/10
9:04
Page 125
TABLE 51 CAUSES
Type of cause
Condition
Comments
Infective
Pyogenic abscess
Amoebic abscess
Hydatid cyst
Benign tumours
Simple cyst
Haemangioma
Multiple cysts often found in adult polycystic kidney disease (Fig. 68)
Extremely common, occurring in up to 20% of people, and detected
usually as an incidental finding
Occurs in 34 per 100,000 women on oestrogen-containing
contraceptives, and may occur in men on androgen treatment
Hepatic adenoma
Focal nodular hyperplasia/focal
regenerative hyperplasia
Secondary deposits
Colorectal cancer
Other gastrointestinal tract cancer
including pancreatic and carcinoid
tumours (Fig. 69)
Breast, cervix, ovary, prostate,
lung, skin cancer
Cholangiocarcinoma
Hepatocellular carcinoma
developing in hepatic adenoma
Uncommon
Hepatic bruit with hepatocellular
carcinoma.
Investigations/staging
Blood tests
Any patient with a focal liver lesion
will require routine blood tests
including FBC, liver function tests,
albumin, clotting screen and
inflammatory markers. Some
specific blood tests (Table 52)
may help to confirm or refute a
particular diagnostic possibility.
Imaging
Fig. 69 CT scan showing multiple liver metastases from adenocarcinoma of the pancreas.
Physical signs
Common
There are often few signs but there
may be:
jaundice;
125
GAH_C02
12/9/10
9:04
Page 126
TABLE 52 BLOOD
Uncommon
Test
Disease
Alpha-fetoprotein
Rare
Carcinoembryonic antigen
Colorectal carcinoma
Tissue sampling
Histological diagnosis may be
established by liver biopsy, but
beware of vascular lesions that may
bleed catastrophically on biopsy. If
the patient has ascites, cytological
examination may provide a
diagnosis, particularly if the lesion
is a secondary malignant deposit.
Short-term
Biliary obstruction can be relieved
endoscopically or radiologically.
Small hepatocellular carcinomas
can be treated locally (eg by
percutaneous alcohol injection,
radiofrequency ablation,
transarterial chemoembolisation),
reducing tumour load and
prolonging patient survival. Local
resection of secondary deposits
may be feasible in some cases.
Long-term
Beware of haemangiomas and
hydatid cysts, where biopsy may
result in catastrophic bleeding or
disseminated infection.
Differential diagnosis
Common causes of focal liver lesions
are shown in Table 51.
Treatment
Treatment of a focal liver lesion will
depend on the cause. For benign
lesions the most important aspect is
to reassure patients that they have
not got cancer.
Emergency
Liver abscess requires prompt
antimicrobial treatment, and may
require diagnostic or therapeutic
aspiration or drainage. Rupture of
liver abscess or haemangioma
requires surgical intervention.
126
Complications
Common
Septicaemia in patients with
pyogenic abscess.
Haemorrhage or rupture of
haemangioma or large adenoma.
Malignant transformation of
adenoma.
Prognosis
Morbidity
Incidental liver lesions rarely cause
morbidity. Fever, pain or vague right
upper quadrant discomfort are
common.
Mortality
Without curative resection hepatic
secondaries and hepatocellular
carcinoma usually have a dire
prognosis.
Hepatocellular carcinoma
Usually arises in the setting
of cirrhosis, with untreated 1-year
survival of 50 90% in patients with
ChildsPugh class A cirrhosis and 20%
in those with ChildsPugh class C
disease. Metastases may develop in
the lung, portal vein, periportal nodes,
bones or brain, with 5-year survival
rates less than 5% without treatment.
Alpha-fetoprotein (AFP) is elevated in
75% of cases, and the higher the level
the worse the prognosis. An elevation
of greater than 400 ng/mL predicts
hepatocellular carcinoma with
specificity greater than 95%, and in the
setting of a growing mass, cirrhosis
and the absence of acute hepatitis,
many centres use a level greater than
1000 ng/mL as presumptive evidence
of hepatocellular carcinoma (without
biopsy). However, two-thirds of
hepatocellular carcinomas <4 cm have
GAH_C02
12/9/10
9:04
Page 127
FURTHER READING
Choi BY and Nguyen MH. The diagnosis
and management of benign hepatic
tumors. J. Clin. Gastroenterol. 2005;
39: 40112.
Garden OJ, Rees M, Poston GJ, et al.
Guidelines for resection of colorectal
cancer liver metastases. Gut 2006; 55
(Suppl. 3): iii1iii8. Full text available at
http://www.bsg.org.uk/
Llovet JM, Burroughs A and Bruix J.
Hepatocellular carcinoma. Lancet 2003;
362: 190717.
Ryder SD (on behalf of the British
Society of Gastroenterology).
Guidelines for the diagnosis and
treatment of hepatocellular carcinoma
(HCC) in adults. Gut 2003; 52 (Suppl. 3):
iii1iii8. Full text available at
http://www.bsg.org.uk/
Disease associations
Pyogenic liver abscess: cholangitis,
diverticular disease, inflammatory
bowel disease, appendicitis,
colorectal neoplasia.
Amoebic liver abscess: amoebic
colitis.
Adenoma: glycogen storage disease.
Hepatocellular carcinoma: liver
cirrhosis.
Cholangiocarcinoma: PSC.
Indications
Ethical issues
These are largely related to donor
shortage and include the following.
Should patients with liver failure
due to paracetamol overdose or
alcohol be transplanted?
127
GAH_C02
12/9/10
9:04
Page 128
Timing of transplantation
Emergency transplantation
There are two liver transplant
waiting lists in the UK: acute liver
failure (super-urgent list) and
chronic liver disease. Strict criteria
need to be met before an individual
can be placed on the acute liver
failure waiting list as these patients
take priority over all other patients
(Table 53).
128
Paracetamol
Non-paracetamol
Contraindications
There are very few absolute
contraindications to transplantation
(eg cholangiocarcinoma, active
bacterial infection) and patients
should where possible be given the
opportunity of assessment by a liver
centre, but potential areas of
concern include the following.
Alcohol intake within the last
6 months: liver function can
improve on abstinence, and this
is also a risk factor for recidivism
after transplantation. However,
consideration should be given to
patients who deteriorate before
6 months has elapsed if they are
likely to remain abstinent.
Increasing age, advanced endstage disease, poor nutrition and
cardiorespiratory disease.
Psychiatric disease and absence
of social support: may adversely
affect compliance with
immunosuppressive medication.
Note that HIV is not a
contraindication to transplantation
(if adequately treated).
Practical details
Surgery lasts between 4 and
24 hours and postoperative stays
can be as short as 10 days, but
are more typically 23 weeks.
Anastomoses between donor and
recipient hepatic artery, portal vein,
inferior vena cava and biliary tree
need to be fashioned and are sites
of potential complications. Biliary
anastomosis is usually a duct-to-duct
anastomosis, but in the presence of
recipient biliary disease (eg cystic
fibrosis, primary sclerosing
cholangitis) a Roux-en-Y biliary
anastomosis is fashioned (Fig. 70).
Postoperative immunosuppression is
typically with an initial combination
of prednisolone and azathioprine/
mycophenolate mofetil and
GAH_C02
12/9/10
9:04
Page 129
FURTHER READING
Clavein PA, Petrowsky H, DeOliveira ML
and Graf R. Strategies for safer liver
surgery and partial liver transplantation.
N. Engl. J. Med. 2007; 356: 154559.
Devlin J and OGrady J (on behalf of the
British Society of Gastroenterology).
Indications for referral and assessment
in adult liver transplantation: a clinical
guideline. Gut 1999; 45 (Suppl. 6):
vi1vi22. Full text available at
http://www.bsg.org.uk/
Said A, Einstein M and Lucey MR. Liver
transplantation: an update 2007. Curr.
Opin. Gastroenterol. 2007; 23: 2928.
2.11 Nutrition
tacrolimus, although many
regimens now seek to avoid
steroids completely. All
patients require long-term
immunosuppression, but this
can often be with a single agent.
Outcome
The 1-year survival rate following
transplantation for chronic liver
disease is now approaching 95%,
falling to 80% at 5 years primarily
due to recurrent disease,
cardiovascular events, malignancy
and renal failure. The 1-year
survival is only 61% following
transplantation for acute liver
failure, reflecting the presence of
infection and multiorgan failure at
the time of transplantation. Survival
is lower following retransplantation,
and in those receiving a liver and
kidney at the same time.
Biliary complications
These affect 1020% of patients
and include anastomotic biliary
strictures and biliary leaks.
Disease recurrence
Complications
Early complications
Comorbid illness
129
GAH_C02
12/9/10
9:04
Page 130
TABLE 54 VITAMIN
REQUIREMENTS
(VITAMIN B
IS COVERED SEPARATELY IN
TABLE 55)
Vitamin
Requirement
Effect of deficiency
Notes
1000 IU/day
60100 mg/day
Scurvy
200 IU/day
1020 mg/day
Neurological disorders
1 g/kg daily
Bleeding diathesis
TABLE 55 VITAMIN B
Vitamin
Requirement
Effect of deficiency
Notes
B1 (thiamine)
0.51 mg per
1000 kcal intake
B2 (riboflavin)
0.6 mg per
1000 kcal intake
B6 (pyridoxine)
1.62 mg/day or
0.038 mg/g protein
intake
Niacin
6.6 mg NE1
Biotin
0.030.1 mg/day
Deficiency rare
B12 (cobalamin)
2 g/day
Folic acid
3 g/kg daily
130
REQUIREMENTS
GAH_C02
12/9/10
9:04
Page 131
TABLE 56 MINERALS
Mineral
Requirement
Effect of deficiency
Notes
Iron
1 mg/day
Calcium
8001000
mg/day is normal
Western intake
Copper
24 mg/day
Magnesium
Zinc
Myopathy
15 mg/day
Selenium
Chromium
History
The following features from the
history are important in assessing
the nutritional state.
Altered intake and pattern of
intake.
Recent weight loss (>10%
significant).
Ability to chew or swallow,
presence of dysphagia.
Anorexia, early satiety.
Recent vomiting.
Examination
The following findings suggest
impaired nutrition.
General muscle and fat mass:
hollow cheeks, wasting of
temporalis, squaring of shoulders
(loss of deltoid), wasting of
quadriceps.
Oedema: may indicate
hypoalbuminaemia.
Petechial or subcutaneous
haemorrhage: consider vitamin
C/K deficiencies.
Wrinkling, dryness of conjunctiva:
possible vitamin A deficiency.
Ophthalmoplegia: thiamine
deficiency; may be other signs of
Wernickes encephalopathy.
Cheilosis, angular stomatitis,
glossitis: vitamin B complex
deficiency.
Myelopathy, ataxia, retinopathy,
blindness: vitamin E deficiency.
underweight
normal
overweight
obese
Investigations
Blood tests Malnutrition may
be indicated by albumin <30 g/L
(but this usually reflects coexistent
disease and is a very poor marker
of nutritional state), lymphocytes
131
GAH_C02
12/9/10
9:05
Page 132
Fig. 71 The Malnutrition Universal Screening Tool (MUST). (Reproduced with permission from BAPEN, and available from http://www.bapen.org.uk/.)
132
GAH_C02
12/9/10
9:05
Page 133
Anthropometric measurements
These include triceps and
subscapular skinfold thickness,
which provides an index of body fat,
and the mid-arm circumference
which provides a measure of muscle
mass. However, there are problems
with both the reference database
and considerable interobserver
measurement variability. Generally
only used in trial settings.
Dynamometry This refers to the use
of hand grip strength, which has
been shown to predict postoperative
complications in surgical patients.
Other tests have used electrical
stimulation of the adductor pollicis
muscle in the hand to measure
forcefrequency curves, fatiguability
and relaxation.
Others Delayed cutaneous
hypersensitivity tests may also be
used as indicators of nutritional
status.
Total body water Body composition
may be divided into four
Prognosis
There is a near linear relationship of
increasing BMI with morbidity and
mortality. A BMI <15 kg/m2 is also
associated with increased mortality.
2.11.2 Proteincalorie
malnutrition
Kwashiorkor and marasmus are
the two classical primary nutrition
disorders seen in children. Although
described as distinct entities,
features of both are often present.
Marasmus is defined as present
when weight is less than 60% that
expected for the age, and is termed
marasmic kwashiorkor when
oedema is additionally present. Less
severe proteincalorie malnutrition
is present when weight is 6080%
that expected for age, and is termed
undernutrition in the absence of
oedema, and kwashiorkor in its
presence.
2.11.3 Obesity
Aetiology/pathophysiology
Obesity, defined as a BMI >30 kg/m2,
is a large and increasing problem. In
addition to the total body-fat mass
(estimated by BMI), the distribution
of fat is also important. Truncal
obesity is associated with
dyslipidaemia, hypertension,
insulin resistance, diabetes mellitus,
cardiovascular disease and stroke.
In clinical practice, the distribution
of fat can be simply assessed by
the waist/hip circumference ratio
(WHR). The WHR should not exceed
1.0 in men and 0.85 in women.
Genetic factors are involved. A signal
protein, leptin, produced by adipose
tissue, has recently been discovered
that may modulate body weight and
energy expenditure.
Epidemiology
In the UK, the prevalence of obesity
increased from 8% in 1980 to 15%
by 1995. In Europe and the USA the
figures are 1525%. As the BMI
increases, so does morbidity and
mortality. Obesity is a result of
energy input exceeding output
over a sustained period.
Treatment
Dietary
The principle of treatment is to
induce negative energy balance,
133
GAH_C02
12/9/10
9:05
Page 134
Behaviour modification
Behaviour modification is important
and includes a diary of food intake,
meal frequency and separating
eating from other activities. Regular
exercise probably raises the basal
metabolic rate and favours energy
expenditure.
Drug treatments
These are considered if diet, exercise
and behaviour modification has
failed, and the risks of obesity
outweigh the risks of the drug in
that individual. Serotoninergic
agonists suppress appetite but may
cause pulmonary hypertension and
pulmonary valve disease. Orlistat is
a potent pancreatic lipase inhibitor
that causes malabsorption of fats
and has recently been shown to be
effective in treating obesity, although
a limiting side effect is that it
produces a high incidence of
steatorrhoea. Administration of
appetite-suppressing hormones may
provide an effective pharmacological
treatment of obesity in the future.
134
Surgery
Vertical banded gastroplication,
reducing the reservoir capacity of
the stomach, is reserved for morbid
obesity (BMI >35 kg/m2). Jejunoileal
bypass surgery is no longer
performed because it causes
severe hepatic abnormalities.
Other issues
Other cardiovascular risk factors
present in the obese patient
should be addressed (eg
smoking, hypertension, diabetes,
hyperlipidaemia), and alcohol intake
should be minimised (7 kcal/g).
Hypothyroidism should be excluded.
Indications
Enteral nutrition
Enteral nutrition is the preferred
option in all malnourished patients
who have a normal or near-normal,
functioning, accessible gut. It is
trophic for the upper intestinal
mucosa, maintains epithelial barrier
integrity, and is cheaper and safer
than parenteral feeding. If the upper
gastrointestinal tract is obstructed,
for example by oesophageal disease,
a percutaneous enterogastrostomy
(PEG) tube can be used to bypass
the obstruction and maintain enteral
feeding.
Parenteral nutrition
FURTHER READING
Dietz WH and Robinson TN. Clincal
practice: overweight children and
adolescents. N. Engl. J. Med. 2005; 352:
21009.
Farooqi S and ORahilly S. Genetics of
obesity in humans. Endocr. Rev. 2006;
27: 71018.
Li Z, Maglione M, Tu W, et al. Metaanalysis: pharmacologic treatment of
obesity. Ann. Intern. Med. 2005; 142:
53246.
McNatt SS, Longhi JJ, Goldman CD and
McFadden DW. Surgery for obesity: a
review of the current state of the art
and future directions. J. Gastrointest.
Surg. 2007; 11: 37797.
Contraindications
Enteral nutrition
This is contraindicated in paralytic
ileus, mechanical obstruction and
major intra-abdominal sepsis, and in
those with complex fluid balance
problems.
Practical details
Enteral nutrition
Many patients can take oral
supplements (eg Fortisip, Fortijuice)
by mouth. In those with swallowing
GAH_C02
12/9/10
9:05
Page 135
Special diets
Elemental diet
This comprises low-molecularweight nutrients, usually
with 10% free amino acids, 85%
oligosaccharides and <5% fat. It is as
effective as steroids in the treatment
of active Crohns disease, but many
patients find it distasteful and need
nasogastric feeding over a 6-week
period. Its mechanism of action is
unknown, but it may exert its effect
by reducing immunogenic load and
altering bacterial flora.
Parenteral nutrition
Venous access is secured via the
internal jugular, subclavian or
antecubital veins. A tunnelled
central venous catheter should be
sited unless it is anticipated that
feeding is only required for a few
days.
Complications
Parenteral nutrition
The complications of parenteral
nutrition include central venous
access-related complications,
metabolic complications, vitamin
and trace element deficiencies and
hepatobiliary dysfunction. The
metabolic complications include
hyperglycaemia/hypoglycaemia,
hypernatraemia/hyponatraemia,
hypercalcaemia/hypocalcaemia and
magnesaemia, hypophosphataemia,
mineral/vitamin/trace element
deficiency and cholestatic jaundice.
advocates avoidance of
carbohydrates and favours a
relatively high intake of fats
and proteins, with the lack of
carbohydrate promoting ketogenesis
from fats and the high protein
content possibly suppressing
appetite and resulting in loss of
weight. Long-term consequences
may include dyslipidaemia, vitamin
and mineral deficiencies, and
possibly an increased risk of
colorectal cancer, which is
associated with a diet rich
in meat products and deficient
in insoluble fibre.
Exclusion diets
The most common conditions
requiring exclusion of specific
foods from the diet are coeliac
disease (where gluten provokes
an immunological response),
cows milk protein intolerance
and hypolactasia. Some patients
with irritable bowel syndrome
seem to benefit from avoiding
certain foods.
FURTHER READING
Baldwin C, Parsons T and Logan S.
Dietary advice for illness-related
malnutrition in adults. Cochrane
Database Syst Rev 2007; (1): CD002008.
Milne AC, Potter J and Avenell A.
Protein and energy supplementation
in elderly people at risk from
malnutrition. Cochrane Database
Syst Rev 2005; (2): CD003288.
National Collaborating Centre for
Acute Care. Nutrition Support for
Adults: Oral Nutrition Support, Enteral
Tube Feeding and Parenteral Nutrition.
Methods, Evidence and Guidance. NICE
guideline CG32. London: National
Institute for Health and Clinical
Excellence, 2006. Full text available
at http://www.nice.org.uk/
Stroud M, Duncan H and Nightingale J.
Guidelines for enteral feeding in adult
hospital patients. Gut 2003; 52 (Suppl.
7): vii1vii12. Full text available at
http://www.bsg.org.uk/
Zaloga GP. Parenteral nutrition in
adult inpatients with functioning
gastrointestinal tracts: assessment of
outcomes. Lancet 2006; 367: 110111.
135
GAH_C03
12/9/10
9:07
Page 136
136
In gastroenterological practice
hypoalbuminaemia may reflect
nutritional disease, liver disease or
inflammatory disease.
Stool examination
Determining relevant facts about
the amount and composition
of stool is a key aspect of the
gastroenterological assessment.
Stool may also be examined for
occult blood, fat globules,
leucocytes, erythrocytes and
pathogens. Normal stool volume
is about 200 mL per day, and the
normal frequency of defecation
varies from approximately three
times a day to once every 3 days.
Examples of abnormalities in the
stool and their interpretation are
shown in Table 57.
TABLE 57 ABNORMALITIES
OF THE STOOL
Abnormality
Interpretation
Leucocytes present
GAH_C03
12/9/10
9:07
Page 137
3.2 Tests of
gastrointestinal and
liver function
The main measure of gastrointestinal
function is determined by clinical
history-taking. Most blood tests,
radiological investigations and
endoscopic modalities do not give
a measure of function but quantify
structural abnormalities and
damage. However, there are a
number of tests used to determine
whether there has been disruption
of normal physiology, which will be
considered in anatomical order.
Indirect tests
Faecal fat Either by Sudan staining
of stool sample or microscopy.
This has gone out of favour as it
involves the patient consuming a
large volume of fat in the diet for
3 days after stopping any pancreatic
supplements. It is insensitive in mild
to moderate pancreatic insufficiency
as greater than 90% of acinar tissue
needs to be lost before the test
becomes abnormal.
PABA test/mixed triglyceride breath
test/pancreolauryl test/triolein
breath test A complex substrate
is administered orally, which is
hydrolysed by the pancreatic
enzymes and then absorbed by gut,
with products measured in blood,
urine or breath.
Faecal enzyme measurement
Pancreatic chymotrypsin and
elastase have both been developed
into commercial tests, although
faecal elastase appears to be
superior. Enzymes are released from
the pancreas, pass through the
intestine without degradation and
can be measured in a single stool
sample. Low levels are associated
with reduced exocrine pancreatic
function.
137
GAH_C03
12/9/10
9:07
Page 138
TABLE 58 FUNCTIONAL
Investigation
Indications
Substrate
Metabolite/read-out
Notes
13
13
Hypolactasia
Lactose
Excess H2 from
bacterial fermentation
of lactose
Intestinal bacterial
overgrowth and intestinal
hurry
Lactulose
Intestinal bacterial
overgrowth
Labelled glycineglycocholate
Xylose
Schilling test
Labelled
hydroxocobalamin
(vitamin B12) tracer
administered after
body stores are
saturated by an
intramuscular dose of
unlabelled vitamin B12
Urinary excretion of
labelled vitamin B12
138
C-labelled urea
C-labelled CO2
GAH_C03
12/9/10
9:07
Page 139
TABLE 59 ENDOSCOPIC
Investigation
Indications/abnormalities
Contraindications/notes
Oesophagogastroduodenoscopy
(upper gastrointestinal
endoscopy)
Enteroscopy
Colonoscopy and
terminal ileoscopy
Flexible sigmoidoscopy
Luminal radiology
Pancreaticobiliary investigations
139
GAH_C03
12/9/10
9:07
Page 140
TABLE 60 RADIOLOGICAL
Investigation
Indications/abnormalities
Contraindications/notes
Barium meal
Barium enema
Defecating proctogram
Endoanal ultrasound
Transabdominal ultrasound
User dependent
May be used to direct drainage of collections or target
biopsy of masses
MRI scanning
140
Indications
Altered bowel habit.
Rectal bleeding of unknown cause.
GAH_C03
12/9/10
9:07
Page 141
Fig. 72 Normal barium studies: (a) barium meal; (b) barium follow-through; and (c) barium enema.
TABLE 61 PANCREATICOBILIARY
INVESTIGATIONS
Investigation
Indications/abnormalities
Contraindications/notes
Ultrasound scan
Endoscopic retrograde
cholangiopancreatography
(ERCP)
CT scanning
Cancer staging
Further delineation of pancreatic
abnormalities
Percutaneous transhepatic
cholangiography (PTC)
Magnetic resonance
cholangiopancreatography
(MRCP) (see Fig. 24)
Functional testing
141
GAH_C03
12/9/10
9:07
Page 142
TABLE 62 INVESTIGATION
Investigation
Details/indications/abnormalities
Notes
Meckels scanning
Exploratory laparotomy
Contraindications
Sigmoidoscopy cannot be
performed if:
the patient is unwilling,
apprehensive or uncooperative;
there are inadequate facilities
(lack of privacy, nurse escort or
chaperone, biopsy forceps);
severe anorectal pain (consider
examination under anaesthetic);
biopsy contraindicated in
prescence of bleeding diathesis.
Practical details
Fig. 73 Normal ultrasound of the liver. The liver has normal texture and the bile ducts are not dilated.
Fig. 74 Disposable plastic sigmoidoscope with obturator removed, light source and insufflator with
rubber bulb, and sterilised packaged crocodile biopsy forceps.
142
GAH_C03
12/9/10
9:07
Page 143
The procedure
Explain the procedure and place
the patient comfortably in the left
lateral position, with the buttocks
close to the edge of the couch and
the knees slightly extended. Perform
a gentle rectal digital examination.
Lubricate the sigmoidoscope and
obturator. With the obturator fully
inserted in the sigmoidoscope,
insert the first 5 cm of the
instrument into the anus, pointing
anteriorly and cranially (towards the
umbilicus). Withdraw the obturator
and attach the light-source head and
insufflator. Gently insufflate air and
direct the instrument posteriorly
(towards the sacroiliac joint) until a
luminal view is obtained. Insert the
instrument gently, insufflating and
manoeuvring to maintain a luminal
view. Examine the mucosa in all
directions by angling the instrument
gently. The instrument may safely
be inserted to 20 cm provided a
mucosal view is maintained and
the patient does not complain of
discomfort. If indicated obtain
a mucosal biopsy by inserting a
forceps through the viewing port,
and gently shearing a sample
of mucosa under direct vision.
Withdraw the instrument to 5 cm,
carefully examining the mucosa.
Replace the obturator and remove
the instrument.
3.6 Paracentesis
Paracentesis can be diagnostic
or therapeutic. A diagnostic
paracentesis involves the removal of
50 mL ascitic fluid using a sterile
green needle and syringe. The fluid
should be analysed for albumin,
amylase, cytology and a quantitative
white count. Inoculate blood culture
bottles with ascites to increase the
chance of growing pathogens. If
the fluid is cloudy, then chylous
ascites is confirmed by an ascitic
triglyceride level greater than the
serum level.
Indications
Contraindications
Absolute contraindications are small
or large bowel obstruction with
dilated loops of bowel, and clinically
evident fibrinolysis/disseminated
intravascular coagulation. Most
physicians routinely correct
coagulation if the INR is >2 and/or
transfuse platelets if the platelet count
is <50 109/L, but there is no evidence
that this is required if the patient
has no clinical evidence of bleeding.
Practical details
Before the procedure
Lie the patient flat on the back.
Prepare the following equipment:
suprapubic bladder drainage
catheter or paracentesis catheter
(Fig. 75), lidocaine 1 or 2%, blade,
suture, urine catheter bag, 10-mL
syringe and 18G needle.
The procedure
Insert the catheter into either the
right or left iliac fossa. Clean the
skin and infiltrate with lidocaine
through to the peritoneum: do not
continue with the procedure if you
are unable to draw back ascitic
fluid while anaesthetising. Make
an incision in the skin. Insert the
catheter through the skin and angle
it obliquely for 1 cm or so before
entering the peritoneum at 90 to
the skin and a little way from the
skin entry site. This reduces the risk
of an ascitic leak on removal of the
catheter. Secure the catheter with
adhesive dressings: most liver units
remove paracentesis catheters after
about 6 hours so a suture is not
usually indicated. Attach the end
of the catheter to the urine bag.
Tape the catheter securely to the
abdominal wall.
Allow 510 L of ascites to drain
over 16 hours: if the fluid does not
drain, change the patients position.
In patients with portal hypertension
give 6 g albumin intravenously per
litre of fluid drained (100 mL 4.5%
albumin = 4.5 g; 100 mL 20%
albumin = 20 g).
143
GAH_C03
12/9/10
9:07
Page 144
Indications
Indications for liver biopsy include
acute hepatitis, drug-related hepatitis,
chronic liver disease, cirrhosis, post
liver transplantation, space-occupying
lesions, unexplained hepatomegaly
or liver enzyme elevations. Ultrasoundguided biopsy is specifically
indicated in focal liver lesion, small
liver or emphysema. Transjugular
liver biopsy (Fig. 76) is specifically
indicated in ascites, prolonged
prothrombin time (PT) >4 seconds
or a platelet count <60 109/L.
Contraindications
A percutaneous liver biopsy is
usually contraindicated where
there is ascites, coagulopathy
or an uncooperative patient.
Fig. 75 Paracentesis catheter. Normally used for suprapubic catheterisation, the catheter is easily
introduced and when inserted its end curls up in the abdominal cavity. Fluid drains through side holes in
the distal catheter.
Practical details
Details are for percutaneous nonradiologically guided liver biopsies.
Note that an assistant is needed.
Major
Peritoneal varices are rare but can
be ruptured by the insertion of an
ascitic drain. Severe haemorrhage
after abdominal paracentesis
occurs in 0.2% of patients with
liver disease. This is more likely in
those with severe liver failure or
with significant renal dysfunction,
but bleeding is not related to
operator experience, elevated
INR or low platelets.
Minor
Failure to drain ascites: if
the patient has had previous
paracenteses the abdominal
fluid often becomes loculated
and the drain may need to be
inserted under ultrasound
guidance.
Infection at exit site.
144
GAH_C03
12/9/10
9:07
Page 145
The procedure
Lie the patient flat on the back.
Mark the first dull intercostal space
on expiration in the mid-axillary
line: the needle should be inserted
over the top of a rib, avoiding the
intercostal vessels below the rib.
Clean the skin with antiseptic.
Anaesthetise down to the liver
capsule with lidocaine: do this
by advancing the needle slowly
perpendicular to the skin with the
patient holding their breath in
Complications
Mortality rate is 0.01%.
Major
Haemorrhage occurs in 0.5%,
usually in the first 34 hours post
biopsy. There is a higher rate in
malignancy and it is rare in the nonjaundiced patient. If there is major
bleeding, angiography followed by
transcatheter hepatic embolisation
may be needed. Intrahepatic
haematomas are rare, but may be
145
GAH_C03
12/9/10
9:07
Page 146
146
Minor
A small amount of bleeding is
universal and minor discomfort is
common. Pain is more likely during
and after the procedure if the
capsule is inadequately
anaesthetised.
FURTHER READING
Grant A, Neuberger J, Day C and
Saxseena S (on behalf the British
Society of Gastroenterology and the
British Association for the Study of the
Liver). Guidelines on the Use of Liver
Biopsy in Clinical Practice. London:
British Society for Gastroenterology,
2004. Full text available at
http://www.bsg.org.uk/
GAH_C04
12/9/10
9:08
Page 147
SELF-ASSESSMENT
4.1 Self-assessment
questions
Question 1
Clinical scenario
A 24-year-old student with wellcontrolled ulcerative colitis treated
with sulfasalazine and azathioprine
develops acute diarrhoea during a
brief visit to Thailand.
Question
Which is the most seriously incorrect
response from the list below?
Answers
A The most likely diagnosis is an
acute exacerbation of ulcerative
colitis, which could be treated
with a higher dose of
sulfasalazine, or with oral or
parenteral corticosteroids
B The most likely diagnosis is
infectious diarrhoea, which
could be treated with a course of
antibiotics such as ciprofloxacin
or metronidazole
C Long-term treatment with
azathioprine might predispose
the patient to opportunistic
infection and broad-spectrum
antimicrobial, antiviral,
antiprotozoal and antifungal
therapy might be indicated
D The likely diagnosis is acute
exacerbation of ulcerative
colitis or infectious diarrhoea,
which could be treated with
antidiarrhoeals such as codeine
or loperamide, used judiciously
for a short time to provide
symptomatic relief
Question
Question 2
Clinical scenario
A 50-year-old woman who is
generally well apart from having
troublesome osteoarthritis of the
knees complains of profuse watery
diarrhoea that has steadily worsened
over the last 3 months.
Question
Select the most appropriate response
from the list below:
Answers
A A full clinical evaluation, followed
by blood tests and colonoscopy
are probably required
B It is likely that this is an adverse
event related to medications she
might be taking, such as NSAIDs
C Watery diarrhoea with
hypokalaemia, caused by a
vasoactive intestinal peptide
(VIP)-secreting tumour, is the
likely diagnosis
D The progressive nature of the
symptoms suggests a malignant
process
E Microscopic colitis is the most
likely diagnosis
Question 3
Clinical scenario
A 40-year-old man presents to your
clinic with a history of alternating
Answers
A The risk of colon cancer increases
markedly after the age of 50 years
B Alternating constipation and
diarrhoea are highly suspicious
of neoplastic obstruction
C Screening for mutations in the
APC and HNPCC genes has
significantly altered the routine
management of familial colon
cancer
D A screening colonoscopy is a
reasonable first step in the
diagnostic algorithm, and should
be arranged as soon as possible
E If the FBC and tumour markers
are normal, there is little chance
that he has colon cancer
F Faecal occult blood testing should
be performed to exclude colon
cancer
G It is likely that the patients father
has a sporadic form of colon
cancer, and the patient is at no
increased risk
H Annual colonoscopy is likely to be
necessary if the patient is found
to have adenomatous polyps
I Regular use of aspirin could halve
the patients risk of developing
adenomatous polyps of the colon
J Regular use of folic acid
supplements could halve the
147
GAH_C04
12/9/10
9:08
Page 148
Question 4
Clinical scenario
A young white woman is referred for
investigation of low BMI. She denies
any gastrointestinal symptoms and
seems generally quite healthy,
although thin and with a BMI of 17.
Question
Which of the following statements is
probably not correct?
Answers
A Coeliac disease is a cause of low
body weight and may be
asymptomatic
B Anorexia nervosa should be
considered in the differential
diagnosis
C Thyroid disease is unlikely and
isolated biochemical
abnormalities in the absence of
symptoms should be interpreted
with caution, as they can lead to
over-diagnosis and treatment
D Crohns disease is unlikely to
cause low body weight unless it is
very severe, when it is likely to be
symptomatic
E Occult colorectal cancer is highly
unlikely in this scenario
Question 5
Clinical scenario
You are devising a management
algorithm to be used in a rapidaccess, nurse-led clinic for patients
complaining of dysphagia.
Question
Which of the following
recommendations would you
support?
Answers
A Patients with a history of weight
loss and progressive dysphagia
should be assessed urgently with
a water-soluble contrast swallow
148
C
D
Question 6
Clinical scenario
A 70-year-old woman with
pneumonia who has been
treated with a third-generation
cephalosporin develops profuse
diarrhoea.
Question
Which of the following statements
about her situation is correct?
Answers
A The patient is likely to have
developed pseudomembranous
colitis due to infection with
Clostridium difficile
B Significant infection with
C. difficile is associated with
enterotoxin A, which can be
rapidly detected by a sensitive
ELISA test
C Rectal bleeding associated with
diarrhoea makes it unlikely that it
is related to the use of antibiotics
D Her antibiotic treatment should
be broadened to include a
fluoroquinolone such as
ciprofloxacin to cover infection
with dysentery-causing organisms
E The concurrent use of antibiotics
means that it will be impossible
to determine if her diarrhoea is
Question 7
Clinical scenario
A 20-year-old man with HIV
infection develops profuse
watery diarrhoea.
Question
Which of the following statements
regarding HIV infection and
the gastrointestinal tract is
correct?
Answers
A HIV infects CD4-positive
lymphocytes and is therefore
minimally present in the
gastrointestinal tract, which is
predominantly populated with
CD8-positive lymphocytes
B HIV infection reduces adaptive
immunity by reducing the
number of CD4-positive cells
and therefore has minimal
effects on intestinal immunity
because it is mainly mediated by
innate defence mechanisms
C Opportunistic infections such
cryptosporidiosis are unlikely if
the patient has a CD4-positive
lymphocyte count >200 cells/mL
D The most likely cause of
diarrhoea is an opportunistic
infection, even if the patients
CD4-positive lymphocyte count
is normal
E If the diarrhoea is profuse,
there is a small risk of fecaloral
transmission of HIV infection to
carers
Question 8
Clinical scenario
An obese patient reports to you
that he has recently been following
the Atkins diet, in which all forms
of carbohydrate are avoided and
subjects eat high-protein, high-fat
meals.
GAH_C04
12/9/10
9:08
Page 149
Question
Which of the following statements is
correct?
Answers
A It is unlikely that the subject will
lose weight because of the high
energy density of the foods
consumed
B The long-term consequences of
following this diet might include
vitamin and micronutrient
deficiency, dyslipidaemia,
accelerated atherosclerosis
and neoplasia
C The absence of carbohydrate in
the diet results in significant
hypoglycaemia
D The absence of carbohydrate in
the diet inhibits the absorption
of other nutrients, such as amino
acids and triglycerides
E The diet has not been tested in
clinical trials
Question 9
Clinical scenario
A 56-year-old woman presents to
her GP with lethargy and tiredness.
Her routine blood tests are normal
apart from an alkaline phosphatase
twice the upper limit of normal.
Subsequent testing of liver
antibodies show her to be positive
for anti-mitochondrial antibody
(M2 subtype).
Question
What should the patient be told?
Answers
A That she has primary biliary
cirrhosis and will urgently
need referral to a liver transplant
unit
B That she has symptomatic
primary biliary cirrhosis and will
need a liver biopsy to stage her
disease
C That she has primary biliary
cirrhosis and will need follow-up
in a liver clinic
Question 10
Clinical scenario
A 25-year-old heavily pregnant
woman returns to the UK from a
holiday in Bangladesh where she
visited family. Two weeks later she
presents jaundiced and confused to
casualty with an INR of 2, alanine
transaminase (ALT) of 2,000 U/L and
bilirubin of 200 mol/L.
Question
Which viral infection is most likely
to have caused this illness?
Answers
A
B
C
D
E
Hepatitis
Hepatitis
Hepatitis
Hepatitis
Hepatitis
A
B
C
D
E
Question 11
Clinical scenario
Prior to starting medical school, a
prospective student is tested for
hepatitis B. Her liver tests show
alanine transaminase (ALT) 120 U/L
and serology shows her to be
positive for HBsAg, HBcAb and
HBeAg, with a viral load of 105
genome equivalents/mL. A liver
biopsy is reported as showing early
fibrosis with evidence of moderate
inflammation.
Question
Treatment should be offered to this
patient in the form of:
Answers
A Interferon beta
B Interferon alfa 2b
C Pegylated interferon alfa 2a and
ribavirin
D Basiliximab
E Entecavir
Question 12
Clinical scenario
An 18-year-old man admits to
having taken 12 g of paracetamol
1 day prior to presentation in the
Emergency Department with
abdominal pain.
Question
Which of the following factors is
most important in determining
treatment?
Answers
A
B
C
D
E
His
His
His
His
His
paracetamol level
serum bilirubin
serum alanine transaminase
history
serum creatinine
Question 13
Clinical scenario
You are looking after a 35-year-old
woman with a 10-year history of
alcohol abuse (>50 units/week).
She has been given a diagnosis of
alcoholic hepatitis based on her
history, and investigations show a
bilirubin of 250 mol/L, alanine
transaminase (ALT) of 120 U/L
and INR of 2. Her creatinine has
increased over the last 2 days from
90 to 250 mol/L.
Question
In managing her further which
single investigation would be most
helpful?
Answers
A Urine osmolality
B Urine microscopy
C Serum antineutrophil cytoplasmic
antibody
D Creatinine clearance
E Spot urine sodium
Question 14
Clinical scenario
You are reviewing an 80-year-old
man who presents to clinic with
149
GAH_C04
12/9/10
9:08
Page 150
Question
Which of his medications may
explain his jaundice?
Answers
A
B
C
D
E
Atorvastatin
Aspirin
Augmentin (co-amoxiclav)
Amiodarone
Diclofenac
Question 15
Clinical scenario
A 35-year-old woman has an
ultrasound scan for investigation
of epigastic pain. Her liver function
tests are all normal, and by the time
of her scan her symptoms have
abated on ranitidine. The report
reads as follows: There are multiple
small hyperechoic lesions in both
lobes of the liver. No other focal
lesions. No features to suggest
cirrhosis or portal hypertension.
Intrahepatic and extrahepatic biliary
tree normal. Pancreas, kidneys,
spleen normal.
Clinical scenario
You admit a 45-year-old man who
had a liver transplant just over
3 months ago for primary sclerosing
cholangitis. He complains of fever,
abdominal pain and diarrhoea,
which has come on over the last
week. He has a platelet count of
60 109/L and alanine transaminase
(ALT) of 300 U/L with a normal
bilirubin. He is taking tacrolimus
and prednisolone for
immunosuppression. He tells you
that he recently stopped taking
valganciclovir.
Question
What is the most likely diagnosis?
Answers
A
B
C
D
E
Acute rejection
Chronic rejection
Donor-acquired toxoplasmosis
Donor-acquired cytomegalovirus
Recurrence of his primary
sclerosing cholangitis
Question 18
Clinical scenario
A 45-year-old man presents
with chronic epigastric pain
radiating through to the back
and steatorrhoea. He consumes
45 units of alcohol per week and
has no family history of pancreatic
disease. He has no other significant
past medical history. CT scanning
of the abdomen reveals a dilated
pancreatic duct with associated
calcification of the gland.
Subsequent endoscopic retrograde
cholangiopancreatography (ERCP)
shows similar findings with no
dominant structure. He is started
on Creon (pancreatin) 3 tablets tds
and there is improvement in his
steatorrhoea.
Question
Question 17
Clinical scenario
Answers
A Magnetic resonance
cholangiopancreatography
(MRCP)
B Serum lipid profile
C Endoscopic ultrasound
D Serum amylase
E Pancreatic biopsy
Question
Question
Question 19
Answers
A
B
C
D
E
150
Question 16
Multiple metastasis
Focal nodular hyperplasia
Adenomas
Haemangiomas
Liver abscesses
Answers
A
B
C
D
E
F
G
Clinical scenario
A 66-year-old woman is referred
urgently with painless jaundice and
weight loss. Bilirubin is 212 mol/L,
alanine transaminase (ALT) 60 U/L,
alkaline phosphatase (ALP) 605 U/L,
albumin 34 g/L and prothrombin
time 17 seconds. Ultrasound scanning
of the abdomen shows a grossly
dilated biliary tree and a dilated
pancreatic duct, but no mass is seen.
GAH_C04
12/9/10
9:08
Page 151
Question
What is the next most appropriate
step in her management?
Answers
A Endoscopic retrograde
cholangiopancreatography
(ERCP)
B Abdominal CT scan
C Pancreatic endoscopic ultrasound
D Check CA19-9
E Laparoscopy
Question 20
Clinical scenario
A 30-year-old man is admitted
with haemoglobin 5.2 g/dL, mean
corpuscular volume 55.4 fL and
ferritin 3 g/L (normal range
14200). B12 and folate levels
are normal. He has had no
haematemesis or malaena and no
abdominal symptoms. An upper
gastrointestinal endoscopy is
performed. Figure 78 shows the
appearance in the second part
of the duodenum.
Question
What should be the next step in
management?
Answers
A Sclerotherapy with alcohol and
adrenaline
B Angiography and embolisation
C Thermal ablation with argon
plasma coagulation
D Application of endoscopic bands
E Biopsy
Question
What would be the most appropriate
next step?
Answers
Question 21
Clinical scenario
A 40-year-old woman presents to the
outpatient clinic with intermittent
epigastric discomfort. FBC, urea
and electrolytes are normal. Liver
function tests reveal alkaline
phosphatase (ALP) 600 U/L,
-glutamyltransferase (GGT)
768 U/L, bilirubin 13 mol/L,
A Endoscopic retrograde
cholangiopancreatography and
bile duct trawl
B CT scan
C CA19-9
D Magnetic resonance
cholangiopancreatography
(MRCP)
E Refer for laparoscopic
cholecystectomy and bile duct
exploration
Question 22
Clinical scenario
A 79-year-old man presents
with obstructive jaundice and is
found to have a non-resectable
adenocarcinoma of the pancreatic
head. The decision at the
multidisciplinary team meeting
is that he should receive palliative
care and that his jaundice should be
relieved by inserting a biliary stent.
Question
Which of the following factors
would favour stent insertion
via percutaneous transhepatic
cholangiography (PTC) rather
than endoscopic retrograde
cholangiopancreatography (ERCP)?
Answers
A
B
C
D
E
151
GAH_C04
12/9/10
9:08
Page 152
Question 23
Clinical scenario
A 48-year-old man with type 1
diabetes mellitus of 8 years duration
attends outpatients with a history of
opening his bowels five to six times
per day over the last 6 months.
There is no blood or mucus in
the stool and he has not had any
abdominal pain. His HbA1c is 7.0%.
FBC, urea and electrolytes, liver
function tests, thyroid function
tests, abdominal ultrasound and
colonoscopy with random biopsies
are all normal.
Question
Which two of the following tests are
most likely to lead to a diagnosis?
Answers
A Autonomic function tests
B Helicobacter serology
C Stool for microscopy, culture and
sensitivity
D Abdominal CT scan
E Small bowel enema
F Stool for faecal elastase
G Lactose hydrogen breath test
H Small bowel manometry
I Glycocholate hydrogen breath test
J Rigid sigmoidoscopy and rectal
deep rectal biopsy
Question 24
Clinical scenario
A 40-year-old man is referred
with a 12-month history of
diarrhoea.
Question
Which one of the following features
would be against a diagnosis of
irritable bowel syndrome?
Answers
A Passage of mucus with the
motions.
B Nocturnal diarrhoea
152
4.2 Self-assessment
answers
Answer to Question 1
D
Question 25
Clinical scenario
A 66-year-old man is referred to the
gastroenterology outpatient clinic
for investigation of a 6-month
history of diarrhoea.
Question
Which two of the following
statements are true?
Answers
A Colonoscopic investigation should
only be offered if alert symptoms
such as weight loss or rectal
bleeding are present
B Rigid sigmoidoscopy and rectal
biopsy will exclude microscopic
colitis
C Normal inflammatory markers
(ESR/CRP) do not exclude
inflammatory bowel disease
as a cause of his symptoms
D Coeliac antibodies should only be
performed if the patient gives a
history of symptoms worsening
on exposure to wheat
E Crohns disease is an unlikely
diagnosis in a man of his age
F A history of cholecystectomy
preceding the onset of his
symptoms may suggest a
diagnosis of microscopic colitis
G The presence of abdominal pain
is highly suggestive of ulcerative
colitis
H Colorectal cancer is a possible
diagnosis
I Nocturnal diarrhoea is common
in the elderly
J Peptic ulceration is a likely cause
Answer to Question 2
A
Chronic diarrhoea may be due to a
large number of different causes,
hence a full evaluation of patients
presenting in this way is mandatory.
This patient may well have used
NSAIDs that are associated with
the development of microscopic
or lymphocytic colitis, which is a
typical cause of watery diarrhoea
in middle-aged and elderly women.
GAH_C04
12/9/10
9:08
Page 153
Answer to Question 3
A, F
Colorectal cancer is the third
commonest cause of cancer-related
death, and the lifetime risk of
developing the condition is about
1 in 50. However, this risk is very
low in early life and rises steeply
after the age of 50 years. Typically,
colorectal cancer may be
asymptomatic or it may present
with constipation, diarrhoea,
rectal bleeding, abdominal pain,
unexplained iron deficiency or
anaemia. Alternating constipation
and diarrhoea, especially if longstanding, is more indicative of
irritable bowel syndrome.
Germline mutations in the APC
gene are exceedingly rare, although
when they occur, they cause an
autosomally dominant form of
hereditary colorectal cancer.
Hereditary non-polyposis colon
cancer (HNPCC) is a clinical
syndrome describing an inherited
tendency to develop cancer without
a preceding history of adenomatous
polyps. It is associated with
mutations in a number of different
genes, particularly those associated
with correcting defects in DNA
replication at the cellular level
(mismatch-repair genes). Genetic
testing for HNPCC is complex and
not easily applied in clinical practice.
Even in cases of apparently sporadic
colorectal cancer there is probably
an increased risk in first-degree
relatives, probably as a consequence
of genetic and environmental factors
such as diet. Strategies for screening
Answer to Question 4
C
Low body weight or weight loss may
be caused by many processes,
including dietary habits, exercise,
smoking and undiagnosed medical
illnesses such as coeliac disease,
Crohns disease and thyrotoxicosis.
The symptoms and signs of these
conditions may be very mild, and
with an insidious onset the patient
may complain of few or no
symptoms at all. This is most
true for coeliac disease and
hyperthyroidism, which might only
be detected by special tests (coeliac
serology and thyroid function tests).
Crohns disease is unlikely to cause
significant weight loss without
also causing abdominal pain and
diarrhoea, which might be mistaken
for symptoms of irritable bowel
syndrome. At this age, occult
colorectal cancer is highly unlikely.
Answer to Question 5
A
A barium swallow should be
obtained before endoscopy in
Answer to Question 6
B
Antibiotic-associated diarrhoea
frequently develops after use of
broad-spectrum antibiotics. In
many cases it is not associated
with toxigenic C. difficile infection
and may clear simply on withdrawal
of the antibiotics. Significant
C. difficile infection is associated
with production by the bacteria
of enterotoxins, which can be
rapidly detected in the stool using
tests such as ELISA. Detection
of C. difficile infection is not
compromised by concurrent
use of antibiotics. In severe
cases, toxigenic C. difficile infection
can cause pseudomembranous
colitis, which is associated with
the passage of blood and mucus
per rectum. In these cases the
appropriate first line of treatment
is withdrawal of broad-spectrum
antibiotics if possible, and
administration of metronidazole
or oral vancomycin.
153
GAH_C04
12/9/10
9:08
Page 154
Answer to Question 7
C
There is increasing evidence that
HIV infection has profound effects
on the gastrointestinal immune
system, despite the relative
predominance of CD8-positive T
lymphocytes in this compartment.
Patients on long-term antiretroviral
treatment may harbour a reservoir
of infection in the intestine that
allows reactivation when
medications are withdrawn.
Defence mechanisms in the intestine
are critically dependent on the
function of T lymphocytes, including
a specialised group of intraepithelial
lymphocytes confined to the
intestine. Opportunistic intestinal
infections are rare when the CD
count is satisfactory and more
frequent when the count is low.
Despite the high levels of virus in
gastrointestinal secretions, including
saliva, HIV does not seem to infect
via the oral route, although infection
by rectal, vaginal and parenteral
routes occurs readily.
Answer to Question 8
B
Anecdotal reports and clinical
studies demonstrate that ketogenic
diets such as the Atkins diet can lead
to substantial loss of weight. This
probably occurs through ketogenic
metabolism of fat and suppression
of appetite by the high intake of
protein. The relative paucity of
carbohydrate in the diet is unlikely
to affect the absorption of other
nutrients, although the lack of fruit,
vegetables and starchy foods may
lead to deficiencies of calcium, iron,
folate and other vitamins. With the
paucity of glucose in the diet, blood
levels can be maintained by
gluconeogenesis. The relatively high
intake of fats and red meat and low
intake of vitamins and fibre may
154
Answer to Question 9
C
Primary biliary cirrhosis (PBC)
is a disease characterised by
inflammatory destruction of the
small bile ducts within the liver,
eventually leading to cirrhosis
of the liver. The cause of PBC is
unknown, but because of the
presence of autoantibodies it
is generally thought to be an
autoimmune disease. In the
presence of typical symptoms,
liver enzyme abnormalities and
positive M2 anti-mitochondrial
antibodies, the diagnosis can
confidently be made without a liver
biopsy. Most patients with PBC do
not come to liver transplantation,
which is reserved for those with
documented decompensated liver
disease or (very occasionally)
uncontrollable symptoms (usually
pruritus). In symptomatic patients
ursodeoxycholic acid prolongs
survival, and because of this along
with the need for surveillance for
progressive liver disease patients
should have ongoing follow-up,
usually performed by their local
gastroenterologist/hepatologist.
Answer to Question 10
E
Infective hepatitis can be caused
by a variety of different viruses
such as hepatitis A, B, C, D and E.
The incubation period following
exposure to hepatitis E ranges
from 3 to 8 weeks, with a mean
of 40 days. Hepatitis E is usually
a self-limiting infection followed
by complete recovery; prolonged
viraemia or faecal shedding is
unusual and there is no chronic
infection. A fulminant form of
hepatitis E can develop, most
Answer to Question 11
B
Government estimates are that
about 180,000 people in the UK
have chronic hepatitis B and the
prevalence of hepatitis B surface
antigen (HBsAg) among blood
donors is around 1 in 1,500.
Around one-fifth of HBsAg-positive
individuals are HBeAg positive, with
720% spontaneously losing HBeAg
positivity per year.
There are five therapies for chronic
hepatitis B that are currently
approved: interferon alfa-2b,
lamivudine, adefovir, entecavir
and pegylated interferon
(peginterferon) alfa-2a. Given
the need for long-term treatment,
current guidelines recommend
treatment only for patients with
elevated aminotransferase levels or
histological evidence of moderate or
severe inflammation or advanced
fibrosis. For patients with HBeAgpositive chronic hepatitis B who do
not yet have cirrhosis, the goal is
to achieve HBeAg seroconversion,
and interferon alfa alone has the
best chance of achieving this.
Viral suppression without HBeAg
clearance is invariably associated
with relapse, whereas viral
suppression with HBeAg clearance
GAH_C04
12/9/10
9:08
Page 155
Answer to Question 12
D
The history is most important
in determining the risk of
hepatotoxicity: a dose of
paracetamol of as little as
75 mg/kg in someone at risk
can be fatal. Risk factors include:
regular ethanol consumption in
excess of 21 units/week in males
and 14 units/week in females;
regular use of enzyme-inducing
drugs (carbamazepine, phenytoin,
phenobarbital, rifampacin);
conditions causing glutathione
depletion (malnutrition, HIV,
eating disorders, cystic fibrosis).
Answer to Question 13
E
Although not diagnostic, a low
spot urinary sodium (<5 mmol/L)
is in keeping with a diagnosis of
hepatorenal syndrome (HRS),
assuming that the patient does
not have intravascular volume
depletion. HRS is defined as an
acute, functional and progressive
reduction in renal blood flow and
glomerular filtration rate (GFR)
secondary to intense renal cortical
vasoconstriction in the setting of
decompensated liver disease. Other
aetiologies for renal failure in liver
disease must be excluded. HRS
can be classified as type 1, with a
rapidly progressive decline in GFR
(<2 weeks), or type 2, which is not
as rapidly progressive (>2 weeks).
Answer to Question 14
C
Virtually all drugs can cause liver
injury. In this case the most recently
introduced medication is most likely
to be the cause of liver injury,
assuming other investigations for
chronic liver disease are negative.
The prescription drugs to be
particularly aware of when assessing
a patient with an undiagnosed liver
disorder include Augmentin (coamoxiclav), diclofenac, isoniazid,
erythromycin, sodium valproate,
amiodarone and phenytoin.
Answer to Question 15
D
Liver imaging must always be
interpreted in the context of the
clinical information, particularly
the presence or absence of relevant
symptoms, the presence or absence
Answer to Question 16
D
Cytomegalovirus (CMV) infection
is an important consideration in
any organ transplant recipient,
particularly where the recipient has
never had infection but the donor is
a carrier, since the recipient is then
at risk of primary infection. For this
reason close attention is given to
prophylaxis, particularly in the first
3 months after transplantation.
When prophylaxis is stopped there is
still a chance of infection, which in
the case of liver transplant recipients
155
GAH_C04
12/9/10
9:08
Page 156
Answer to Question 19
Answer to Question 17
E, H
The most common cause of
ongoing gastrointestinal symptoms
in patients with coeliac disease
is continued gluten exposure.
Dietitians are best equipped to
assess this and therefore should
be involved in assessment. Up to
30% of patients with coeliac disease
and unresolved diarrhoea have
associated exocrine pancreatic
insufficiency. The faecal elastase-1
test is cheap, non-invasive and
simple to use in an outpatient
setting. Positive coeliac antibodies
may suggest continued gluten
exposure but are not diagnostic.
Repeat duodenal biopsy may still
show villous atrophy even in
compliant patients. Colonoscopy in a
patient under 45 years is unlikely to
demonstrate a significant cause for
diarrhoea. Although thyroid disease
is associated with coeliac disease
and should be screened for, only
12% of patients develop new
thyroid dysfunction over a
12-month period.
Answer to Question 18
B
Chronic pancreatitis is most
commonly caused by alcohol but
this man consumes only small
quantities. MRCP may help to
exclude obstructive causes or
156
B
This scenario is highly suspicious
of cancer in the pancreatic head as
there is obstructive jaundice and
ultrasound demonstrates the double
duct sign. The absence of a mass
on ultrasound does not exclude
this diagnosis and therefore a CT
scan is required to further image the
pancreatic head and simultaneously
stage the disease. ERCP would
demonstrate the stricture but
gives no staging information,
and endoscopic ultrasound may
not pick up liver metastases. CA19-9
is not specific for pancreatic cancer
and is often raised in obstructive
jaundice of any aetiology.
Laparoscopy is too invasive at this
stage without further imaging.
Answer to Question 20
C
This is duodenal angiodysplasia and
very likely to be the source of blood
loss in this patient. It can be dealt
with directly by applying argon
electrocoagulation, with minimal
time added to the procedure.
Sclerotherapy and banding
techniques are not appropriate
for such a lesion. Angiography may
not identify this lesion if it is not
actively bleeding and embolisation
may not be possible. Biopsy is
hazardous as it may lead to
torrential bleeding.
Answer to Question 21
D
As this woman is not acutely ill,
there is time to perform further
investigations of the biliary tree
without moving directly to invasive
procedures. MRCP has a higher
sensitivity than CT for detecting
distal bile duct stones, which are the
most likely cause of this womans
presentation. CA19-9 is useless in
this situation. If her MRCP is
negative, then laparoscopic removal
of the gallbladder would be
appropriate.
Answer to Question 22
E
ERCP is usually preferable to PTC
for insertion of biliary stents, unless
ERCP has previously failed or there
is altered anatomy. Patients who
have had a Billroth II gastrectomy
have grossly different anatomy
and ERCP can be impossible to
perform. Impaired clotting (raised
prothrombin time, low platelets or
liver disease) are contraindications
to a percutaneous approach, as is
the presence of ascites.
Answer to Question 23
F, I
The three most likely associations
with type 1 diabetes mellitus that
cause diarrhoea are coeliac disease
(up to 5%, so check coeliac
serology), exocrine pancreatic
insufficiency (over 30% in some
studies) and small bowel bacterial
overgrowth (SBBO). SBBO
commonly occurs when there is
autonomic dysfunction, but tests of
the autonomic nervous system may
be normal, and SBBO may not be
present in those with dysfunction.
This patient also has good metabolic
control of his diabetes as judged by
HbA1c of 7.0%. It will be appropriate
GAH_C04
12/9/10
9:08
Page 157
Answer to Question 24
B
The Rome II diagnostic criteria for
irritable bowel syndrome require
the presence of abdominal pain
for 12 weeks (not necessarily
consecutive) with two of the
following: relieved by defecation;
onset associated with change in
form of stool; onset associated
with change in frequency of stool.
Associated features may include
Answer to Question 25
C, H
All patients over the age of 50 years
with a persistent change in bowel
habit should undergo colonoscopy
(or double-contrast barium enema)
to exclude colonic neoplasm.
Rectal biopsies alone do not
exclude microscopic colitis: it is
recommended that biopsies are
157
GAH_Z01
12/9/10
9:08
Page 158
Scientific Background
to Medicine 1
GENETICS AND
MOLECULAR
MEDICINE
Nucleic Acids and
Chromosomes 3
Inammation 120
Nucleotides 61
Immunosuppressive Therapy
125
Self-assessment 66
CELL BIOLOGY
Ion Transport 71
1.1 Ion channels 72
1.2 Ion carriers 79
Techniques in Molecular
Biology 11
BIOCHEMISTRY
AND METABOLISM
Requirement for Energy 35
Carbohydrates 41
Fatty Acids and Lipids 45
3.1 Fatty acids 45
3.2 Lipids 48
158
Haem 59
Self-assessment 130
ANATOMY
Heart and Major Vessels 135
Lungs 138
Liver and Biliary Tract 140
Spleen 142
Kidney 143
Haematopoiesis 94
Endocrine Glands 144
Self-assessment 97
IMMUNOLOGY AND
IMMUNOSUPPRESSION
Eye 150
Nervous System 152
Self-assessment 167
PHYSIOLOGY
T Cells 109
B Cells 112
Tolerance and Autoimmunity
115
GAH_Z01
12/9/10
9:08
Page 159
Self-assessment 220
Scientific Background
to Medicine 2
CLINICAL
PHARMACOLOGY
Introducing Clinical
Pharmacology 3
1.1 Risks versus benefits 4
1.2 Safe prescribing 4
Pharmacokinetics 7
2.1
2.2
2.3
2.4
2.5
2.6
Introduction 7
Drug absorption 7
Drug distribution 11
Drug metabolism 12
Drug elimination 17
Plasma half-life and steadystate plasma concentrations 19
2.7 Drug monitoring 20
Pharmacodynamics 22
3.1 How drugs exert their effects
22
3.2 Selectivity is the key to the
therapeutic utility of an agent
25
3.3 Basic aspects of the
interaction of a drug with
its target 27
3.4 Heterogeneity of drug
responses, pharmacogenetics
and pharmacogenomics 31
Self-assessment 70
Prescribing in Special
Circumstances 33
4.1 Introduction 33
4.2 Prescribing and liver disease
33
4.3 Prescribing in pregnancy 36
4.4 Prescribing for women of
childbearing potential 39
4.5 Prescribing to lactating
mothers 39
4.6 Prescribing in renal disease 41
4.7 Prescribing in the elderly 44
STATISTICS,
EPIDEMIOLOGY,
CLINICAL TRIALS
AND METAANALYSES
Statistics 79
Epidemiology 86
2.1 Observational studies 87
159
GAH_Z01
12/9/10
9:08
Page 160
Clinical Skills
CLINICAL SKILLS
FOR PACES
Introduction 3
History-taking for PACES
(Station 2) 6
160
2.1
2.2
2.3
2.4
2.5
2.6
2.7
2.8
Pain 82
Breathlessness 87
Nausea and vomiting 88
Constipation 89
Bowel obstruction 90
Anxiety and depression 91
Confusion 93
End-of-life care:
the dying patient 94
2.9 Specialist palliative care
services 96
Self-assessment 98
MEDICINE FOR
THE ELDERLY
PACES Stations and Acute
Scenarios 107
1.1 History-taking 107
1.1.1 Frequent falls 107
1.1.2 Recent onset of confusion
110
1.1.3 Urinary incontinence and
immobility 114
1.1.4 Collapse 116
1.1.5 Vague aches and pains
119
1.1.6 Swollen legs and back
pain 121
1.1.7 Failure to thrive: gradual
decline and weight loss
127
GAH_Z01
12/9/10
9:08
Page 161
Self-assessment 181
Acute Medicine
ACUTE MEDICINE
PACES Stations and Acute
Scenarios 3
1.1 Communication skills and
ethics 3
1.1.1 Cardiac arrest 3
1.1.2 Stroke 4
1.1.3 Congestive cardiac
failure 5
1.1.4 Lumbar back pain 6
1.1.5 Community-acquired
pneumonia 7
1.1.6 Acute pneumothorax 7
1.2 Acute scenarios 8
1.2.1 Cardiac arrest 8
1.2.2 Chest pain and
hypotension 12
1.2.3 Should he be
thrombolysed? 15
1.2.4 Hypotension in acute
coronary syndrome 20
1.2.5 Postoperative
breathlessness 21
1.2.6 Two patients with
tachyarrhythmia 23
1.2.7 Bradyarrhythmia 27
1.2.8 Collapse of unknown
cause 30
1.2.9 Asthma 33
1.2.10 Pleurisy 36
3.2
3.3
3.4
3.5
3.6
3.7
3.8
Self-assessment 120
INFECTIOUS
DISEASES
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 A cavitating lung lesion 3
1.1.2 Fever and
lymphadenopathy 5
1.1.3 Still feverish after
6 weeks 7
1.1.4 Chronic fatigue 10
161
GAH_Z01
12/9/10
9:08
Page 162
162
2.10.6
Antimicrobial prophylaxis 94
Immunisation 95
Infection control 97
Travel advice 99
Bacteria 100
2.5.1 Gram-positive
bacteria 101
2.5.2 Gram-negative
bacteria 104
2.6 Mycobacteria 108
2.6.1 Mycobacterium
tuberculosis 108
2.6.2 Mycobacterium leprae
113
2.6.3 Opportunistic
mycobacteria 114
2.7 Spirochaetes 115
2.7.1 Syphilis 115
2.7.2 Lyme disease 117
2.7.3 Relapsing fever 118
2.7.4 Leptospirosis 118
2.8 Miscellaneous bacteria 119
2.8.1 Mycoplasma and
Ureaplasma 119
2.8.2 Rickettsiae 120
2.8.3 Coxiella burnetii
(Q fever) 120
2.8.4 Chlamydiae 121
2.9 Fungi 121
2.9.1 Candida spp. 121
2.9.2 Aspergillus 123
2.9.3 Cryptococcus
neoformans 124
2.9.4 Dimorphic fungi 125
2.9.5 Miscellaneous fungi
126
2.10 Viruses 126
2.10.1 Herpes simplex
viruses 127
2.10.2 Varicella-zoster virus
128
2.10.3 Cytomegalovirus 130
2.10.4 EpsteinBarr virus
130
2.10.5 Human herpesviruses
6 and 7 130
2.11
2.12
2.13
2.14
Human herpesvirus 8
131
2.10.7 Parvovirus 131
2.10.8 Hepatitis viruses 132
2.10.9 Influenza virus 133
2.10.10 Paramyxoviruses 134
2.10.11 Enteroviruses 134
2.10.12 Coronaviruses and
SARS 135
Human immunodeficiency
virus 135
2.11.1 Prevention following
sharps injury 140
Travel-related viruses 142
2.12.1 Rabies 142
2.12.2 Dengue 143
2.12.3 Arbovirus infections
143
Protozoan parasites 144
2.13.1 Malaria 144
2.13.2 Leishmaniasis 145
2.13.3 Amoebiasis 146
2.13.4 Toxoplasmosis 147
Metazoan parasites 148
2.14.1 Schistosomiasis 148
2.14.2 Strongyloidiasis 149
2.14.3 Cysticercosis 150
2.14.4 Filariasis 151
2.14.5 Trichinosis 151
2.14.6 Toxocariasis 152
2.14.7 Hydatid disease 152
Self-assessment 159
DERMATOLOGY
PACES Stations and Acute
Scenarios 175
1.1 History taking 175
1.1.1 Blistering disorders 175
1.1.2 Chronic red facial rash
177
GAH_Z01
12/9/10
9:08
Page 163
2.4
2.5
2.6
2.7
2.8
2.9
2.10
2.11
2.12
2.13
2.14
2.15
2.16
2.17
2.18
2.19
2.20
2.21
2.22
2.23
2.24
2.25
2.26
2.27
2.28
Self-assessment 285
Haematology and
Oncology
HAEMATOLOGY
PACES Stations and Acute
Scenarios 1
1.1 History-taking 3
1.1.1 Microcytic hypochromic
anaemia 3
1.1.2 Macrocytic anaemia 5
1.1.3 Lymphocytosis and
anaemia 8
1.1.4 Thromboembolism
and fetal loss 11
1.1.5 Weight loss and
thrombocytosis 12
1.2 Clinical examination 14
1.2.1 Normocytic anaemia
14
1.2.2 Thrombocytopenia
and purpura 14
1.2.3 Jaundice and anaemia
16
1.2.4 Polycythaemia 17
1.2.5 Splenomegaly 18
1.3 Communication skills and
ethics 19
1.3.1 Persuading a patient
to accept HIV testing 19
1.3.2 Talking to a distressed
relative 20
1.3.3 Explaining a medical
error 22
1.3.4 Breaking bad news 23
1.4 Acute scenarios 25
1.4.1 Chest syndrome in sickle
cell disease 25
1.4.2 Neutropenia 27
1.4.3 Leucocytosis 29
1.4.4 Spontaneous bleeding
and weight loss 31
1.4.5 Cervical
lymphadenopathy and
difficulty breathing 32
1.4.6 Swelling of the leg 35
163
GAH_Z01
12/9/10
9:08
Page 164
2.2
2.3
2.4
164
Causes of anaemia 37
2.1.1 Thalassaemia
syndromes 38
2.1.2 Sickle cell syndromes 39
2.1.3 Enzyme defects 41
2.1.4 Membrane defects 41
2.1.5 Iron metabolism and
iron-deficiency
anaemia 43
2.1.6 Vitamin B12 and folate
metabolism and
deficiency 44
2.1.7 Acquired haemolytic
anaemia 44
2.1.8 Bone-marrow failure
and inflitration 46
Haematological malignancy
46
2.2.1 Multiple myeloma 46
2.2.2 Acute leukaemia: acute
lymphoblastic leukaemia
and acute myeloid
leukaemia 49
2.2.3 Chronic lymphocytic
leukaemia 52
2.2.4 Chronic myeloid
leukaemia 54
2.2.5 Malignant lymphomas:
non-Hodgkins
lymphoma and
Hodgkins lymphoma 55
2.2.6 Myelodysplastic
syndromes 58
2.2.7 Non-leukaemic
myeloproliferative
disorders (including
polycythaemia vera,
essential
thrombocythaemia
and myelofibrosis) 60
2.2.8 Amyloidosis 62
Bleeding disorders 64
2.3.1 Inherited bleeding
disorders 64
2.3.2 Aquired bleeding
disorders 67
2.3.3 Idiopathic
throbocytopenic
purpura 68
Thrombotic disorders 69
Self-assessment 94
ONCOLOGY
PACES Stations and Acute
Scenarios 109
1.1 History-taking 109
1.1.1 A dark spot 109
1.2 Clinical examination 110
1.2.1 A lump in the neck 110
1.3 Communication skills and
ethics 111
1.3.1 Am I at risk of cancer?
111
1.3.2 Consent for
chemotherapy (1) 113
Self-assessment 185
GAH_Z01
12/9/10
9:08
Page 165
Cardiology and
Respiratory Medicine
CARDIOLOGY
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 Paroxysmal
palpitations 3
1.1.2 Palpitations with
dizziness 6
1.1.3 Breathlessness and
ankle swelling 9
1.1.4 Breathlessness and
exertional presyncope
12
1.1.5 Dyspnoea, ankle
oedema and cyanosis 14
1.1.6 Chest pain and
recurrent syncope 16
1.1.7 Hypertension found at
routine screening 19
1.1.8 Murmur in pregnancy
23
1.2 Clinical examination 25
1.2.1 Irregular pulse 25
1.2.2 Congestive heart
failure 27
1.2.3 Hypertension 29
1.2.4 Mechanical valve 29
1.2.5 Pansystolic murmur 30
1.2.6 Mitral stenosis 31
1.2.7 Aortic stenosis 32
1.2.8 Aortic regurgitation 33
1.2.9 Tricuspid regurgitation
34
1.2.10 Eisenmengers
syndrome 35
1.2.11 Dextrocardia 36
1.3 Communication skills and
ethics 37
1.3.1 Advising a patient against
unnecessary
investigations 37
1.3.2 Explanation of
uncertainty of
diagnosis 38
2.2
2.3
2.4
165
GAH_Z01
12/9/10
9:08
Page 166
3.5
166
ECG 147
3.1.1 Exercise ECGs 151
Basic electrophysiology
studies 152
Ambulatory monitoring 154
Radiofrequency ablation and
implantable cardioverter
defibrillators 156
3.4.1 Radiofrequency
ablation 156
3.4.2 Implantable
cardioverter
defibrillator 157
3.4.3 Cardiac
resynchronisation
therapy 158
Pacemakers 159
3.6
Self-assessment 176
RESPIRATORY
MEDICINE
PACES Stations and Acute
Scenarios 191
1.1 History-taking 191
1.1.1 New breathlessness
191
1.1.2 Solitary pulmonary
nodule 193
1.1.3 Exertional dyspnoea
with daily sputum 195
1.1.4 Dyspnoea and fine
inspiratory crackles
197
1.1.5 Nocturnal cough 199
1.1.6 Daytime sleepiness and
morning headache 202
1.1.7 Lung cancer with
asbestos exposure 204
1.1.8 Breathlessness with a
normal chest
radiograph 206
2.3
2.4
GAH_Z01
12/9/10
9:08
Page 167
2.5
2.6
2.12.3 Non-invasive
ventilation 292
2.13 Lung transplantation 294
Self-assessment 312
Gastroenterology and
Hepatology
GASTROENTEROLOGY
AND HEPATOLOGY
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 Heartburn and dyspepsia
3
1.1.2 Dysphagia and feeding
difficulties 5
1.1.3 Chronic diarrhoea 8
1.1.4 Rectal bleeding 10
2.2
Oesophageal disease 60
2.1.1 Gastro-oesophageal
reflux disease 60
2.1.2 Achalasia and
oesophageal
dysmotility 62
2.1.3 Oesophageal cancer
and Barretts
oesophagus 63
Gastric disease 66
2.2.1 Peptic ulceration and
Helicobacter pylori 66
2.2.2 Gastric carcinoma 68
2.2.3 Rare gastric tumours
69
2.2.4 Rare causes of
gastrointestinal
haemorrhage 70
167
GAH_Z01
12/9/10
9:08
Page 168
2.3
2.4
2.5
2.6
2.7
2.8
2.9
168
Self-assessment 147
Neurology,
Ophthalmology and
Psychiatry
NEUROLOGY
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 Episodic headache 3
1.1.2 Facial pain 6
1.1.3 Funny turns/blackouts 8
1.1.4 Increasing seizure
frequency 11
1.1.5 Numb toes 12
1.1.6 Tremor 15
1.1.7 Memory problems 17
1.1.8 Chorea 19
1.1.9 Muscle weakness and
pain 20
1.1.10 Sleep disorders 21
1.1.11 Dysphagia 24
1.1.12 Visual hallucinations 26
1.2 Clinical examination 27
1.2.1 Numb toes and foot
drop 27
1.2.2 Weakness in one leg 28
1.2.3 Spastic legs 32
1.2.4 Gait disturbance 33
1.2.5 Cerebellar syndrome 36
1.2.6 Weak arm/hand 37
1.2.7 Proximal muscle
weakness 40
1.2.8 Muscle wasting 41
1.2.9 Hemiplegia 42
1.2.10 Tremor 44
1.2.11 Visual field defect 45
1.2.12 Unequal pupils 47
1.2.13 Ptosis 48
1.2.14 Abnormal ocular
movements 51
1.2.15 Facial weakness 53
1.2.16 Lower cranial nerve
assessment 55
1.2.17 Speech disturbance 57
1.3 Communication skills and
ethics 60
GAH_Z01
12/9/10
9:08
Page 169
2.2
2.3
2.4
2.5
2.6
2.7
2.8
Epilepsy 110
Cerebrovascular disease
116
2.8.1 Stroke 116
2.8.2 Transient ischaemic
attacks 120
2.8.3 Intracerebral
haemorrhage 122
2.8.4 Subarachnoid
haemorrhage 125
2.9 Brain tumours 127
2.10 Neurological complications
of infection 131
2.10.1 New variant
CreutzfeldtJakob
disease 131
2.11 Neurological complications
of systemic disease 132
2.11.1 Paraneoplastic
conditions 132
2.12 Neuropharmacology 133
OPHTHALMOLOGY
PACES Stations and Acute
Scenarios 161
1.1 Clinical scenarios 161
1.1.1 Examination of the eye
161
1.2 Acute scenarios 164
1.2.1 An acutely painful red eye
164
1.2.2 Two painful red eyes and
a systemic disorder 166
1.2.3 Acute painless loss of
vision in one eye 168
1.2.4 Acute painful loss of vision
in a young woman 170
1.2.5 Acute loss of vision in an
elderly man 171
Self-assessment 148
2.1
2.2
2.3
2.4
2.5
2.6
Iritis 173
Scleritis 174
Retinal artery occlusion 175
Retinal vein occlusion 178
Optic neuritis 179
Ischaemic optic neuropathy in
giant-cell arteritis 180
2.7 Diabetic retinopathy 181
Self-assessment 188
PSYCHIATRY
PACES Stations and Acute
Scenarios 195
1.1 History-taking 195
1.1.1 Eating disorders 195
1.1.2 Medically unexplained
symptoms 197
169
GAH_Z01
12/9/10
9:08
Page 170
170
2.11
2.12
2.13
2.14
Self-assessment 241
Endocrinology
ENDOCRINOLOGY
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 Hypercalcaemia 3
1.1.2 Polyuria 5
1.1.3 Faints, sweats and
palpitations 8
1.1.4 Gynaecomastia 12
1.1.5 Hirsutism 14
1.1.6 Post-pill amenorrhoea
16
1.1.7 A short girl with no
periods 17
1.1.8 Young man who has not
developed 20
1.1.9 Depression and diabetes
21
1.1.10 Acromegaly 23
1.1.11 Relentless weight gain 24
1.1.12 Weight loss 26
1.1.13 Tiredness and lethargy 29
1.1.14 Flushing and diarrhoea
32
1.1.15 Avoiding another
coronary 34
1.1.16 High blood pressure and
low serum potassium 37
1.1.17 Tiredness, weight loss
and amenorrhoea 39
GAH_Z01
12/9/10
9:08
Page 171
Self-assessment 174
Nephrology
NEPHROLOGY
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 Dipstick haematuria 3
1.1.2 Pregnancy with renal
disease 5
1.1.3 A swollen young woman
8
1.1.4 Rheumatoid arthritis with
swollen legs 11
1.1.5 A blood test shows
moderate renal failure 13
1.1.6 Diabetes with impaired
renal function 16
1.1.7 Atherosclerosis and renal
failure 18
1.1.8 Recurrent loin pain 20
1.2 Clinical examination 22
1.2.1 Polycystic kidneys 22
1.2.2 Transplant kidney 23
1.3 Communication skills and
ethics 23
1.3.1 Renal disease in
pregnancy 23
1.3.2 A new diagnosis of
amyloidosis 24
1.3.3 Is dialysis appropriate?
25
1.4 Acute scenarios 26
1.4.1 A worrying potassium
level 26
1.4.2 Postoperative acute renal
failure 30
1.4.3 Renal impairment and
a multisystem disease 33
1.4.4 Renal impairment and
fever 36
1.4.5 Renal failure and
haemoptysis 38
1.4.6 Renal colic 41
1.4.7 Backache and renal
failure 43
1.4.8 Renal failure and coma
47
171
GAH_Z01
12/9/10
9:08
Page 172
172
Self-assessment 116
Rheumatology and
Clinical Immunology
RHEUMATOLOGY
AND CLINICAL
IMMUNOLOGY
PACES Stations and Acute
Scenarios 3
1.1 History-taking 3
1.1.1 Recurrent chest
infections 3
1.1.2 Recurrent meningitis 5
1.1.3 Recurrent facial swelling
and abdominal pain 7
1.1.4 Recurrent skin abscesses
9
1.1.5
1.1.6
GAH_Z01
12/9/10
9:08
Page 173
2.3.4 Seronegative
spondyloarthropathies
94
2.3.5 Idiopathic inflammatory
myopathies 98
2.3.6 Crystal arthritis: gout 99
2.3.7 Calcium pyrophosphate
deposition disease 101
2.3.8 Fibromyalgia 101
2.4 Autoimmune rheumatic
diseases 103
2.4.1 Systemic lupus
erythematosus 103
2.4.2 Sjgrens syndrome 105
2.4.3 Systemic sclerosis
(scleroderma) 106
2.5 Vasculitides 109
2.5.1 Giant-cell arteritis and
polymyalgia rheumatica
109
2.5.2 Wegeners
granulomatosis 111
2.5.3 Polyarteritis nodosa 113
2.5.4 Cryoglobulinaemic
vasculitis 114
2.5.5 Behets disease 115
2.5.6 Takayasus arteritis 117
2.5.7 Systemic Stills disease
119
3.2
3.3
3.4
3.5
3.6
3.7
3.1.1 Erythrocyte
sedimentation rate 121
3.1.2 C-reactive protein 121
Serological investigation of
autoimmune rheumatic
disease 122
3.2.1 Antibodies to nuclear
antigens 122
3.2.2 Antibodies to doublestranded DNA 123
3.2.3 Antibodies to extractable
nuclear antigens 124
3.2.4 Rheumatoid factor 125
3.2.5 Antineutrophil
cytoplasmic antibody 125
3.2.6 Serum complement
concentrations 125
Suspected immune deficiency
in adults 126
Imaging in rheumatological
disease 129
3.4.1 Plain radiology 129
3.4.2 Bone densitometry 130
3.4.3 Magnetic resonance
imaging 131
3.4.4 Nuclear medicine 131
3.4.5 Ultrasound 132
Arthrocentesis 132
Corticosteroid injection
techniques 133
Immunoglobulin replacement
135
Self-assessment 138
173
GAH_Z02
12/9/10
9:09
Page 174
INDEX
Note: page numbers in italics refer to figures, those in bold refer to tables.
174
aetiology 62
chest radiograph 63
complications 623
differential diagnosis 62
epidemiology 62
investigation/staging 62
pathology 62
pathophysiology 62
treatment 62
aciclovir 59
acid reflux see gastro-oesophageal reflux
disease; reflux
Acute Physiology and Chronic Health
Evaluation (APACHE II) system 76
Addisons disease 17
adenomatous polyps of colon 103 4
colorectal cancer risk 104, 104
adevofir 114
albendazole 95
albumin 18
infusion 23
alcohol abuse 17
jaundice 51, 51, 54
alcoholic hepatitis 54
alcoholic liver disease 20, 22, 26
alcohol intake 19
and dyspepsia 4
alcohol-related liver disease 116 18
aetiology/pathophysiology/pathology
116, 116
clinical presentation 116, 117
complications 118
differential diagnosis 117
disease associations 118
epidemiology 116
investigation 117
physical signs 116
prevention 118
prognosis 118
treatment 11718, 122
alcohol withdrawal 52
alkaline phosphatase 18, 83, 136
primary biliary cirrhosis 86
allopurinol, hepatotoxicity 119
alpha-fetoprotein 22, 126
ALT 18
ambulatory pH monitoring 61
5-aminosalicylic acid
Crohns disease 97
ulcerative colitis 100
amiodarone, hepatotoxicity 119
amoebiasis 19, 38
intestinal 95
liver 95
amoebic abscess 125
anaemia 136
anal fissure 11, 110
analgesia
acute pancreatitis 77
chronic pancreatitis 80
angiodysplasia
duodenal 151, 151, 156
gastric 70, 70
angiography, abdominal pain 17
angular cheilosis 24
anorexia 12, 14, 102
anthropomorphic measurements 133
antibiotic-associated diarrhoea 94, 148, 153
antibiotics
acute pancreatitis 49, 77
oesophageal varices 46
antiemetics 37
antihistamines 37
anti-mitochondrial antibody 86
antimuscarinics 37
antioxidants 80
anti-tissue transglutaminase antibody 74
1-antitrypsin deficiency 20, 122
treatment 122
anxiolytics 37
aphthous ulceration 24
appendicitis 47
appetite 14
appetite suppressants 134
apple-core lesions 105, 105
arthritis 38, 94
artificial feeding 279, 29
ascites 21, 25, 26, 48, 52, 123
aspiration 23
causes 27
diagnostic approach 27
symptomatic management 23
AST 18
Augmentin 51
auscultation 34
autoimmune chronic active hepatitis 56
autoimmune liver disease 20, 122
treatment 122
azathioprine 86
Crohns disease 97
Bacillus cereus 93
bacterial overgrowth 71, 72
balloon dilatation of oesophagus 62
GAH_Z02
12/9/10
9:09
Page 175
C
CA19-9 81, 90, 126
cachexia 34, 123
caeruloplasmin 58
CAGE questionnaire 51
calcium 131
Campylobacter spp. 92, 93, 94
Campylobacter jejuni 93
caput medusa 25
carbamazepine, hepatotoxicity 119
carcinoembryonic antigen 105, 126
central venous lines 35
cerebral oedema 59
cerebral perfusion pressure 59
Chagas disease 62
Charcots triad 51
Childs-Pugh classification 124
chlorpromazine, hepatotoxicity 119
cholangioarcinoma 125
cholangiocarcinoma 81, 89 92
aetiology/pathophysiology/pathology
8990
clinical presentation 90
complications 92
differential diagnosis 90 1
disease associations 92
epidemiology 90
investigations 90, 90, 91
physical signs 90
prognosis 92
treatment 912
cholangiogram 53, 54
cholangiography, sclerosing cholangitis 88
cholangitis 53 4
cholecystectomy 51
cholecystitis, Murphys sign 84
choledocholithiasis 51, 83 5
aetiology/pathophysiology/pathology 83
clinical presentation 83 4
complications 85
differential diagnosis 84
disease associations 85
epidemiology 83
investigations 84, 84, 85
physical signs 84
prognosis 85
treatment 84 5
cholelithiasis 19
cholera 37
cholestasis of pregnancy 19
chromium 131
chromogranin A 82
chronic viral hepatitis 20
ciclosporin 86
ciprofloxacin 39, 97
cirrhosis 18, 22, 120 4
decompensated 44
histological appearance 121
management 23
clinical examination
abdominal swelling 26 7
175
GAH_Z02
12/9/10
9:09
Page 176
confusion 56, 57
differential diagnosis 55
conjunctivitis 94
constipation 30 1, 47
functional 102
treatment 103
copper 131
corticosteroids 37
Crohns disease 97
Courvoisiers law 52
Courvoisiers sign 81
C-reactive protein 136
acute pancreatitis 76
Crohns disease 96
CREST syndrome 87
Crohns disease 9, 12, 15, 16, 72, 95 8
aetiology/pathophysiology/pathology
956, 96
clinical presentation 96
complications 97 8
differential diagnosis 96
disease associations 98
epidemiology 96
investigations 96, 97
physical signs 96
prevention 98
prognosis 98
skip lesions 96
treatment 96 7, 98
Cryptosporidium spp. 37
Cullens sign 34, 48, 76
13
C urea breath test 66
cushingoid features 25
Cushings triad 59
cyclizine 37, 49
cysts, htdatid 125
cytomegalovirus 11213, 150, 155 6
176
osmotic 82
public health issues 39
secretory 82
treatment 103
diclofenac 49
Dieulafoy lesion 70
digital rectal examination 34
disulfiram 118
diuretics, ascites 23
diverticulitis 107
domperidone 37
dopamine antagonists 37
double duct sign 81
drowsiness 57
drug hepatotoxicity see hepatic drug
toxicity
duodenal angiodysplasia 151, 151, 156
duodenal ulcer 16
Dupuytrens contracture 24
dynamometry 133
dysentery 37, 93 4
aetiology/pathophysiology/pathology 93
clinical presentation 93 4
complications 94
epidemiology 93
treatment 94
dyspepsia see heartburn/dyspepsia
dysphagia 5 7, 62, 102
differential diagnosis 5
drug history 6
functional 102
history of complaint 5 6
investigation
barium swallow 6, 7
blood tests 6
manometry and pH studies 7
radiological tests 6
management 7
medical history 6
referral letter 5
social history 6
early satiety 4
elemental diet 135
ELISA 94
encephalopathy 122
endoanal ultrasound 140
endoscopic ablative therapy 66
endoscopic electrocoagulation 70, 70
endoscopic retrograde
cholangiopancreatography 35, 49,
53, 53, 141, 151, 156
acute pancreatitis 77
cholangiocarcinoma 90, 90
choledocholithiasis 84
chronic pancreatitis 79, 79
pancreatic carcinoma 81
endoscopic ultrasound 64
acute pancreatitis 77
cholangiocarcinoma 90
GAH_Z02
12/9/10
9:09
Page 177
G
gallstones 17, 51, 52
gallstone disease 47
gamma-glutamyltransferase 18, 83
ganciclovir 59
gastrectomy, partial 40, 41
gastric carcinoma 68 9
aetiology/pathophysiology/pathology
68
clinical presentation 68
complications 68
disease associations 69
epidemiology 68
investigations 68, 69
physical signs 68
prevention 68
prognosis 68
red flag symptoms 68
treatment 68
gastric obstruction 33
gastric stasis 33
gastric tumours 69 70
gastric and MALT lymphomas 69
gastrinoma 69 70
leiomyoma 69
gastrinoma 69 70, 83
gastroenteritis 923, 93
causes 92
Gastrograffin swallow 140
achalasia 62
Barretts oesophagus 64, 65
gastrointestinal haemorrhage 70 1
Dieulafoy lesion 70
hereditary haemorrhagic telangiectasia
70
Meckels diverticulum 71
vascular ectasia (angiodysplasia) 70,
70
gastro-oesophageal reflux disease 6,
602
aetiology/pathophysiology/pathology
60
clinical presentation 60 1
common 60
physical signs 60 1
uncommon 60
complications 61
differential diagnosis 61
disease associations 62
epidemiology 60
investigation/staging 61
prevention 612
prognosis 61
treatment
emergency 61
long-term 61
short-term 61
gastro-oesphageal varices 43
gastroscopy 61, 62
Giardia spp. 37
Giardia intestinalis 93, 94
giardiasis 72
Glasgow Alcoholic Hepatitis Score 118
Glasgow Coma Scale 34, 38, 47, 57
gliadin peptides 73
antibodies 74
globus 102
glucagonoma 83
gluten-free diet 74
gluten-sensitive pathology see coeliac
disease
glycocholate breath test 138
Grey Turners sign 34, 48, 76
Guillain-Barr syndrome 94
gynaecomastia 24
detection 66
CLO test 66, 67
13
C urea breath test 66
eradication of 67
and gastric lymphoma 69
histology 67
see also peptic ulcer
HELLP syndrome 19
hepatic adenoma 125
hepatic drug toxicity 56, 11820, 14950,
155
aetiology/pathophysiology/pathology
118 19, 119
chronic liver disease 120
clinical presentation/physical signs
119, 119
complications 120
differential diagnosis 120
disease associations 120
epidemiology 119
investigations 119 20
prognosis 120
treatment 120
hepatic encephalopathy 52, 57, 589
hepatitis 56, 109, 11115, 149, 154
autoimmune chronic active 56
chronic 20, 113 14, 122
treatment 122
histology 111
ischaemic 56
hepatitis A 51, 109, 11112
aetiology/pathology 109
clinical presentation 109
differential diagnosis 112
epidemiology 109
investigation 111, 111
physical signs 109
prevention 112
prognosis 112
treatment 112
hepatitis B 113 14, 149, 1545
aetiology/pathophysiology/pathology
113
clinical presentation 113, 113
complications 114
epidemiology 113
investigation 113
physical signs 113
prevention 114, 114
prognosis 114
serological markers 114
treatment 114
hepatitis C 19, 114 15
aetiology/pathophysiology/pathology
114
clinical presentation 114
epidemiology 114
investigation 115
physical signs 115
prevention 115
prognosis and complications 115
treatment 115
177
GAH_Z02
12/9/10
9:09
Page 178
ibuprofen 51
ileus 21
immunosuppression, coeliac disease 74
inflammatory bowel disease 24, 37,
95101
abdominal examination 24
Crohns disease 9, 12, 15, 16, 72, 95 8
idiopathic 8, 94
microscopic colitis 101
rectal examination 24
ulcerative colitis 10, 98 101
infliximab, Crohns disease 97
insulinoma 83
intestinal ischaemia 108 9
intestinal obstruction 21, 32, 33, 47
Crohns disease 97
intrahepatic cholestasis 89
inherited 89
iron 131
iron-deficiency anaemia 15
irritable bowel syndrome 152, 157
limitation of investigation 30 1
treatment 103
see also functional bowel disorders
ischaemic colitis 108
ischaemic heart disease 47
ischaemic hepatitis 56
178
Kayser-Fleischer rings 57
ketogenic diets 148 9, 154
Klatskin tumour 90, 91
Korsakoffs dementia 118
kwashiorkor 133
lactase 72
lactose breath test 138
lactulose breath test 138
lamivudine 59, 114
laparoscopy, rectal bleeding 13
laparotomy
exploratory 142
rectal bleeding 13
large bowel disorders 103 9
adenomatous polyps of colon 103 4
anorectal diseases 110
colorectal carcinoma 12, 13, 13, 24,
1047
diverticular disease 107 8, 108
intestinal ischaemia 108 9
laxatives, oesphageal varices 46
leiomyoma 69
leptospirosis 56
leuconychia 24
levomepromazine 37
liver
amoebiasis 95
examination 52
ultrasound 142
liver biopsy 20, 21, 21, 53, 144 6, 145
abdominal distension 23
complications 145 6
contraindications 144
hepatitis C 115
indications 144
primary biliary cirrhosis 86, 87
procedure 145
sclerosing cholangitis 88, 88
liver disease 109 29
alcohol-related 116 18
autoimmune 20, 122
chronic 24 5, 40, 1204
abdominal examination 25
aetiology/pathophysiology/pathology
120, 121
causes 25, 122
Childs-Pugh classification 124
clinical presentation 1201
complications 1223, 123
epidemiology 120
investigations/staging 121
prognosis 123 4, 124
treatment 121, 122
see also liver failure
cirrhosis 18, 120 4
causes 122
focal liver lesion 1247
hepatitis 11115
liver function tests 1821
liver failure
acute 54 9, 115 16
aetiology/pathophysiology/pathology
115
cause of 55
clinical presentation 115
complications 11516
differential diagnosis 55
examination 56 7
history of complaint 55
investigation 57 8
management 58 9, 59
physical signs 115
prognosis 116
chronic 56
liver flukes 19
liver function tests 18 21, 18, 1378
abdominal pain 17
acute liver failure 57
history of complaint 19
interpretation of 18 19
investigation 19 20
blood tests 19 20
imaging 20
liver biopsy 20, 21
management 20 1
referral letter 18
liver transplantation 59, 1279
biliary cirrhosis 86
biliary complications 129
cholangiocarcinoma 92
comorbid illness 129
contraindications 128
disease recurrence 129
emergency 128, 128
GAH_Z02
12/9/10
9:09
Page 179
magnesium 131
magnetic resonance
cholangiopancreatography 53, 54,
141, 151, 156
choledocholithiasis 84
chronic pancreatitis 79
major histocompatibility complex 73
malabsorption 713
bacterial overgrowth 71, 72
chronic pancreatitis/pancreatic
insufficiency 72
Crohns disease 98
giardiasis 72
hypolactasia 72
post gastric surgery 723
short bowel syndrome 72
tropical sprue 72
Whipples disease 72
Mallory-Weiss tear 40
Malnutrition Universal Screening Tool
132
MALT lymphoma 69
manometry, oesophageal 62, 137
marasmus 133
mebendazole 95
Meckels diverticulum 71
Meckels scanning 142
melaena 4, 11, 29, 39 46, 52
differential diagnosis 39
history of complaint 39 41, 40, 41
Meckels diverticulum 71
mesenteric angiography, rectal bleeding
13
mesenteric ischaemia 17
methotrexate 86
Crohns disease 97
hepatotoxicity 119
metoclopramide 37, 62
metronidazole 39, 72, 94, 95, 97
microscopic colitis 101
Minnesota tube 45
mixed triglyceride breath test 137
morphine 49
mouth ulcers 102
mucosal-associated lymphoid tissue see
MALT
multiple endocrine neoplasia 82
Murphys sign 84
Mycobacterium paratuberculosis 95
179
GAH_Z02
12/9/10
9:09
Page 180
P
PABA test 137
pain
abdominal see abdominal pain
chronic diarrhoea 9
dyspepsia 3
jaundice 50
nocturnal 3, 16
on swallowing 6
palmar erythema 24
palpation 34
pancreas 52
pancreas divisum 75
pancreatic abscess 50
pancreatic carcinoma 80 2, 150 1,
156
aetiology/pathophysiology/pathology
80
clinical presentation 80 1
differential diagnosis 81
epidemiology 80
imaging 81, 81
investigation/staging 81
jaundice 50
physical signs 81
prognosis 82
treatment 82
pancreatic enzyme replacement 80, 82
pancreatic function tests 80, 137
faecal enzyme measurement 137
faecal fat 137
Lundh test meal 137
mixed triglyceride breath test 137
PABA test 137
secretin-caerulein test 137
triolein breath test 137
pancreatic insufficiency 72
pancreaticobiliary investigations 141
pancreatic pain 47
pancreatic pseudocyst 76, 77
pancreatitis 48, 48
acute 75 8
aetiology/pathophysiology/pathology
75
cause 76
causes 75
clinical presentation 75 6
complications 76, 78
CT grading 77
differential diagnosis 76
Glasgow/Ranson criteria 76
investigation/staging 76, 76
management 49, 77 8, 77
physical signs 76
prevention 78
prognosis 78, 78
chronic 16, 17, 72, 78 80, 150, 156
aetiology/pathophysiology/pathology
78
causes 78 9
clinical presentation 79
180
complications 80
differential diagnosis 80
epidemiology 79
investigation/staging 79 80, 79
physical signs 79
prevention 80
prognosis 80
treatment 80
Cullens sign 34, 48, 76
Grey Turners sign 34, 48, 76
hereditary 75
panproctocolectomy 100
paracentesis 23, 143 4, 144
paracetamol
hepatotoxicity 119
overdose 54 9, 116, 149, 155
treatment 59, 59
see also liver failure
paralytic ileus 21
parasitic infections, intestinal 39, 72,
94 5
parenteral nutrition 134 5
parvovirus 113
PEG tube 279, 29
pelvic disease 12
peptic ulcer 4, 66 8
aetiology/pathophysiology/pathology
66
clinical presentation 66
complications 67
differential diagnosis 67
disease associations 68
epidemiology 66
investigations/staging 66, 67
pain 47
prevention 67
prognosis 67
treatment 67
percutaneous transhepatic
cholangiography 141
cholangiocarcinoma 90, 91
pancreatic carcinoma 81
peritonitis 46, 48
spontaneous bacterial 23
pernicious anaemia 69
pethidine 49
Peutz-Jeghers syndrome 103
pharyngeal pouch 7
pinworm 94
piperacillin/tazobactam 54
portal hypertension 25, 25, 86
postural hypotension 47
prednisolone 59
pregnancy, intrahepatic cholestasis 89
prochlorperazone 37
proctalgia fugax 102
protein-calorie malnutrition 133
prothrombin time 18, 19
acute liver failure 58
proton pump inhibitors 70
pruritus 22
pyogenic abscess 125
R
radiation-induced oesophagitis 6
radiography
abdominal 48, 79
chest 63
ulcerative colitis 99
radiology, gastrointestinal lumen
139 40, 140
ranitidine 58
Raynauds disease 19
rectal biopsy 96
rectal bleeding 8 9, 1013, 102
differential diagnosis 11
drug history 12
family history 12
history of complaint 1112
investigation 1213, 13
management 13
medical/surgical history 12
referral letter 10
rectal ulcer 110
red cell scanning 142
reflux 3 4, 6
reflux oesophagitis 6, 60
regurgitation 6
Reiters syndrome 94
rifampicin 86
hepatotoxicity 119
right iliac fossa mass 11
rigid sigmoidoscopy 140, 1423, 142
Rockall score 41
rotavirus 92, 93
roundworm 94
Roux-en-Y biliary anastomosis 128, 129
GAH_Z02
12/9/10
9:09
Page 181
telangiectasiae 25, 70
Tenckhoff catheter 27
Vibrio cholerae 93
Vibrio parahaemolyticus 93
VIPoma 83
viral hepatitis see hepatitis
Virchows triad 83
visceral pain 16
visual hallucinations 56
vitamin A 130
vitamin B1 (thiamine) 130
vitamin B2 (riboflavin) 130
vitamin B6 (pyridoxine) 130
vitamin B12 (cobalamin) 130
Crohns disease 96
deficiency 723
vitamin C 130
vitamin D 130
vitamin E 130
vitamin K 130
volvulus 21
vomiting see nausea and vomiting
von Hippel-Lindau syndrome 82
zinc 131
Zollinger-Ellison syndrome 6970, 83
181